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Summary 
 
Introduction: Adherence to antiretroviral regimens is recognized as an essential component 
of treatment success and high levels are recommended. Previous Portuguese studies regarding 
adherence to highly active antiretroviral therapy (HAART) reported prevalence rates ranging 
from 46 to 91%. 
Study Aims: To characterize prevalence and determinants of patient non-adherence to 
HAART among HIV-1 infected adult subjects followed up at the HIV outpatient clinic from 
Hospital de Santa Maria (HSM - Lisbon, Portugal). 
Methods: Retrospective cohort study with a random sample of HIV-1 infected adult subjects 
that had at least one antiretroviral refill between 01-01-2005 and 31-12-2008. Non-adherence 
was defined as medication possession ratio (MPR) <95%. HAART regimens, viral load (VL), 
CD4 cell count and other clinical variables related to HIV/AIDS infection were retrieved. 
Results: A total of 186 subjects were included in the study. Over the period 2005-2008, the 
proportion of MPR <95% significantly increased from 12.3% in 2005 to 25.9% in 2008 
(P=0.03), being higher among injection drug users (IDUs) and subjects with 
depression/anxiety and during second calendar semesters, during the study period. The 
proportion of detectable VL has significantly decreased from 43.5% in the first semester of 
2005 to 29.2% in the second semester of 2008 (P=0.01). For the analysis of non-adherence 
determinants in 2008, a total of 157 subjects were included. Having periods >12 months 
without medical appointments previous to baseline and ≤3 years of HAART experience were 
significantly associated to non-adherence. The majority (81.6%) of the non-adherent subjects 
had more than one medication gap with length <30 days. A significant decrease in the 
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proportion of subjects with CD4 count <350/µl and VL >40copies/ml was observed when 
increasing the average adherence to HAART. 
Discussion: Adherence seems to be lower among IDU and subjects with depression / anxiety, 
and during second calendar semesters. Subjects with less HAART experience and those that 
had already abandoned medical appointments are more likely to be non-adherent and should 
have more frequent monitoring of adherence. Future studies should provide national 
information on adherence to HAART. 
Keywords: HIV/AIDS infection; patient adherence; antiretroviral therapy 
 
 
 
Resumo 
 
Introdução: A adesão à terapêutica anti-retrovírica é reconhecida como essencial para o 
sucesso do tratamento, sendo recomendados níveis elevados. Em Portugal, estudos anteriores 
sobre adesão à terapêutica anti-retrovírica combinada (HAART) reportaram prevalências de 
46 a 91%. 
Objectivos: Caracterizar a prevalência e determinantes da não-adesão à HAART entre 
indivíduos adultos infectados com VIH-1 e sob tratamento, acompanhados no Hospital de Dia 
de Infecciologia do Hospital de Santa Maria (Lisboa, Portugal). 
Métodos: Estudo de coorte retrospectivo com amostra aleatória de adultos seropositivos para 
VIH-1 com pelo menos uma dispensa de medicação antiretrovírica entre 01-01-2005 e 31-12-
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2008. A não-adesão foi definida como razão de posse de medicação (MPR) <95%. Foi 
recolhida informação sobre a HAART, carga viral (CV), contagem de células CD4 e outras 
variáveis relacionadas com a infecção VIH/SIDA. 
Resultados: Foram incluídos 186 indivíduos. Durante o período 2005-2008, verificou-se um 
aumento significativo da proporção de indivíduos com MPR <95% de 12,3% em 2005 para 
25,9% em 2008 (P=0,03), maior entre utilizadores de drogas injectáveis (UDI), indivíduos 
com depressão/ansiedade e durante os segundos semestres de cada ano do período em análise. 
A proporção de indivíduos com CV detectável diminuiu de 43,5% no 1º semestre de 2005 
para 29,2% no 2º semestre 2008 (P=0,01). Para a análise dos determinantes da não-adesão em 
2008, foram incluídos 157 indivíduos. Os principais determinantes foram a existência de 
períodos >12 meses de falta à consulta e ter ≤3 anos de experiência em HAART. A maioria 
(81,6%) dos não-aderentes tiveram mais de um intervalo sem medicação com duração <30 
dias. Verificou-se uma diminuição na proporção de indivíduos com CD4 <350/μl e CV >40 
cópias/ml, com o aumento da adesão média. 
Discussão: A adesão parece ser menor entre UDI e indivíduos com depressão/ansiedade, e 
durante os segundos semestres de cada ano. Indivíduos com menos tempo em HAART e 
aqueles que abandonaram previamente a consulta têm maior probabilidade de serem não 
aderentes e devem ter uma monitorização mais frequente. No futuro, propomos um estudo de 
coorte multicêntrico para recolha de informação nacional sobre adesão à HAART. 
Palavras-chave: infecção VIH/SIDA, adesão à terapêutica, terapêutica antiretrovírica. 
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Context of the Dissertation 
 
This dissertation is part of the pilot study for a national, multicentre cohort study – the 
ATAR-VIH project – that aims to evaluate the prevalence and determinants of patient non-
adherence to antiretroviral treatment, among HIV1-infected adult subjects, in Portugal. 
 
The pilot study of the ATAR-VIH project is still ongoing and comprehends both a 
retrospective and a prospective phase, aiming 1) to provide a characterization of the pattern of 
Highly Active Antiretroviral Therapy (HAART) prescription and non-adherence, over the 
period from 2005 to 2008 calendar year; 2) to verify which factors may be associated to non-
adherence to HAART; 3) to evaluate the completeness of the clinical and pharmacy records, 
and to define which variables are able to be collected from these sources, according to the 
study aims; 4) to gather preliminary data necessary to confirm the sample size estimation of 
the national study; and 5) to evaluate precision and effectiveness of different measures for 
assessment of adherence to HAART, and HAART change. 
 
This dissertation integrates the retrospective phase of the pilot study and aims to address the 
following research questions: 
 What is the prevalence of non-adherence to antiretroviral treatment among HIV1 infected 
adult subjects followed up at a Portuguese HIV outpatient clinic? (aim 1 of the pilot study) 
 Which variables are associated with this medication-taking behaviour? (aim 2 of the pilot 
study) 
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We also aimed to evaluate completeness of the clinical and pharmacy records, according to 
the study variables presented in Annex IV and for the retrospective data collection (aim 3 of 
the pilot study). In this retrospective phase, we retrieved data from a single hospital (HIV 
outpatient clinic of Hospital de Santa Maria, Lisbon) to assess if a retrospective study would 
provide information to characterize adherence to HAART and its determinants. The sample 
size was calculated based in the initial assumptions for the ATAR-VIH project, which 
summary is presented in Annex VI. 
 
Besides this dissertation, other analyses were conducted for the retrospective phase. 
 We aimed to estimate the incidence and describe the reasons for first, second and third 
changes of HAART in HIV1-infected subjects. This study was proposed as a student’s project 
in 2009/2010 scholar year and resulted in an integrated Master in Medicine’ Dissertation 
(student: Andreia Heitor Leite). A total of 194 subjects were included, from which 136 
(70.1%) had changed therapy at least once, with an incidence rate (I) of 23.4 per 100 person-
year of follow-up. Furthermore, 102 (75.0%) subjects changed treatment twice (I=33.0) and 
79 (77.5%) changed three times (I=34.3). First change was mainly due to adverse drug 
reactions, the second to immunological/virological failure and the third to resistance. Also, 
discontinuation was observed in 19.9% of the total number of observed HAART changes, 
mostly due to subjects’ non-persistence to treatment. Overall treatment changes were 
frequent, and different reasons were observed for the three first HAART changes. A 
longitudinal analysis of determinants of HAART change will also be conducted as a Master in 
Biostatistics’ Dissertation. 
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 Preliminary results of 60 subjects, corresponding to 1791 intervals between dispenses, 
were analysed. Each participant had an average of 11.4 ± 8.9 intervals with medication gaps. 
A 38.3% of non-adherence was determined (subjects with at least one interval with gap >30 
days). However, 5% of the participants presented gaps in every interval and 92% of the 
patients had at least one interval with at least one day without medication. This preliminary 
analysis was also proposed as a student’s project in scholar year 2009/2010 (student: José 
Alexandre Freitas). The student is now developing is Master in Medicine’ Dissertation, with a 
focus on physician evaluation of patient adherence to HAART.  
 
The retrospective data is still being analysed, aiming to address the longitudinal evaluation of 
adherence determinants and the comparison of adherence measures. As for the prospective 
phase of the pilot study, data from clinical records was complemented through patient’s and 
physician’s questionnaires. It is now being conducted at the HIV Outpatient Clinic of the 
Hospital de Santa Maria. 
 
 Synopsis 
In Chapter I – General Introduction, we contextualize the dissertation research questions 
and its relevance, by providing a brief review of HIV/AIDS infection main characteristics and 
treatment options (section I.1) and the impact of non-adherence on HIV infection outcomes 
(section I.2). We also review the heterogeneity and consequent difficulty in defining and 
measuring patient adherence to antiretroviral treatment, followed by a summary of variables 
that have been described in previous studies as associated to non-adherence (section I.2). 
Then, we introduce the Portuguese context with an attempt to update disperse data related to 
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the epidemiology of HIV/AIDS infection and to the antiretroviral expenditure (section I.3). In 
this final introductory section, we summarize similar Portuguese studies on patient adherence. 
In Chapter II – Study Objectives and Chapter III – Study Design & Methods, we present 
the dissertation aims and methods, as part of the retrospective phase of the pilot study of the 
ATAR-VIH project. 
In Chapter IV – Results, we present and discuss the results of the analyses addressing the 
dissertation research questions. First, we aimed to describe trends of patient non-adherence 
and HAART prescription, over the period 2005-2008. Next we assessed determinants and 
patterns of non-adherence, for those subjects that were prescribed to HAART during 2008. 
We also explore the impact of non-adherence, in terms of virological and immunological 
outcomes. Hence, we assessed the following specific aims: 
 
Section IV.1. Antiretroviral Prescription and Adherence in a Portuguese Cohort of HIV-1 
infected subjects: an overall analysis of changes over the years 2005 - 2008 
We aimed to evaluate the trends in patient non-adherence to HAART over the period 2005-
2008, for overall population receiving HAART and among the groups that had a clinical 
record of past or current injection drug use, a clinical record of past or current depression or 
anxiety or that had started antiretroviral treatment with a pre-HAART regimen. We also 
aimed to analyze trends in the proportion of subjects presenting detectable viral load, as well 
as to assess the HAART prescription pattern for overall population, regarding antiretroviral 
drugs and regimens, and the use of dose-fixed associations. 
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Section IV.2. Determinants, pattern, virological and immunological outcomes of non-
adherence to HAART in a Portuguese cohort of HIV-1 infected subjects 
A second analysis aimed to identify the determinants of patient non-adherence to HAART 
during 2008, among subject characteristics, aspects of health care utilization, and other 
variables related to treatment and HIV infection. We also aimed to identify possible patterns 
of non-adherence to HAART, namely, to assess how frequent it is for a subject to be without 
antiretroviral medication. Another specific aim was to analyse the association of average non-
adherence and duration of medication gaps, with immunological and virological outcomes, 
defined as CD4 cell count <350/µl and viral load >40 copies/ml, during 2008. 
 
Finally, Chapter V – General Discussion & Future Research aims to present an overall 
perspective and main conclusions of the study presented in this dissertation. We also present 
and discuss the results related to the evaluation of clinical and pharmacy records’ 
completeness. 
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Chapter I 
 
Chapter I General Introduction 
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I.1. 
A brief review of HIV/AIDS infection immunopathogenesis 
and antiretroviral treatment 
 
Infection with Human Immunodeficiency Virus (HIV) leads to a chronic infection 
characterized by a long clinical latency period and progressive immunodeficiency. The 
destruction of the immune function may result in opportunistic infections, autoimmune 
diseases and malignancies, as well as clinical manifestations related to the virus itself [1]. 
 
 HIV-1 replication cycle and immunopathogenesis 
Figure I.1.1 describes the replication cycle of HIV and targets for antiretroviral drugs [2]. 
After binding and fusing to the cellular membrane of Lymphocytes T, via CD4 molecules and 
chemokine receptors (CCR5 and CXCR4), the HIV-1 core enters the host cell and viral RNA 
and enzymes are released. Then, viral replication occurs through a reverse transcriptase, 
which synthesizes proviral DNA. The reverse transcriptase is highly prone to errors and the 
HIV mutations lead to viral resistance to the host's immune system and to antiretroviral drugs. 
Proviral DNA is transported to the nucleus and integrated into the host DNA, through the HIV 
integrase. At each cell division, a duplication of the integrated proviral DNA occurs along 
with the host DNA, followed by the transcription to viral RNA and translation to HIV 
proteins. The HIV proteins are assembled into HIV virions at the inner cell membrane and 
released from the cell surface. At the end, a protease cleaves viral proteins, converting the 
immature virion into a mature viral form [2, 3]. 
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Figure I.1.1. HIV replication cycle, and targets inhibited by antiretroviral drugs [2]. 
 
The HIV infection is associated with several changes at the immune system level, mainly 
related to the CD4 cell depletion, which may result from the direct cytotoxic effects of HIV 
replication, cell-mediated immune cytotoxicity or thymic damage that impairs lymphocyte 
production [4]. When the CD4 cell count decreases to <350/μl, immunity is compromised, 
and when <200/μl the patient is at increased risk of various opportunistic infections, such as 
Pneumocystis jiroveci pneumonia, and neoplasms such as lymphoma and Kaposi’s sarcoma. 
HIV infection can affect the humoral immune system, with hyperplasia of B-lymphocyte in 
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lymph nodes and lymphadenopathy, and it may also disrupt nonlymphoid monocytic cells, 
such as blood monocyte, tissue macrophage, and nervous microglia. As a result, there is an 
increased susceptibility to infections by encapsulated bacteria, and HIV meningitis and 
peripheral neuropathy may develop [5]. 
The average time from acquisition of HIV to an AIDS-defining event is 8 to10 years, without 
treatment (Figure I.1.2). After the primary HIV infection via the mucosal or parenteral route, 
an increase in viral load and a decrease of T-cells expressing CD4 antigen are observed, 
sometimes with fever, diarrhoea and lymphadenopathy. An immunological response occurs in 
weeks, resulting in partial control of viral replication [6, 7]. 
 
Figure I.1.2. Natural history of HIV-1 infection: evolution of CD4 cell count and plasma viremia [6].  
 
The prognosis of HIV-infected persons is defined by combined measurement of plasma  
HIV-1 RNA and CD4 cells [8], even though the observed changes in plasma levels are poorly 
indicative of the much higher activity in lymphoid tissue [7]. Viral load, expressed as HIV 
RNA copies/ml, stabilize after about 6 months at set points that average 30000 to 100000 
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copies/ml. After this point, a seroconversion occurs but the immune response cannot fully 
control the infection due to the development of mutant forms of HIV. Thus, the 6-month viral 
load is a relevant prognostic indicator of the disease progression: the higher this set point, the 
more quickly the CD4 count decreases to levels <200 cells/μl that compromise immunity and 
results in the opportunistic infections and other AIDS-defining events [7, 8]. In fact, the 
clinically asymptomatic period of 8 to 10 years is not a “latent” period since viral replication 
and immunological decline also develops during this period. 
Different clinical models were proposed to the dynamics of virus replication and of CD4 cell 
turnover. The use of antiretroviral drugs and the introduction of HAART may enable a better 
comprehension of HIV immunopathogenesis, including the processes that contribute to the 
CD4 cell recovery during treatment [7, 9]. 
 
 Antiretroviral treatment 
It is recognized that antiretroviral therapy and prophylaxis against opportunistic infections 
have markedly improved the overall prognosis of HIV disease at individual level [10]. As a 
result, the availability of potent combination antiretroviral regimens is associated to a 
significant reduction in HIV–associated morbidity and mortality in the developed world 
[11,12]. This was early observed in 1998, for the US data (Figure I.1.3), when the reductions 
in mortality and in the hospitalization of HIV-infected patients were clearly related to specific 
antiretroviral regimens, namely those with protease inhibitors [11]. 
 29 
 
Figure I.1.3. Mortality and frequency of use of combination antiretroviral therapy including a PI,  
among HIV-infected patients with <100 CD4 cells/mm
3
 [11]. 
 
Antiretroviral treatment aims to reduce the viral load and to restore the CD4 count and the 
immune function. It has undergone considerable changes (Table I.1.1), from early 
monotherapy with zidovudine, until the number of antiretroviral options that are available 
nowadays [2, 13]. 
 
Table I.1.1. Timeline of advances and approvals in HIV treatment in Europe (adapted from 2, 13, 14) 
Year Advances 
ARV generic name 
(year of EMA approval) 
ARV class 
1981  Recognition of a new disease to be known as AIDS -  
1982  Disease recognition hampered by lack of diagnostic tests 
 Clinical diagnosis was the only tool available 
-  
1983  Isolation of the HIV-1 -  
1985  Isolation of the HIV-2 -  
1987  First FDA-approved therapy directed against HIV-1 1990, Zidovudine* NRTI 
1991  Additional NRTIs ready for FDA approval 1992, Didanosine* 
 
NRTI 
 
1994  Shortcomings and limitations of monotherapy noted 
 Clinical trial revealed that use of zidovudine in pregnancy markedly reduces 
HIV-1 transmission to neonates 
1994, Zalcitabine* NRTI 
1995 
- 
1997 
 Initial understanding of HIV-1 viral dynamics 
 Release of the first protease inhibitors in triple combination therapy 
(HAART) - 1996 
 Dissemination of plasma viral load testing 
 First NNRTI is approved by the FDA 
1996, Stavudine 
1996, Lamivudine 
1996, Saquinavir-HCG  
1996, Ritonavir 
1996, Indinavir 
NRTI 
NRTI 
PI 
PI 
PI 
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Year Advances 
ARV generic name 
(year of EMA approval) 
ARV class 
 Ongoing declines in AIDS incidence and death in developed countries, 
primarily due to availability of HAART 
 Recognition of limitations of HAART: development of resistance and 
adverse effects of therapy 
 
1998  Recognition of HIV latency and reservoirs 
 Restoration of immune function with HAART 
 Finding that initial treatment with efavirenz-based regimens was at least as 
effective as with protease inhibitors 
1998, Nevirapine 
1998, Nelfinavir 
1997, Delavirdine** 
1998, Lamivudine+ 
          Zidovudine 
1998, Saquinavir 
NNRTI 
PI 
NNRTI 
2NRTI 
 
PI 
1999  In treatment-experienced patients with virological failure, adding two active 
drugs is more likely to result in suppression than adding one 
 Use of new combinations of agents added to HAART, in an attempt to 
eradicate HIV-1 from infected subjects 
1999, Efavirenz 
1999, Abacavir 
NNRTI 
NRTI 
 
2000  Greater understanding of reservoirs making eradication of HIV 
unachievable with current agents 
 Ritonavir boosted PIs are more effective than unboosted PIs in both 
treatment-experienced and naive patients; they also are less likely to select 
drug resistance mutations 
 Genotypic resistance testing can guide selection of optimal salvage and 
initial regimens 
2000, Amprenavir 
2000, Didanosine (EC)** 
2000, Abacavir+ 
Lamivudine+Zidovudine 
 
PI 
NRTI 
3NRTI 
 
2001  Thymidine analogue reverse transcriptase inhibitors (especially stavudine) 
cause many of the long term adverse effects of HAART (neuropathy, 
lipoatrophy, lactic acidosis), with these side effects absent in tenofovir- and 
abacavir-based therapies  
2001, Lopinavir+ 
          Ritonavir 
 
PI 
2002  Prevention of HIV-1 neonatal transmission in the developed world 
 New guidelines for initiating HAART (CD4 <350 cells/µl) 
2002, Tenofovir N(t)RTI 
2003 
- 
2006 
 Introduction of fusion inhibitors 
 Need to translate progress to the developing world – Millennium 
Declaration 
 Availability of potent regimens with reduced pill burden and dosing 
frequency; several treatments as fixed-dose combinations 
 Early vaccine attempts 
2003, Enfuvirtide 
2003, Emtricitabine 
2003, Fosamprenavir 
2004, Atazanavir 
2004, Abacavir+ 
          Lamivudine 
2005, Tenofovir+ 
          Emtricitabine 
2005, Tripanavir 
EI 
NRTI 
PI 
PI 
2NRTI 
 
N(t)RTI+ NRTI 
 
PI 
2006 
- 
2008 
 Several antiretroviral agents in existing and novel classes with activity 
against highly drug-resistant viruses are approved; use of at least 2 and 
sometimes 3 active agents in clinical practice, yielding high rates of viral 
suppression even in treatment-experienced patients 
 Approval of fixed-dose combination, one pill, once daily 
2007, Darunavir 
2007, Efavirenz+ 
Emtricitabine+Tenofovir 
2007, Maraviroc 
2007, Raltegravir 
PI 
NNRTI+ NRTI 
+N(t)RTI 
EI 
II 
2008 
- 
2010 
 Increased understanding of both benefits of earlier therapy and risk of 
interruption treatment at high CD4 cell counts 
 Guidelines recommend lifelong ART for asymptomatic patients and  earlier 
initiating HAART (CD4 <500 cells/µl) 
 Growing interest in ‘therapeutic’ vaccines, to improve the immune response 
to act synergistically with the antiretroviral therapy 
  
2011  United Nations Political Declaration on HIV/AIDS: Intensifying Our Efforts 
to Eliminate HIV/AIDS 
  
* INFARMED approval. ** Unavailable in Europe (FDA approval only). ARV, antiretroviral. N(t)RTI, nucleoside (nucleotide) reverse transcriptase 
inhibitors. NNRTI, non-nucleoside reverse transcriptase inhibitors. PI, protease inhibitors. EI, entry (fusion) inhibitors.  II, integrase inhibitors.  
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In fact, treatment of adult HIV infection is now based in the selection of different drugs, three 
or four taken in combination, an approach that is known as Highly Active Antiretroviral 
Therapy (HAART). There are several classes of antiretroviral drugs:  
 Nucleoside and nucleotide reverse transcriptase inhibitors [N(t)RTIs] inhibit 
reverse transcription by being incorporated into the newly synthesized viral DNA strand as a 
faulty nucleotide, leading to the chain termination of HIV-1 proviral DNA. 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind directly to the 
reverse transcriptase enzyme, at a position distant from the active site, resulting in 
conformational changes at the active site with a resultant inhibition of the enzyme. 
 Protease inhibitors (PIs) inhibit the viral protease enzyme responsible for the 
maturation of immature HIV virions after being released from CD4 host cells. 
 Entry inhibitors (EIs), or fusion inhibitors, interfere with the binding of HIV to 
CD4+ receptors and chemokine co-receptors which are required for HIV to enter cells. 
 Integrase inhibitors prevent proviral DNA from being integrated into human DNA. 
 
The choice of specific antiretroviral drugs is based on factors such as concomitant conditions, 
the patient’s risk to develop drug interactions and regimen potential to maximize patient’s 
adherence to treatment. With the expansion of treatment options and evolving knowledge, 
guidelines from expert panels were developed for the initiation and long-term management of 
antiretroviral treatment in adults with HIV infection [15]. 
Starting HAART should be decided based on the assessment of benefits of treatment on 
morbidity and mortality and also of its risks, such as toxicity, resistance, drug interactions, 
and the convenience of life-long treatment. It is important to note that the advances in 
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antiretroviral drug development have changed the therapeutic risk-benefit balance. The usual 
recommendations are to initiate treatment when CD4 count is less than 350/μl. When CD4 
count >350/μl, treatment may also be considered in conditions such as HCV treated co-
infection. In addition, treatment may be considered if CD4 count >500/μl for conditions such 
as symptomatic HIV disease (CDC classification B). [15, 16]. The lower the pre-treatment 
CD4 count and the higher the HIV RNA level, the less likely treatment is to succeed, but 
improvement is likely even in patients with advanced immune suppression or that had already 
developed HIV-related cancers and opportunistic infections [15]. 
 
After starting or changing HAART, it is expected that the CD4 cell count increase by more 
than 50 cells/µl at 4 to 8 weeks, followed by an additional increase of 50 to 100 cells/µl per 
year thereafter [17, 18]. Regardless previous treatment experience, effective therapy should 
result in viral suppression to non-detectable values (<40 copies/ml) up to 24 weeks [15]. Viral 
load should be monitored frequently when treatment is initiated, in order to assess virological 
failure. Resistance testing should be performed while the patient is receiving the failing 
regimen. In fact, if a patient was not on HAART recently, the full extent of resistance may not 
be apparent through resistance testing, but strains with resistance mutations often re-emerge 
when resuming treatment [19]. 
Once the viral load is suppressed for a year and CD4 cell counts are stable at ≥350/μl these 
markers can be monitored at intervals of up to 6 months. During treatment, other factors 
should be also monitored, such as adherence, interactions, and adverse reactions. If 
virological rebound occurs, poor adherence and drug interactions, as well as concurrent 
infections and recent vaccination, should be reviewed before the decision of changing 
HAART [15]. 
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Interactions with antiretroviral drugs should always be checked before any new drug is 
started, to prevent toxicities and loss of efficacy. Interactions may also occur between 
different antiretroviral drugs, resulting in either synergistic increase efficacy (e.g., ritonavir 
boosted-PIs) or decreasing it (e.g., NRTI combinations). 
On the other hand, antiretroviral drugs may be associated with several adverse effects, such as 
anemia, pancreatitis, hepatitis, and glucose intolerance, as well as hyperlipidemia and other 
metabolic changes among other reactions. Patients should be monitored regularly, both 
clinically and with appropriate laboratory testing, especially when new drugs are started or 
unexplained symptoms develop. In fact, if persistent adverse effects occur, delaying HAART 
switch may affect adherence and promote the emergence of resistance [15]. 
In the last decade, several advances regarding knowledge about HIV/AIDS infection 
pathogenesis and antiretroviral treatment were achieved. There are more drugs and fixed-dose 
associations available, and drug development continues to evolve. There was also a continued 
effort to assess complications or disease states associated with HIV or its treatment, alongside 
with the identification of non-AIDS events as a major cause of morbidity and mortality in 
people living with HIV. In fact, it has been showed that AIDS can be prevented with 
HAART, and recent evidence also indicates that early ART initiation may reduce the 
insidious damage during asymptomatic HIV infection, thus preventing AIDS and non-AIDS  
events [16]. 
On the other hand, maintaining patient’s adherence to treatment, assessing and preventing 
drug resistance, toxicity and clinical manifestations related to both the drugs, to the HIV 
infection or to the increased survival of the subjects had increased the complexity of the 
medical follow-up. Hence, despite the above mentioned advances - and of other recent 
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achievements in the development of a HIV vaccine -, clinical management of the HIV/AIDS 
infection remains a challenge. 
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I.2. 
Adherence to Antiretroviral Treatment in HIV infection 
 
The introduction of HAART in the mid-1990s has led to significant reductions in HIV-related 
morbidity and mortality, transforming HIV infection into a chronic medical condition [1,2]. 
However, effective suppression of viral replication cannot be achieved if patients do not take 
their prescribed regimens, thus patient adherence to therapy is considered a major determinant 
of HAART effectiveness [ 3 , 4 ]. In fact, it has been demonstrated that adherence is 
fundamental to achieve viral suppression and avoid rebound [5, 6], to increase levels of CD4 
cell counts [7] and to minimize the risk of drug resistance [8], progression to AIDS [17] and 
of death [9, 10]. The costs of antiretroviral medication are high but cost-effective, since high 
levels of adherence were associated with decreased healthcare utilization and related costs, 
namely direct costs due to hospitalizations, in different settings [11, 12]. Hence, adherence to 
HAART is recognized as an essential component of individual treatment success and 
maintaining adherence is necessary to maximize the benefits of treatment [13, 14]. Although 
the minimum cut-off for HAART adherence is not clearly established [15], it usually ranges 
between ≥90% and ≥95% [16, 17]. 
 
Nevertheless, assessing adherence remains a challenge. Besides being a complex and dynamic 
behaviour, there are several definitions and measures to evaluate patients’ adherence to 
HAART, which may lead to misclassification and unclear public health messages, in both 
clinical and research settings [ 18 , 19 ]. The 2011 European AIDS Clinical Society 
recommendations for the HIV management and treatment state that adherence barriers should 
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be assessed alongside with the patient’s readiness to start HAART and that adherence’ 
problems should be screened in each medical appointment [16]. Thus, physicians should be 
provided with efficient, practical, and inexpensive measures to identify subjects in need of 
adherence interventions [19]. On the other hand, HIV researchers and public health 
professionals require accurate estimates of rates and predictors of poor adherence, to identify 
high-risk populations that would benefit from adherence interventions as well as to verify its 
efficacy and effectiveness [19]. The use of different adherence measures can lead to 
discrepancies in conclusions about adherence rates and predictors of adherence, a problem 
that may even be more relevant in poor-resource settings, where second line antiretroviral 
options are limited if resistance occurs [17, 20]. 
 
 Defining Adherence to Treatment 
The World Health Organization (WHO) defines adherence to long-term therapy as “the extent 
to which a person’s behaviour – taking a medication, following a diet, and/or executing 
lifestyle changes, corresponds with agreed recommendations from a health care provider” 
[18]. Nevertheless, adherence is usually considered as related to medication, at both clinical 
practice and research settings, and several definitions have been proposed to describe the 
medication-taking behaviour [21]. Adherence was first described as patient compliance, 
regarding “the extent to which a person’s behaviour coincides with medical healthcare or 
health advice”, a definition proposed in 1979 by Haynes et al. [22]. In the following years, 
patient compliance was associated with a negative and judgmental connotation of the patient, 
which led to the introduction of the term adherence [23]. The definition adopted by WHO 
aimed to recognize patients as active collaborators in the treatment process, but both terms are 
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frequently used as synonyms, revealed to be uninformative, and its application to patients 
who do not consume all medication at the desired time can stigmatize them and impact their 
future relationships with health care providers [23,24]. Concordance is a recent and wider 
term that focuses in the process in which physician and patient agree on therapeutic goals and 
decisions, referring to the extent to which patients are successfully involved in shared 
decision processes about medication and medication intake [23,25]. However, concordance is 
difficult to be quantified as it may be considered as an ongoing process, and compliance or 
adherence are the recommended terms when assessing the intensity of medication intake 
[23,25]. For instance, a recent study has found that physician-patient concordance in HIV 
treatment decision-making was associated with greater adherence, although stating that more 
research is needed to clarify the relationship between concordance and adherence [26]. 
 
It is recognized that non-adherence to HAART can take many different forms. The patient 
may unintentionally fail to fill the prescription, forget a dose or may take it incorrectly 
because misunderstanding or forgetfulness of health professional’s instructions. On the other 
hand, non-adherence may also be defined as intentional, when patients consciously self-adjust 
their regimen or prematurely terminate the medication, because of side-effects and toxicity, 
personal beliefs or convenience [18,27]. As a consequence, intentional versus unintentional 
non-adherent HIV-positive patients may struggle with different adherence determinants, 
requiring different interventions [27]. 
 
Finally, another feature of medication-taking behaviour is related to its dynamic and 
variability through different moments of patients’ dosing histories [28]. As shown in Figure 
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I.2.1, it has been proposed a new definition of adherence that comprehends three main 
attributes associated with medication-taking behaviour [28]: 
 acceptance, representing if whether or not the patient ever starts the treatment; 
 compliance, also described as “quality of execution” [29] and defined as the extent to 
which the patient’s drug dosing history conforms to the prescribed regimen; 
 persistence, defined as the time between the first and the last dose or time between the 
first dose until the compliance fall below a defined minimal level. 
 
Figure I.2.1. Attributes of patient adherence to treatment [30]. 
 
Regarding antiretroviral use for the HIV/AIDS infection, an adherent subject should accept 
and maintain the prescribed regimen, with a high compliance level [28]. We have found few 
studies on HAART acceptance, mostly related to evaluation of access to HAART in poor-
resource settings [31,32]. On the other hand, evaluating compliance seems to be a more 
common approach. A recent meta-analysis has reviewed eighty-four observational studies on 
adherence assessed mainly as compliance [17]. With the inclusion of studies conducted across 
twenty countries, the average rate of subjects who reported ≥90% adherence to HAART was 
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62%. Persistence on HAART seems to have been less assessed [33]. A 2000 study quantified 
persistence rate at 12 months of 87% among a cohort of 100 HIV-infected subjects, followed 
at a regional HIV treatment centre in Canada [34]. Other studies have assessed treatment 
interruptions and its association with virological failure. In a cohort with 8.3 years of median 
duration of follow-up, 43% of the subjects had an interruption longer than 3 days, therefore 
with a higher risk of treatment failure [35]. In a poor-resource setting, another study showed 
that 23% of the subjects had a history of treatment interruption higher than 4 days which was 
associated with virological failure [36]. Treatment interruptions also seemed to be frequent 
among injection drug users, in the setting of active drug use and disruption of health care, as a 
study showed that 78% of individuals had one or more treatment discontinuations, and that 
20% never resumed HAART [37].  
 
 
 Measuring Patient’s Adherence to Antiretroviral Treatment 
The measurement of patient’s adherence to HAART is a difficult endeavour both in clinical 
care and research settings [19]. There is no gold standard to measure adherence, although 
several strategies are available, with specific strengths and weaknesses (Table I.2.1). 
Some authors also classify the available measures as objective or more reliable vs. subjective 
or which information is more susceptible to being modified by patients [29,38]. Table I.2.2 
presents this classification and its relation to continuous assessment over time. 
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Table I.2.1. Characteristics of the available methods to assess adherence [19, 24, 39]. 
Method Advantages Disadvantages 
Challenges and 
Comments 
Measurement of 
the level of 
medicine or 
metabolite in 
blood 
- Therapeutic Drug 
Monitoring 
 Objective, direct adherence 
measure 
 Plasma concentration 
directly determines 
virological response 
 May allow for detection or 
prevention of drug toxicity 
 May be advantageous for 
populations at risk for 
altered pharmacokinetics 
 Susceptible to variations in 
metabolism and “white-coat 
adherence” 
 Only provides information of 
recent adherence 
 Expensive 
 Invasive 
 Non-standard procedures for 
collection, testing and 
interpretation 
 Cannot routinely measure 
NRTI levels because active 
metabolites are intracellular 
 Levels may be low for other 
reasons than non-adherence  
 Higher plasma levels may be 
necessary to suppress 
replication of resistant virus 
 Standardize of 
procedures for collection, 
testing, and interpretation 
 Develop protocols for 
quality assurance 
 Determine optimal 
monitoring frequency 
 Determine optimal 
parameters (e.g., 
minimum concentration, 
ratio of an individual's 
level to a population or 
expected level, or area 
under the concentration-
time curve) 
Patient 
questionnaires, 
patient diaries, 
patient self-
reports 
 Simple 
 Inexpensive 
 Useful and easily 
implemented in clinical 
settings 
 Moderate correlation with 
virological outcomes 
 Allows discussion of 
reasons for non-adherence 
 Low participant burden 
 Patient diaries help to 
correct for poor recall 
 Susceptible to error with 
increases in time between 
visits 
 No standardized questions 
 Overestimates adherence 
 Relies on recall of forgotten 
events 
 Vulnerable to social 
desirability bias 
 Poor sensitivity 
• Mitigate ceiling effect 
• Include measurement of 
all aspects of adherence 
(e.g., dose-interval) 
• Continue to rigorously 
develop and test new 
measures (e.g. cognitive 
interviewing or item 
response theory) 
Pill count  Objective, quantifiable, and 
easy to perform 
 Moderate correlation with 
virological outcomes 
 Time consuming 
 Inappropriate for most 
clinical settings 
 May overestimate adherence 
 Vulnerable to “pill dumping”  
 Difficult to determine refill 
start date 
 Assumes no medication 
stockpile or alternative 
supply 
 Manage logistic 
challenges of 
unannounced pill counts 
Prescription / 
Pharmacy refill 
 Objective 
 Data are easily obtained in 
“closed pharmacy systems” 
 Moderate correlation with 
virological outcomes 
 Allows for population level 
analyses 
 Immune to social 
desirability, recall bias, and 
tampering 
 Feasible only in “closed 
pharmacy systems” 
 May poorly adherence 
 Cannot measure dose-interval 
adherence 
 Cannot differentiate non-
adherence from other forms 
of treatment interruptions 
(e.g. discontinuation by 
provider) 
 Evaluate use in “open 
systems” 
 Determine optimal 
method for evaluate 
adherence 
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Method Advantages Disadvantages 
Challenges and 
Comments 
 Assumes that patients have 
one source of medication 
 Assumes that medication 
acquisition reflects adherence 
- a prescription refill is not 
equivalent to ingestion of 
medication 
 No standard method for 
operationalize adherence 
 Not useful if refills are 
mailed automatically or if 
several months' supply is 
dispensed at one time 
Electronic 
medication 
monitors 
 Precise 
 High sensitivity 
 results are easily quantified; 
 Best correlation with 
virological outcomes 
 Allows analysis of dose-
interval adherence and 
patterns of adherence over 
time 
 Expensive 
 Not feasible for most clinical 
settings 
 May underestimate adherence 
 Vulnerable to technological 
malfunction 
 Potential for selection bias 
 High participant burden  
 Potential Hawthorne effect 
 Understand 
interventional effect 
 Accurately censor of data 
(e.g. standard questions 
about periods of non-use, 
“pocket doses,” or 
“curiosity openings”) 
 Develop evidence based 
guidelines for use, 
quality control, and data 
management 
Clinical response 
- viral load and 
CD4 cell count 
 Objective 
 High sensitivity 
 Applicable in poor-resource 
settings 
 Factors other than medication 
adherence can affect clinical 
response 
 
Directly observed 
therapy 
 Most accurate  Patients can hide pills in the 
mouth and then discard them; 
 Impractical for routine use 
 Interventional rather than 
a observational measure 
of adherence 
 
 
Table I.2.2. Classification of the different methods to assess adherence [29,38] 
 
Provide information about 
aggregate medication omissions 
but unable to show when 
omissions occurred 
Continuous assessment of 
adherence over time 
Susceptible to censorship of the 
data by the patient 
 Pill counts 
 Self-report questionnaire 
 Patient diary 
Reliable / Objective 
 Therapeutic drug monitoring 
 Pharmacy refill data 
 Electronic monitoring 
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Self-reports 
Patient self-reports of adherence is one the most commonly used measure in both clinical and 
research settings, due to its low burden, being inexpensive and, in clinical setting, allowing 
the physician to review patient’s reasons for missed doses [19]. Simoni et al. (2006), found 
that self-reported adherence was significantly correlated with viral load in 84% of 
comparisons, while Nieuwerk et al. (2005) found that the pooled odds ratio of having 
detectable HIV viral load was 2.31 in non-adherent patients compared to adherent patients 
[40 ,41]. However, self-report measures tend to overestimate adherence, due to a recall 
provider and social-desirability bias [42]. Also, some patients often improve medication-
taking behaviour around a scheduled medical appointment, drug monitoring or viral load 
assessment. This is defined as white-compliance and can only be identified when considering 
adherence as a continuous variable [18]. Other factors that may contribute for this “ceiling 
effect” are questions’ misinterpretation and poor or differential recall between adherents and 
non-adherents [19]. Self-report shows lack of sensitivity for identifying non-adherence, and 
even specificity may also be affected by inaccurate reports among patients who report missing 
doses [19]. Finally, there is a high variety of self-report questions and the lack of 
standardization on aspects such as time frames, questions and response tasks indicates a need 
to optimize and validate this measure [42]. 
 
Providers’ Assessment 
In the clinical setting, physicians often estimate patients’ adherence to HAART, but evidence 
suggests that estimates made by health care providers are frequently inaccurate and may 
return an overestimated adherence [43,44]. In fact, many providers believe that factors 
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associated with socioeconomic status, such as lack of education and poverty, are good 
predictors of non-adherence. However, predictors of adherence vary greatly across 
populations and settings and no factor has been consistently associated with non-adherence 
across all studies [18]. 
 
Patient self-reports 
Pill counts can be conducted at clinical appointments or scheduled visits, to which the subject 
brings his medication [19,39]. The assessment of adherence based in pill counting is 
calculated by counting the remaining doses of medication since the start date of the 
prescription and assuming that remaining pills in excess of what is expected represent missed 
doses [45]. This measure has shown moderate correlations with viral load but its sensitivity is 
compromised by patient’s "pill dumping" that leads to an overestimation of adherence. Other 
factors that limit the use of pill count in clinical practice are the inability to define a start date 
for the prescription or to correctly count medication when the patient uses multiple pill 
containers, as well as the lack of time during the clinical appointment to perform this 
assessment [19]. Subjects may also perceive pill counting as intrusive and suggestive of lack 
of trust in their self-reported adherence [19]. In the research setting, unannounced pill counts 
remain costly and often impractical, and the above mentioned problems are prone to happen, 
even though the bias due to pill dumping may be reduced [19,46]. Nevertheless, recent studies 
have evaluated unannounced phone-based pill count, which seems to offer an economically 
and feasible method for monitoring medication adherence, providing estimates that are 
associated to patient viral load [46,47]. 
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Biological assays and Therapeutic Drug Monitoring 
Biological assays are direct ways of measuring adherence to antiretroviral therapy that may be 
feasible in clinical and research setting [19]. When performed by a quality-assured laboratory, 
monitoring of PI and NNRTI levels may be useful to minimize toxicity and adverse effects, to 
identify drug-drug interactions, or to evaluate virological failure in the absence of resistance 
in patients such as those with renal or liver impairment [15]. Nevertheless, the relevance of 
therapeutic drug monitoring (TDM) in patients’ management remains controversial, and the 
existing evidence is not enough to recommend that the drug levels should be checked in all 
patients who use antiretrovirals [15, 48]. Thus, although low drug levels have been associated 
with virological failure, a recent review shown that the included studies were underpowered 
to show outcomes of TDM compared with standard of care [19,48]. When used to assess 
adherence, TDM provide limited information: due to short half-lives of antiretroviral 
medication, it can only assess adherence for the most recent doses taken and white-
compliance may occur [19, 49 ]. The evaluation of TDM value is also constrained by 
heterogeneity of procedures for sample collection, cross-validation of analytic procedures, 
and interpretation of assay results, as well as the poor uptake of expert recommendations by 
the physicians [19,48,50]. Also, other factors besides adherence may affect drug levels, such 
as drug interactions and patient variability of pharmacokinetics parameters [48,50]. 
There are other surrogate markers being evaluated, although with limited use in clinical 
practice [51]. An increased mean corpuscular volume has been associated with zidovudine 
and stavudine treatment [51, 52]. One study identified an association between serum lactate 
levels with viral suppression in children receiving NRTI or PI, suggesting that elevated lactate 
levels may be useful in evaluating adherence [53]. Recently, antiretroviral concentrations in 
hair samples were associated to virological outcomes and presented as a patient-friendly 
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method to be used in the identification of subjects in need of adherence’ interventions or 
resistance testing, in poor-resource settings [54,55]. 
 
Electronic Drug Monitoring 
Prescription refills and electronic monitoring systems relay on patients’ having medication 
and actually taking it. Electronic monitoring has been considered by some authors as the gold 
standard method, associated with virological outcomes and presenting a high sensitivity in the 
estimate of non-adherence [28,29,56]. Another advantage is its ability to examine patterns of 
adherence over time and dose-interval adherence [45,57,58]. In fact, a recent study showed 
that a mean dose-timing error ≤ 3hours over a one-month period was independently 
associated with viral suppression, and this time precision is only possible with a continuous 
measurement of medication intake [5]. It also seems more feasible when compared to 
unannounced pill counts, and with a moderate correlation with self-report estimates [59, 60]. 
The ‘electronic medication event monitoring’ is obtained by incorporating micro-circuitry 
into pharmaceutical packages (for instance, a bottle), such that the manoeuvres needed to 
remove a dose of drug are detected, time-recorded, analysed, stored and communicated to the 
appropriate caregiver. In this way, it is assumed that each opening corresponds to a dose 
intake and average adherence is determined by dividing the number of time-appropriate 
openings by the number of expected doses over the study period [29]. 
However, this method presents potential limitations at methodological and feasibility levels, 
besides its high costs [19]. Underestimates of medication adherence may result from 
inappropriate use of the device or “pocket dosing”, e.g., the act of removing more than one 
dose for each bottle opening and pocketing the extra doses to ingest at a later time [61]. 
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Overestimates of adherence may result from “curiosity opening”, e.g., opening the monitored 
pill bottle without removing any pills. Other sources of measurement error are being unable to 
assess adherence to more than one prescribed antiretroviral, as well as the number of pills 
withdrawn at each opening [61]. Studies on electronic monitoring have also shown that pill 
box users are more reluctant to travel with this device, and that some subjects felt 
uncomfortable using it in front of others, perceptions that may lead to a biased estimate of 
adherence [19,62]. 
Another important feature of electronic monitoring is that it seems to promote an 
improvement in patient adherence in the first months of assessment, suggesting that a  
short-term electronic monitoring period is insufficient to obtain valid data [63, 64]. 
Other factors that can affect validity of electronic monitoring data are related to the optimal 
interval between adherence data downloads, to the HAART discontinuation by the physician 
and to the inclusion of periods of time when a subject is not responsible for his or her 
medication taking (e.g., hospitalizations, incarceration, drug treatment programs). Based in a 
predefined and clear algorithm, it is possible to adjust electronic monitoring data based on 
additional patient information [65]. 
 
Pharmacy Refills 
Pharmacy data have been used to assess adherence for several chronic treatments [66]. The 
use of pharmacy refill counts to assess medication adherence has been increasing, due to the 
availability of accurate data in a less expensive way than previous measures [ 67 , 68 ]. 
Considering that data is easily obtainable from electronic records without additional efforts 
from the subjects, it is possible to perform retrospective assessments of patient adherence, 
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namely in those settings where an evaluation method was not early defined [69]. It also 
provides objective estimates on account of being less susceptible to patient recall or social 
desirability bias, which are disadvantages of self-reports [66]. 
Pharmacy refill provides assessment of medication possession, based on refill dates and on 
the number of doses that were provided to the patient [68]. The evaluation of patient 
adherence assumes that patient will use a given drug starting the day of prescription refill, as 
prescribed and until medication runs-over [68]. On the other hand, if a subject does not 
receive timely refills, it is assumed that he is missing doses or not taking the medication 
during this period of time. This premise may be invalid if patients are obtaining medication in 
free samples, family and friends or from other pharmacies [19,70]. 
Nevertheless, the relationship between antiretroviral adherence and HIV-related clinical 
outcomes was mainly established with the results of large pharmacy refill studies [19, 66]. In 
1999, Maher et al. showed that patients who consistently refill antiretroviral prescription for 
longer than 4 months, were significantly more likely to achieve viral suppression and better 
immunological outcomes than were less-adherent patients [71]. Pharmacy refill measures 
were also associated with viral load and CD4 cell count [7, 72], as well as with the risk of 
drug resistance and progression to AIDS and death in several studies [8, 9]. In fact, Low-Beer 
et al. (2000) found a significant dose-response relationship between adherence to PIs and 
virological failure, in which 84% of the subjects showing pharmacy adherence ≥95% had 
undetectable viral load whereas only 64% of those with adherence between 90% and <95% 
achieved this clinical outcome [72]. In the same year, Paterson et al. (2000) presented a 
similar study based on electronic monitoring, with similar results [14]. 
Other studies with assessment of adherence through pharmacy refills have shown different 
impact in viral load and drug resistances according to individual drug classes. Nachega et al. 
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(2007) have observed that, for NNRTI-based regimens, virological outcomes improved with 
lower adherence levels (beyond 50%) than the one defined for PI-based regimens [73]. 
Regarding drug resistance, Tam et al. (2008) described that cumulative resistance among PIs 
and NRTIs showed a weaker adherence-resistance relationship, compared to lamivudine and 
NNRTIs [74, 75]. 
Even though most of the studies that have used pharmacy refill data have been conducted in 
developed countries, there is now some evidence that this method may also be feasible and 
valid in developing world [66]. A recent study conducted in Côte d’Ivoire showed a 
pharmacy-measure of adherence to be strongly associated with virological outcomes, thus 
recommending its use at month 6 of follow-up, to identify patients who might benefit from 
interventions to reinforce adherence [76]. Other studies have also demonstrated that refill 
adherence estimates were associated to CD4 cell counts and were accurate for detecting 
virological failure, in patients receiving HAART from countries in southern Africa, thus 
recommending the inclusion of adherence-based monitoring approach in poor-resource 
settings [77, 78]. 
 
Several measures and definitions of adherence have been described in studies conducted using 
automated pharmacy databases (Table I.2.3), with differences that would be expected to make 
the comparison of results difficult [79].  Some methods assess the duration or continuation of 
drug refills while others assess the sufficient amount or timely refill of medication within a 
period of consecutive refills [80]. The “anniversary model” and “minimum-refills model” are 
two simple and rough estimates of patient adherence that follow the first approach. The 
anniversary model classifies a subject as adherent based on having or not one refill at the end 
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of the study period. The minimum-refills model assesses if a specified number of 
prescriptions is refilled during the study period [81].  
 
Table I.2.3. Adherence measures reported in studies with pharmacy refills [68,79,80] 
Measure Formula Value Type 
CMA  
Continuous Measure of 
Medication Acquisition 
 cumulative days’ supply of 
medication obtained / total days to 
next fill or to end of observation 
period  
 adherence value for 
cumulative time 
period 
 medication 
availability 
CMG  
Continuous Measure of 
Medication Gaps 
 total days of medication gaps / total 
days to next fill or end of 
observation period 
 non-adherence value 
for cumulative 
period, censored at 
zero 
 based upon 
medication 
gaps 
CMOS  
Continuous Multiple Interval 
Measure of Oversupply 
 (total days of medication gaps - 
leftovers) / total days in 
observation period 
 non-adherence value 
for cumulative 
period, allowing for 
leftovers 
 based upon 
medication 
gaps 
CR 
Compliance Ratio 
 (total days supplied – last days’ 
supply) / (last claim date-first claim 
date) x100 
 adherence value for 
period between fills 
 medication 
availability 
CSA 
Continuous, Single interval 
measure of medication 
Acquisition 
 days’ supply obtained at beginning 
of interval / days in interval 
 adherence value for 
interval of study 
participation 
 medication 
availability 
DBR 
Days Between fills adherence 
Rate 
 1 – {[(last claim date – first claim 
date) – total days’ supply] / (last 
claim date – first claim date)} x100 
 overall adherence 
percentage 
 refill 
adherence 
MPR 
Medication Possession Ratio 
 days’ supply / days in period  ratio of medication 
available 
 medication 
availability 
MPRm 
Medication Possession Ratio, 
modified 
 [total days supplied/(last claim 
date-first claim date + last days’ 
supply)] x100 
 adherence 
percentage, adjusted 
to include final refill 
period 
 medication 
availability 
MRA 
Medication Refill Adherence 
 (total days’ supply/total number of 
days evaluated) x100 
 overall adherence 
percentage 
 medication 
availability 
PDC 
Proportion of Days Covered 
 (total days’ supply/total number of 
days evaluated) x100, capped at 1.0 
 percentage of days 
with medication 
available 
 medication 
availability 
RCR 
Refill Compliance Rate 
 [sum of quantity dispensed over 
interval / quantity to be taken per 
day) x100] / number of days in 
interval between first and last refill 
 overall adherence 
percentage 
 medication 
availability 
GAP 
 
 total days of the maximum 
medication gap / total days in 
observation period 
 non-adherence value 
for cumulative period 
 based upon 
medication 
gaps 
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When considering the amount of medication provided to the patient, it is possible to evaluate 
medication availability (e.g. through the use of continuity measures) or potential medication 
gaps (e.g. discontinuity measures), in single or multiple time periods [68, 79, 80]. The 
comparison of these approaches in the assessment of adherence to HAART is not clear but 
equivalent results were shown in other chronic medication [68,80]. Thus, the choice of a 
specific measure should consider its potential advantages and limitations, as well as the 
overall goals and definitions of the study [79].  Furthermore, there are other questions to be 
addressed when defining how to measure adherence to HAART using refill measures, 
namely, whether to include or not leftover medications, to compare pharmacy refill data with 
prescribed treatment time, and whether to use an index drug, the lowest adherence percentage 
among the individual drugs in the regimen or to calculate the regimen average adherence [67]. 
Additionally, it is also relevant to define how to control bias due to patients receiving 
medication from other sources and if it is feasible to collect adherence data when patients may 
use multiple pharmacies [67].  
 
More recently, pharmacy-based measures are being reviewed to account for the assessment of 
the dynamics of adherence and for the earlier identification of non-adherence in shorter 
periods of time. Gross et al. (2006) proposed a time-to-refill approach, by measuring 
adherence in each patient, across multiple prescription intervals, and found this time-updated 
measure of adherence was associated with viral suppression [66, 82]. This approach was 
recently used to assess the impact of including or not leftovers in the adherence estimates, a 
study that showed that 43% of the subjects were misclassified as non-adherent when 
disregarding leftover medication [67]. Both studies used a prescription interval of at least 
three monthly refills. Shorter intervals might allow more rapid detection of non-adherence in 
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clinical practice but if intervals are too short, they might overestimate this problem because 
few missed doses may decrease adherence below the defined thresholds, leading to useless 
interventions [66,83]. Acri et al. (2010) found that pharmacy refill adherence over 60-day and 
30-day periods were significantly associated with virological outcomes and with 90-day 
adherence if these periods started at least 90 days before the measure of viral load, a finding 
that suggest that upstream measures of adherence are better predictors of virological outcome 
than adherence measured more proximally of the viral load assessment. [83]. 
 
The comparison of pharmacy-based adherence with other measures is needed. Refill 
adherence was compared to a 4-day recall self-report measure, and presented a higher 
sensitivity to non-adherence [66, 69]. On the other hand, a recent study with retrospective 
pharmacy data and electronic monitoring reveal a lack of association between both measures 
[84]. The small sample size and limitations on data availability could affect the validity of 
these results. Further studies are required, to reassess the relation between pharmacy refills 
and electronic monitoring, as well as to evaluate its predictive value of virological failure in 
both treatment naïve and experienced subjects receiving different HAART regimens [85]. 
 
Composite Measures and other approaches 
It is usually recommended to use more than a single strategy, since “a multi-method approach 
that combines feasible self-reporting and reasonable objective measures is the current state-
of- the-art in measurement of adherence behaviour” [17, 18].  
In fact, it has been shown that pharmacy refill and pill count measures result in lower 
estimates of adherence than those self-reported and higher than those obtained from electronic 
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monitoring, which indicates a measurement error associated to each measure, and that a best 
method includes multiple measures [19, 51]. 
Composite measures may be obtained in two approaches, through the combination of 
information from different adherence measures or through the inclusion of adherence 
determinants in the final estimate. 
Liu et al. (2001) proposed a first composite adherence score, which is based on an algorithm 
among different measures (Figure I.2.2) [45].  
 
Figure I.2.2. Algorithm for calculating composite adherence score (CAS) [45]. 
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In this model, adherence assessment is first based in electronic monitoring data that may be 
substituted for pill counts or self-reported data in a third option. When compared to individual 
measures, this composite score showed the strongest predictive relationship with viral load 
[45]. However, this measure relies primarily on electronically measured adherence, and 
minimal additional data from pill counts or patient interviews will be integrated if adherence 
data from electronic monitors is nearly complete, besides the high costs related to electronic 
devices [86]. 
More recently, it has been proposed that periods of non-adherence can be identified 
retrospectively based on the relationship between changes in viral load and mutation. 
However, the combination of these two clinical parameters was not compared to other 
adherence measures and access to and costs of sequencing limit its application in clinical 
setting [87]. 
 
Other studies aimed to improve the sensitivity of self-reported measures to detect non-
adherence, by the use of calibration models adjusted by self-reported attitudinal measures 
[ 88 ]. Calibration models have been used to improve the accuracy and precision of 
measurement. Liu et al. used those models predicting electronic monitoring measured 
adherence to test whether multiple attitudinal measures corrected the bias from self-reported 
adherence, and propose a model including self-reported adherence and whether the patient 
were able to take medication according to the healthcare provider instructions [88]. Similar 
results were also found in another study, in which questions about psychosocial, clinical and 
environmental characteristics associated with poor adherence were combined, resulting in a 
composite score that had a sensitivity of 71% for detecting non-adherence [19, 89]. 
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Modelling and statistical approaches have also been useful in evaluating the impact of 
adherence on the estimated exposure-response relationship and in addressing the challenges 
of confounding and measurement error which arise in the clinical trials context [90]. Although 
the calibration approach was mainly explored for categorical measures of adherence retrieved 
from self-reported measures, modelling may be applied to pharmacy refills data, in order to 
assess compliance and persistence [90]. For instance, longitudinal Markov models combined 
with clustering techniques can be used to describe patterns of patient adherence, to assess its 
determinants, and to predict the future event and progression to AIDS [90, 91]. 
 
Composite measures may improve the accuracy of adherence measurement but are still 
difficult to implement in clinical setting, and more practical measurement methods are needed 
[19, 45]. Furthermore, the research setting also requires additional data on ways to combine 
measures, including how many measures and time points to combine [19].  
 
 Assessing Factors associated to Non-adherence 
Four types of factors associated to patient adherence are usually described (Figure I.2.3): 
social and psychological characteristics of the patient, regimen characteristics, patient-
provider relationship and clinical setting, and HIV infection related factors [18, 92]. Table 
I.2.4 describes potential factors related to patient adherence to antiretroviral drugs [18]. 
The association between adherence and demographic characteristics remains unclear  
[18, 93]. Nevertheless, some variables have been frequently described as predictors of non-
adherence, namely female sex, younger age, and lower educational and literacy level [18, 92]. 
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The association between adherence and ethnicity is unclear [18]. Some studies have shown 
that black ethnicity was associated to non-adherence but confounding by socioeconomic 
status may be present [94], since this association was not reported in other studies from 
countries were access to health care and antiretroviral treatment is free [95].  
 
 
Figure I.2.3. The five dimensions of adherence, proposed by WHO (reprinted from [18]). 
 
Among patient-related variables, factors such as being an injection drug user and active 
substance abuse were other variables found to be associated to non-adherence, as well as lack 
of social support, depression and stress [18, 96] . On the other hand, patients’ knowledge and 
beliefs about disease and medication can also affect adherence. For instance, lower perceived 
effectiveness of medication and concerns that taking it might lead to disclosure of the 
subject’s HIV condition were associated with poor adherence to treatment [92,97]. 
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Table I.2.4. Potential factors affecting adherence to HAART, and interventions (adapted from [18, 98]). 
 Factors affecting adherence Interventions to improve adherence 
Socioeconomic-related 
factors 
(–) 
 women: stress of childcare 
 low income 
 lack of social support 
(+) 
 support of family and friends 
 family preparedness 
 support of community-based organizations 
 intensive education on use of medicines for 
patients with low levels of literacy 
 assessment of social needs 
Patient-related factors (–) 
 forgetfulness 
 life stress 
 alcohol use 
 drug use 
 depression 
 hopelessness and negative feelings 
 negative beliefs about disease and 
medication 
(+) 
 positive beliefs regarding the efficacy 
of antiretroviral medication 
 patients’ belief in their ability to take 
medication as prescribed (self-efficacy) 
 monitoring drug and/or alcohol use 
 psychiatric consultation 
 behavioural and motivational intervention 
 counselling/psychotherapy 
 telephone counselling 
 memory aids and reminders 
 self-management of disease and treatment 
Condition-related factors (–) 
 asymptomatic patients 
  
(+)  
 symptomatic patients 
 understanding the relationship between 
adherence and viral load 
 education on use of medicines 
 supportive medical consultation 
 screening for comorbidities 
 attention to mental illness, as well as abuse of 
alcohol and other drugs 
Therapy-related factors (–) 
 complex regimens, pill burden 
 close monitoring 
 severe lifestyle alterations due to 
medication 
 adverse effects of treatment 
 (+) 
 less frequent dose, fewer pills per day 
 fewer dietary restrictions 
 fitting medication to individual’s 
lifestyle 
 simplification of regimens 
 education on use of medicines / adherence 
 patient-tailored prescriptions 
 medications for symptoms 
 assessment and management of side-effects 
 continuous monitoring and reassessment of 
treatment 
Health care team / 
Health system-related 
factors 
(–)  
 lack of clear instructions from health 
professionals 
 poor implementation of educational 
interventions 
 dissatisfaction with past experience of 
healthcare system, leading to avoidance 
(+) 
 good patient-physician relationship  
 support of nurses and pharmacists 
 promote a good patient–physician relationship 
 multidisciplinary care 
 training of health professionals on adherence 
education and monitoring 
 training caregivers 
 identification of the treatment goals and 
strategies to meet them 
 shared-management of HIV/AIDS infection 
 ready availability of information 
 regular consultations with nurses/physicians 
 non-judgmental attitude and assistance 
 rational selection of medications 
(+) factors having a positive effect on adherence; (–) factors having a negative effect on adherence. 
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The relationship with healthcare providers is also pointed out as a determinant of patient’s 
non-adherence to antiretroviral treatment [18, 98, 99]. This relationship may be strengthened 
when patient perceives the healthcare provider as competent, with clear and open 
communication, showing compassion and willingness to include patients in treatment 
decisions, among other characteristics [98]. On the other hand, some identified barriers to 
physicians’ communication with HIV-positive patients include lack of time, resources, which 
may affect patient adherence to treatment [100]. Promoting multidisciplinary adherence teams 
and training of providers in adherence counselling techniques are other healthcare-related 
factors that may lead to improved patient adherence [18, 96, 101]. 
 
Several studies had shown that complexity of treatment and drug side-effects are factors 
negatively associated with adherence [18, 92]. It is recognized that HAART regimens had 
evolved from multiple drugs to nowadays once-daily and more potent regimens [4, 102]. A 
recent meta-analysis showed that adherence was modestly higher with once-daily regimens 
than with twice-daily regimens, while other studies not included also showed higher 
adherence among subjects receiving once-daily regimens [102, 103]. Even though some 
questions remain about the impact of once-daily regimens on adherence to HAART, simpler 
regimens are recommended and physicians should evaluate if switching to an equally 
effective regimen with fewer drugs or lower pill burden will improve patient adherence and 
treatment outcomes [15, 18]. 
Adverse effects are still frequent among the available antiretroviral drugs, even for newer 
options [102]. Patients may experience several problems, ranging from transient problems, 
mainly gastrointestinal effects such as diarrhoea and nausea, to longer-lasting effects such as 
lipodystrophy and neuropathy [18, 102]. Adverse effects that occur early during the treatment 
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were identified as the main reason for drug switches in the first year of HAART, and strong 
predictors of non-adherence [18]. On the other hand, lipodystrophy is a frequent problem 
among subjects on HAART and its physical manifestations may lead patients to abandon 
treatment [18]. Hence, guidelines recommend switching antiretroviral drugs when adverse 
effects occur, to prevent non-adherence and emergence of drug resistance [15].  
 
In summary, patient adherence to antiretroviral treatment is a main determinant of its success 
and high levels are required to avoid drug resistances. We have described several factors that 
are known to influence adherence, which depends on both psychosocial conditions and 
treatment-related characteristics. 
Patient-tailored interventions and regimens with improved tolerance are required to improve 
long-term outcomes for those HIV-infected subjects at risk of adherence failure [96]. Due to 
the impact of clinical context and healthcare system in adherence, evaluating adherence and 
its determinants and how to define goals in a given setting may enable the design of more 
effective interventions [4]. 
 
References 
                                                 
1. Gulick RM: Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006,43(7): 
942-944. 
2. Lucas G.M., Wu AW, Cheever LW: Adherence to antiretroviral therapy: An update of current concepts. 
Curr HIV/AIDS Rep 2004, 1(4):172-180. 
3 . Thompson M: Challenges of improving adherence to HIV therapy. Am Fam Physician  
2011, 83(4):375, 379. 
 61 
                                                                                                                                                        
4. Conway B: The role of adherence to antiretroviral therapy in the management of HIV infection. J 
Acquir Immune Defic Syndr 2007, 45(Suppl 1): S14-S18. 
5. Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, Kaplan AH. Repeated measures longitudinal 
analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, 
and other factors. J Acquir Immune Defic Syndr 2006, 41(3):315-322. 
6. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active 
antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. 
Clin Infect Dis 2001, 33:700–705. 
7. Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS. The impact of adherence on 
CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:261–268. 
8. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, 
Alexander CS, Montaner JS. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive 
cohort initiating triple antiretroviral therapy. J Infect Dis 2005,191(3):339-347. 
9. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS. Intermittent use of 
triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 
 2002, 16(7):1051-1058. 
10. Garcia de OP, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and 
highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 
2002, 30:105–110. 
11. Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ. The association of adherence to 
antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health 
Policy 2008, 6(2-3):145-155. 
12 . Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. 
Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 2010, 152(1):18-25. 
13. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public 
health approach – 2006 revision. World Health Organization; 2006. 
 62 
                                                                                                                                                        
14. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to 
protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133(1): 
21-30. 
15. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can 
lead to viral suppression. Clin Infect Dis 2006, 43:939-941. 
16. Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. Intermediate highly active 
antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance 
mutations. J Acquir Immune Defic Syndr 2008, 47(3):397-399. 
17. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, Warren MR, Vejo J: Adherence to 
Highly Active Antiretroviral Therapy (HAART): a meta-analysis. AIDS and behavior 2011. 
18. Sabaté E, ed: Adherence to long-term therapies: evidence for action. World Health Organization; 2003. 
19. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J 
Acquir Immune Defic Syndr 2006, 43 Suppl 1:S79-87. 
20. Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadeg H, Gitau L, Ntaganira J, Balikuddembe R, Chalker J, 
Wagner AK; INRUD IAA. Measuring adherence to antiretroviral treatment in resource-poor settings: the 
clinical validity of key indicators. BMC Health Serv Res 2010, 10:42. 
21 . Ventura A. Adesão à terapêutica anti-retrovírica na infecção VIH/SIDA. Arq Medicina  
2006, 20(1-2): 37-49. 
22. Haynes RB, Taylor DW, Sackett DL, eds: Compliance in health care. Baltimore: Johns Hopkins University 
Press, 1979. 
23 . Menckeberg T: Adherence to Inhaled Corticosteroids and Patient Perception: towards a better 
understanding and individualized care. PhD thesis. Utrecht University; 2008. 
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005, 353(5):487-497. 
25.  De las Cuevas C. Towards a clarification of terminology in medicine taking behavior: compliance, 
adherence and concordance are related although different terms with different uses. Curr Clin Pharmacol 
2011, 6(2):74-77. 
 63 
                                                                                                                                                        
26. Clucas C, Harding R, Lampe FC, Anderson J, Date HL, Johnson M, Edwards S, Fisher M, Sherr L. Doctor-
patient concordance during HIV treatment switching decision-making. HIV Med 2011, 12(2):87-96. 
27. Norton WE, Amico KR, Fisher WA, Shuper PA, Ferrer RA, Cornman DH, Trayling CA, Redding C, Fisher 
JD. Information-motivation-behavioral skills barriers associated with intentional versus unintentional 
ARV nonadherence behavior among HIV+ patients in clinical care. AIDS Care 2010, 22(8):979-987. 
28. Urquhart J. Variable Compliance and Persistence with Prescribed Drug Dosing Regimens. in Strom’s 
Pharmacoepidemiology, 4th Edition 2005 
29 . Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J 
Antimicrob Chemother 2005, 55(5):616-627.  
30 . Vrijens B. Presentation of draft ABC proposal on taxonomy and terminology. Presentation. 
ESPACOMP, Bangor UK, 2009, in www.espacomp.eu.  
31. Zachariah R, Harries AD, Manzi M, Gomani P, Teck R, Phillips M, Firmenich P. Acceptance of anti-
retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and 
associated with cost of transport. PLoS One 2006;1:e121. 
32. McGrath N, Glynn JR, Saul J, Kranzer K, Jahn A, Mwaungulu F, Ngwira MH, Mvula H, Munthali F, 
Mwinuka V, Mwaungulu L, Fine PE, Crampin AC. What happens to ART-eligible patients who do not start 
ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi. BMC Public 
Health 2010, 10:601. 
33. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a 
review of the literature and implications for future clinical care and research. AIDS 2011, 25(3):279-290. 
34. Ostrop NJ, Gill MJ. Antiretroviral medication adherence and persistence with respect to adherence tool 
usage. AIDS Patient Care STDS 2000, 14(7):351-358. 
35. Knobel H, Urbina O, Gonzalez A, Sorli ML, Montero M, Carmona A, Guelar A. Impact of different 
patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-
term follow-up. HIV Med 2009, 10:364–369.  
 64 
                                                                                                                                                        
36. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC. 
Response to antiretroviral therapy in HIVinfected patients attending a public, urban clinic in Kampala, 
Uganda. Clin Infect Dis 2006, 42:252–259. 
37. Kavasery R, Galai N, Astemborski J, Lucas GM, Celentano DD, Kirk GD, Mehta SH. Non-structured 
treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr  
2009, 50:360–366. 
38. Vrijens B. European strategies to improve the use of medicines. Presentation#1281. European Society of 
Cardiology Congress, Paris France, 2011. available in http://spo.escardio.org/eslides/  
39. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials 
and clinical practice. Clin Ther 1999, 21(6):1074-1090. 
40 . Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of 
antiretroviral therapy adherence: A review with recommendations for HIV research and clinical 
management. AIDS Behav 2006, 10(3):227-45. 
41. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and 
virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr 2005, 38(4):445–448. 
42. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: 
is the glass half full or half empty? Curr HIV/AIDS Rep 2009, 6(4):177-186. 
43 . Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, Moss A. Provider 
assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 26(5):435-442. 
44. Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, Ma Y, Kaplan AH, Wenger NS. How well do 
clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med  
2002, 17(1):1-11. 
45. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan 
AH, Wenger NS. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann 
Intern Med 2001, 134(10):968–977. 
 65 
                                                                                                                                                        
46. Kalichman SC, Amaral CM, Stearns H, White D, Flanagan J, Pope H, Cherry C, Cain D, Eaton L, 
Kalichman MO. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by 
telephone. J Gen Intern Med 2007, 22(7):1003-1006. 
47. Kalichman SC, Amaral CM, Cherry C, Flanagan J, Pope H, Eaton L, Kalichman MO, Cain D, Detorio M, 
Caliendo A, Schinazi RF. Monitoring medication adherence by unannounced pill counts conducted by 
telephone: reliability and criterion-related validity. HIV Clin Trials 2008, 9(5):298-308. 
48. Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for 
people with HIV. Cochrane Database Syst Rev 2009, (3):CD007268. 
49. Jani AA, ed: Adherence to HIV treatment regimens: recommendations for best practices. APHA 2004, 
in http://www.apha.org/programs/resources/HIV+-+AIDS/reshivregimens.htm. 
50. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res 
Hum Retroviruses 2002, 18(12):825–834. 
51. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir 
Immune Defic Syndr 2002, 31 Suppl 3:S103-106. 
52. Steele RH, Keogh GL, Quin J, Fernando SL, Stojkova V. Mean cell volume (MCV) changes in HIV-
positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for 
adherence. Int J STD AIDS 2002, 13(11):748-754. 
53. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral 
therapy. AIDS 2003, 17(10):1565-1568. 
54. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen MH, Sharp 
GB, Huang Y, Greenblatt RM. Atazanavir concentration in hair is the strongest predictor of outcomes on 
antiretroviral therapy. Clin Infect Dis 2011, 52(10):1267-1275. 
55. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, 
van der Merwe L, Gandhi M, Maartens G. Low lopinavir plasma or hair concentrations explain second-line 
protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011, 56(4):333-339. 
56. Deschamps AE, Graeve VD, van Wijngaerden E, De Saar V, Vandamme AM, van Vaerenbergh K, Ceunen 
H, Bobbaers H, Peetermans WE, de Vleeschouwer PJ, de Geest S. Prevalence and correlates of nonadherence 
 66 
                                                                                                                                                        
to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. 
AIDS Patient Care STDS 2004,18(11):644–657. 
57. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, 
Howard AA, Schoenbaum EE. Antiretroviral therapy adherence and viral suppression in HIV-infected 
drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001,33(8):1417-1423. 
58. McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of adherence to antiretroviral medications: the 
value of electronic monitoring. AIDS 2003,17(12):1763–1767. 
59. Haberer JE, Robbins GK, Ybarra M, Monk A, Ragland K, Weiser SD, Johnson MO, Bangsberg DR. Real-
Time Electronic Adherence Monitoring is Feasible, Comparable to Unannounced Pill Counts, and 
Acceptable. AIDS Behav 2011. [Epub ahead of print] 
60. Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates 
measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes  
2010, 8:99. 
61. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic monitoring 
devices to measure antiretroviral adherence: practical considerations. AIDS Behav 2005, 9(1):103-110. 
62. Schoenthaler A, Ogedegbe G. Patients' perceptions of electronic monitoring devices affect medication 
adherence in hypertensive African Americans. Ann Pharmacother 2008,  42(5):647-652. 
63 . Wetzels GE, Nelemans PJ, Schouten JS, van Wijk BL, Prins MH. All that glisters is not gold: a 
comparison of electronic monitoring versus filled prescriptions--an observational study. BMC Health Serv 
Res 2006, 6:8. 
64. Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, Vandamme AM. Use of electronic 
monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr 2006, 
43(2):247-248. 
65 . Fennie KP, Bova CA, Williams AB. Adjusting and censoring electronic monitoring device data. 
Implications for study outcomes. J Acquir Immune Defic Syndr 2006, 43 Suppl 1:S88-95. 
66. Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr 
HIV/AIDS Rep 2007, 4(4):187-191. 
 67 
                                                                                                                                                        
67. de Boer IM, Prins JM, Sprangers MA, Nieuwkerk PT. Using different calculations of pharmacy refill 
adherence to predict virological failure among HIV-infected patients. J Acquir Immune Defic Syndr 2010, 
55(5):635-40. 
68. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative 
databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40: 
1280-1288. 
69. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence 
predicted changes in viral load in HIV. J Clin Epidemiol 2004, 57(10):1107-1110. 
70. Steiner  JF, Prochazka  AV. The assessment of refill compliance using pharmacy records: methods, 
validity, and applications. J Clin Epidemiol 1997, 50(1):105-116. 
71. Maher K, Klimas N, Fletcher MA, Cohen V, Maggio CM, Triplett J, Valenzuela R, Dickinson G. Disease 
progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban 
Veterans Affairs Medical Center. J Acquir Immune Defic Syndr 1999, 22(4):358-363. 
72. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral 
load response. J Acquir Immune Defic Syndr 2000, 23(4):360-361. 
73 . Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to 
nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 
2007, 146(8):564-573. 
74. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, Hogg RS, Harrigan PR. The relationship 
between resistance and adherence in drug-naive individuals initiating HAART is specific to individual 
drug classes. J Acquir Immune Defic Syndr 2008, 49(3):266-271.  
75. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence 
and the development of class-specific antiretroviral resistance. AIDS 2009, 23(9):1035-1046. 
76. Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux 
C, Freedberg KA, Anglaret X. Association between medication possession ratio, virologic failure and drug 
resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr 
2011, 56(4):356-64. 
 68 
                                                                                                                                                        
77. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, Nachega JB. 
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on 
antiretroviral therapy. PLoS Med 2008, 5(5):e109. 
78. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, Morris L, Ekström AM. Adherence 
to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients 
on first-line ART in South Africa. PLoS One 2011, 6(3):e17518. 
79. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and 
persistence using automated databases. Pharmacoepidemiol Drug Saf  2006, 15(8):565-574. 
80. Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication 
refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009, 18(2):159-165. 
81. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with 
drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther 2006, 
28(9):1411-1424. 
82. Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, Harrigan PR, Bangsberg DR, Montaner JS, Hogg RS. 
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 
suppression. J Infect Dis 2006, 194(8):1108-1114. 
83. Acri TL, Grossberg RM, Gross R. How long is the right interval for assessing antiretroviral pharmacy 
refill adherence? J Acquir Immune Defic Syndr 2010, 54(5):e16-8. 
84. Acri T, TenHave TR, Chapman JC, Bogner HR, Gross R. Lack of association between retrospectively 
collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. AIDS Behav 
2010, 14(4):748-754. 
85. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke CA, Lewin SR, Elliott JH. Pharmacy 
adherence measures to assess adherence to antiretroviral therapy: review of the literature and 
implications for treatment monitoring. Clin Infect Dis 2011, 52(4):493-506. 
86. Turner BJ, Hecht FM. Measuring patient adherence. Ann Intern Med 2002, 137(1):72-3; reply 72-3. 
87. Thompson IR, Bidgood P, Petróczi A, Denholm-Price JC, Fielder MD; EuResist Network Study Group. An 
alternative methodology for the prediction of adherence to anti HIV treatment. AIDS Res Ther 2009;6:9 
 69 
                                                                                                                                                        
88. Liu H, Miller LG, Hays RD, Wagner G, Golin CE, Hu W, Kahn K, Haubrich R, Kaplan AH, Wenger NS: A 
practical method to calibrate self-reported adherence to antiretroviral therapy. J Acquired Immune Defic 
Syndr 2006, 43(Suppl 1): S104-S112 
89. Wilson KJ, Doxanakis A, Fairley CK. Predictors for non-adherence to antiretroviral therapy. Sex Health 
2004, 1(4):251-257. 
90. Kenna LA, Labbé L, Barrett JS, Pfister M. Modeling and simulation of adherence: approaches and 
applications in therapeutics. AAPS J 2005, 7(2):E390-407. 
91. Kiwuwa-Muyingo S, Oja H, Walker SA, Ilmonen P, Levin J, Todd J. Clustering based on adherence data. 
Epidemiol Perspect Innov 2011;8:3. 
92. Cambiano V, Lampe FC, Rodger AJ, Smith CJ, Geretti AM, Lodwick RK, Puradiredja DI, Johnson M, 
Swaden L, Phillips AN. Long-term trends in adherence to antiretroviral therapy from start of HAART. 
AIDS 2010, 24(8):1153-1162. 
93. Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, Nakashima AK: Patient and regimen 
characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One 2007, 
2(6):e552. 
94. Silverberg MJ, Leyden W, Quesenberry CP Jr, Horberg MA. Race/ethnicity and risk of AIDS and death 
among HIV-infected patients with access to care. J Gen Intern Med 2009; 24(9):1065-72. 
95. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT, Obel N. The effect 
of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency 
virus type 1-infected patients. Clin Infect Dis 2002; 35(12):1541-8. 
96. Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chêne G, 
Spire B. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up 
analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir 
Immune Defic Syndr 2006; 41(4):477-85. 
97 . Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW; Patient Care 
Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group 
 70 
                                                                                                                                                        
(AACTG). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: 
the AACTG adherence instruments. AIDS Care 2000; 12(3):255-66. 
98. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl 
2:S171-6. 
99. Johnson MO, Chesney MA, Goldstein RB, Remien RH, Catz S, Gore-Felton C, Charlebois E, Morin SF; 
NIMH Healthy Living Project Team. Positive provider interactions, adherence self-efficacy, and adherence 
to antiretroviral medications among HIV-infected adults: A mediation model. AIDS Patient Care STDS 
2006; 20(4):258-68. 
100. Barfod TS, Hecht FM, Rubow C, Gerstoft J. Physicians' communication with patients about adherence 
to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory. BMC 
Health Serv Res 2006; 6:154. 
101. Wilson IB, Laws MB, Safren SA, Lee Y, Lu M, Coady W, Skolnik PR, Rogers WH. Provider-focused 
intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence 
in persons with HIV. J Acquir Immune Defic Syndr; 53(3):338-347. 
102. Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected 
adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. 
Patient Prefer Adherence 2011; 5:357-67. 
103. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral 
regimens: a meta-analysis. Clin Infect Dis 2009;48(4):484–488. 
 71 
I.3. 
Epidemiology of HIV/AIDS infection in Portugal:  
an update of disperse information 
 
 The Global and European context of the HIV/AIDS epidemics 
In recent years, the HIV infection epidemic appears to have stabilized [1]. The annual number 
of new HIV/AIDS cases reported has been declining since the late 1990s (Figure I.3.1). The 
UNAIDS estimated that 2.6 million people became newly infected with HIV during 2009. 
This figure represents a fallen by 19% since 1999 and 21% since 1997, the year in which it 
was observed the higher number of new infections worldwide. Moreover, the use of 
antiretroviral therapy over the past few years has resulted in fewer AIDS cases and AIDS-
related deaths (Figure I.3.1), which were observed earlier in the WHO health region of North 
America and Western and Central Europe (Figure I.3.2). With the reduction of the AIDS 
mortality rate, the number of people living with HIV/AIDS worldwide has increased [1]. 
At the European level, a total of 53 427 HIV/AIDS new cases were reported in 2009, by 49 
out of the 53 countries of the WHO European region, resulting in a rate of 8.5 per 100 000 
population (12.2% aged 15-24 years, 34.7% females) [2]. However, there are epidemiological 
differences regarding the HIV infection geographical distribution, among the three 
geographical areas in WHO European region (Figure I.3.3): the East European region 
reported a higher number of HIV new diagnosis with a rising trend, while the Western and 
Central European areas reported lower rates. With respect to 2009 data from 21 Western 
European countries, a total of 24 703 newly diagnosed HIV cases were reported, with a rate of 
6.7 per 100 000 population.  
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Figure I.3.1. Global HIV trends, 1990 to 2009. Dotted lines represent minimal and maximal ranges; solid lines 
represent the best estimate (reprinted from [1]) 
 
Figure I.3.2. Trend of AIDS-related deaths, in the WHO health region North America and Western and Central 
Europe; dotted lines represent minimal and maximal ranges; solid lines represent the best estimate (reprinted 
from [1]). 
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Figure I.3.3. HIV infection new diagnosis in the three geographical areas of the WHO European Region and  
the EU/EEA, over the period 2004–09 
Also in the West Europe, 40% of the HIV cases were acquired through heterosexual contact 
(n=9 960 cases). However, when cases originating from countries with generalised epidemics 
are excluded (n=3 721 cases), this proportion decreases to 25% [2]. The trends of HIV 
infection by transmission routes is identical as for the EU/EEA region, presented in Figure 
I.3.4. 
 
Figure I.3.4. Number of HIV infection cases reported by transmission route and origin in EU/EEA countries, 
over the period 2004–2009 (reprinted from [2]). 
Countries excluded (data not reported or not available): Austria, Russia, Monaco, Turkey
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Regarding AIDS cases, the 2009 data reported a total of 4 650 cases of AIDS diagnosed in 27 
EU/EEA countries (no data from Austria or Sweden), which represents a rate of 1.0 cases per 
100 000 population, higher among men (1.4 per 100 000) than women (0.5 per 100 000). The 
highest AIDS rates were reported by Latvia (4.3 per 100 000; n=96), Estonia (2.8 per 100 
000; n=38), Portugal (2.8 per 100 000; n=297), and Spain (2.3 per 100 000; n=1037) [2]. 
 
 Epidemiology of HIV/AIDS infection in Portugal 
Portugal presents one of the highest rates of new HIV cases among the countries within 
Western and Central Europe region [2]. Taking into consideration the reporting delay for 
HIV/AIDS diagnoses, the estimated 2009 rate of HIV new infections in Portugal was 15.3 per 
100 000 population, from which 463 were estimated to be AIDS cases [2]. 
 
Figure I.3.5. EU/EEA and Portuguese trends of new HIV/AIDS cases diagnosed (rate per 100 000 population), 
by year of diagnosis and over the period 2000-2009. *rates were adjusted to account for the reporting delay, 
which refers to the time between HIV/AIDS diagnosis and its report at national level [2]. 
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Figure I.3.6. EU/EEA and Portuguese trends of AIDS rates at the time of HIV/AIDS diagnosis (rate per 100 000 
population), by year of diagnosis and over the period 2000-2009. *rates were adjusted to account for the 
reporting delay, which refers to the time between HIV/AIDS diagnosis and its report at national level [2]. 
 
Alongside with a high rate of newly diagnosed infections, there are more Portuguese 
individuals living with HIV/AIDS infection nowadays. The 2010 UNAIDS Report on the 
global AIDS epidemic indicated that the 2009 adult Portuguese prevalence of HIV/AIDS 
infection was 0.6% [lower-higher estimates: 0.4-0.7] for ages between 15 and 49 years, and 
that 42 000 individuals over 15 years were living with HIV/AIDS infection [1]. This 
prevalence estimate was higher than the remaining Western and Central European countries 
and higher than the average of 0.2% for this WHO region. In fact, Portugal was the only 
western and central European country that showed an increase in HIV prevalence estimates: 
in 2001, the prevalence rate was 0.5% [0.4-0.6], while the regional mean was 0.2% [0.2-0.2] 
as in 2009. No information on HIV progression to AIDS regarding the Portuguese reality was 
found. When considering AIDS mortality, the European HIV surveillance system reports that 
0 
2 
4 
6 
8 
10 
12 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
A
ID
S
 r
a
te
 p
e
r 
1
0
0
 0
0
0
 p
o
p
u
la
ti
o
n
 
year of diagnosis 
Portugal Portugal - ajusted rate* 
EU/EEA countries EU/EEA countries - adjusted rate* 
 76 
the number of AIDS deaths in Portugal is decreasing in the period 2004-2009, as shown in 
Figure I.3.7 [1, 2]. However, we also found that the National Institute of Statistics (INE) 
reported higher absolute numbers of deaths due to HIV-related disease (Figure I.3.7) and that 
the decrease seems to be lower when compared to the one reported in the surveillance system 
[3]. 
 
Figure I.3.7. Number of AIDS-related deaths reported in Portugal, over the period from 2005 until 2009. 
 
The observed differences in the absolute numbers of AIDS-related deaths reported by each 
source may be explained by the use of different notification systems and different definitions. 
The HIV/AIDS national surveillance system, which provides data to the European 
surveillance system, is based on case notifications sent by physicians to a national centre. 
Since 2005, notification is mandatory at diagnosis and whenever there is a change in infection 
status. Deaths among confirmed AIDS cases should also be notified [4]. However, a 2009 
evaluation of the national HIV surveillance system revealed that its acceptability was 
relatively low and that reporting of deaths (as well as changes in infection status) were seen as 
problematic, which may explain the observed underreporting [4].  
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Furthermore, this evaluation also focused on timeliness of reporting and completeness of 
information, among other characteristics. Timeliness was measured in terms of number of 
days between the diagnosis as reported by the physician and reception of notification at the 
centre. From 2005 to 2008, the average delay for diagnosed cases was 168 days, with the 
majority (71%) being reported until six months after the diagnosis. For the same period and 
regarding completeness of information, 13 of 20 variables included in the analysis had no 
incompletes, while “date of death” had 90.5% incompletes, a finding which the report justifies 
as related to better care and treatment available to patients [4]. However, this may also be 
seen as an indicator of underreporting which, alongside with the reporting delay, may result in 
a smaller rate of AIDS related deaths reported by this source. 
 
The INE is responsible for the Portuguese general mortality registry, based on medical death 
certificates, also mandatory for all population. Regarding the HIV/AIDS infection, INE 
consider all deaths due to AIDS or other HIV-related disease as the underlying cause (ICD-10 
code B20-24), a broader definition than the one used in the HIV surveillance system since it 
includes deaths in non-AIDS HIV cases [5]. Thus, general mortality rates seem to be more 
accurate and useful for the assessment of HIV-related deaths than HIV surveillance data [5]. 
When considering data from Eurostat, the statistical office of the European Union, we found 
that Portugal presents a 2009 death rate due to AIDS (HIV-disease) of 5.8 per 100 000 
inhabitants, the highest among the 27 EU countries (Figure I.3.8) [6]. 
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Figure I.3.8. AIDS (HIV disease ICD10 B20-24) mortality rates in EU* in 2005 and 2009. *no 2009 data for 
Belgium, France, Italy, Cyprus, Malta. Source: Eurostat [6] 
 
The high prevalence of HIV infection and rate of AIDS newly diagnosed cases, as well as the 
high rate of HIV-related mortality, place a challenge to the Portuguese National Health 
System [7]. It reflects the need for a stronger prevention programme and early HIV detection 
strategies, but also the need for a sustainable treatment response, regarding the continuity of 
its delivery within an efficient and effective HIV/AIDS clinical management [1]. Similar to 
the reported global trends, Portuguese expenditure on HIV treatment has increased over the 
last decade [1, 4]. In fact, recent data from INFARMED showed an increase of 11.2% in the 
overall expenditure related to drugs prescribed for HIV/AIDS treatment, when comparing the 
2011 and 2010 homologous periods January-September. In the first semester of 2011, 
antiretroviral medication accounted already for near 158M€, 20.6% of the total expenditure 
with medication dispensed in Portuguese hospitals (758M€) [8]. However, it is important to 
note that this value may be underestimated due to the number of reporting hospitals. Figure 
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I.3.9 and Figure I.3.10 show the evolution of expenditure related to antiviral medication and 
individual antiretroviral drugs, based on the available data from INFARMED reports of drug 
use in Portuguese hospitals (www.infarmed.pt). Figure I.3.9 also shows the estimates reported 
by IMS Health (Portugal) and CNSida [9], higher than those reported by INFARMED. 
 
 
Figure I.3.9. Estimates of expenditures with antiviral drugs and overall hospital drugs (INFARMED), and with 
antiretroviral drugs (IMS Health and CNSida), from 2007 to September 2011. *estimates from the last available 
report from INFARMED. 
 
Figure I.3.10. Trends in expenditure (eur) with individual antiretroviral drugs or associations, over the period 
2007-2010. Source: INFARMED 
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Differences among sources might result from the different methods for collecting data. In the 
INFARMED approach, each hospital provide monthly uploads of data on drug sales and 
consumption, enabling a closer monitoring of medication consumption [10]. However, since 
hospitals might provide further data corrections, it is possible that the expenditures estimates 
presented in each report might be modified in further ones [8]. CNSida obtains its data by 
asking each hospital to fulfil an annual questionnaire, designed specifically for the HIV/AIDS 
care indicators. However, it might be biased due to refusals and to the type of hospitals that 
voluntarily collaborate. 
 
When considering the number of HIV-infected adults receiving antiretroviral treatment in 
Portugal, the available data is unclear. The UNAIDS reports that 18 107 individuals were 
receiving antiretroviral treatment in 2009, an increase of 32% when comparing to the 12 366 
individuals reported in December 2008 [1]. However, a recent national report showed a 
higher number of subjects receiving antiretroviral treatment: 22 418 individuals in 2009 [9]. 
Another national report also indicated a total number of 22 380 for the same calendar year 
[11]. Differences might be due to reporting delays, refusal rate and missing information from 
the Portuguese hospitals. Table I.3.1 shows that more hospitals have reported the number of 
subjects that were receiving antiretroviral treatment in 2009 (n=33) than for 2007 year (n=22), 
and similar differences were found for other variables. The type and dimension of the 
hospitals that have fulfilled the questionnaire are also relevant. For instance, Centro 
Hospitalar Lisboa Central did not accounted for the 2007 estimates although subjects were 
still being followed at that time: 1 223 and 1 846 subjects followed at that unit were on 
HAART in 2005 and 2009 years, respectively (Table I.3.2).  
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Table I.3.1. Main HIV indicators (CNSida) and number of Portuguese reporting hospitals, for the years 2006, 
2007 and 2009 [9]. 
 2006 2007 2009 
 Number of 
reporting 
hospitals 
Total Number of 
reporting 
hospitals 
Total  Number of 
reporting 
hospitals 
Total  
 (min-max) (min-max) (min-max) 
HIV-infected subjects followed-up in 
the hospital 
21 
16 522 
23 
18 500 
28 
22 816 
(74-2557) (86-2622) (11-3000) 
AIDS subjects followed-up in the 
hospital 
11 
1 461 
14 
2 235 
18 
4 560 
(9-508) (11-516) (0-1675) 
Subjects that had abandoned medical 
appointments 
12 
899 
14 
901 
19 
809 
(2-404) (2-416) (0-229) 
Hospitalizations due to HIV infection 23 
2 875 
23 
3 018 
32 
3 400 
(7-423) (14-398) (0-508) 
Subjects that were hospitalized due to 
HIV infection 
22 
2 112 
22 
2 146 
30 
2595 
(7-318) (9-370) (0-430) 
AIDS-related deaths among subjects 
followed-up in the hospital 
13 
96 
15 
122 
25 
255 
(0-25) (0-40) (0-36) 
AIDS-related deaths during 
hospitalizations of subjects followed-
up in the hospital 
18 
144 
19 
163 
28 
244 
(0-35) (0-42) (0-36) 
AIDS-related deaths during 
hospitalizations of subjects who were 
not followed-up in the hospital 
18 
70 
19 
89 
26 
125 
(0-11) (0-19) (0-37) 
Subjects receiving antiretroviral 
treatment 
21 
13 406 
22 
15 042 
33 
22 418 
(48-2234) (58-2302) (11-2476) 
Subjects initiating antiretroviral 
treatment 
16 
834 
21 
1 370 
30 
1 936 
(10-204) (5-251) (0-174) 
TB cases among HIV-infected subjects 18 
364 
19 
332 
26 
343 
(1-70) (0-75) (0-52) 
 
Table I.3.2. Number of subjects receiving antiretroviral treatment, for each hospital unit with more than 400 
HIV-infected subjects on treatment, in the years 2005 and 2009 [9, 12]. 
Hospital Units 
Portuguese 
Health Region 
number of patients receiving 
antiretroviral treatment  
2005 year 2009 year 
Centro Hospitalar Barreiro/Montijo LVT − 490 
Centro Hospitalar de Cascais LVT 661 1 098 
Centro Hospitalar de Coimbra Centre 428 660 
Centro Hospitalar de Setúbal LVT 996 830 
Centro Hospitalar de Vila Nova de Gaia North 584 851 
Centro Hospitalar do Porto North − 546 
Centro Hospitalar Lisboa Central LVT 1 223 1 846 
Centro Hospitalar Lisboa Norte LVT 2 460 2 138 
Centro Hospitalar Lisboa Ocidental LVT 1 615 1 794 
Hospitais da Universidade de Coimbra Centre 604 860 
Hospital Curry Cabral LVT 1 846 2 574 
Hospital de Joaquim Urbano North 1 398 1 676 
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Hospital Units 
Portuguese 
Health Region 
number of patients receiving 
antiretroviral treatment  
2005 year 2009 year 
Hospital de São João North 1 292 1 602 
Hospital Distrital de Faro Algarve 497 732 
Hospital Distrital de Santarém LVT − 406 
Hospital Fernando da Fonseca LVT 1 006 1 615 
Hospital Garcia de Orta LVT 1 011 1 463 
Unidade Local de Saúde de Matosinhos North 438 593 
LVT = Lisbon and Tagus Valley Health Region    
 
The incompleteness and the lack of updated information on HIV infection and treatment is 
recognized [11]. Data regarding antiretroviral drug use and patient adherence to treatment is 
also dispersed and bias may be present with the use of different definitions and measures. 
 
 What is already known about patient adherence to HAART in Portugal? 
In Portugal, there have been some single-centre studies addressing patient adherence to 
HAART. Table I.3.3 summarizes the studies that to our knowledge have been conducted as of 
2011. This was retrieved from the reference lists of master and doctoral thesis and from other 
available publications, such as conference abstracts.  
 
Table I.3.3. Summary of Portuguese studies regarding patient adherence to HAART. 
Author  
publication 
Hospital  
study period 
Inclusion criteria n 
% 
men 
Age 
(y) 
Measure of 
adherence 
% adherence Ref 
Aragão 
(2009) 
Cascais 
(2002 - 2008) 
 Aged ≥14 y 
 Naïve 
1 333 
(naïve: 
193) 
65 
(naïve
: 65) 
40.1 
± 
0.9 
Pharmacy refill 
(overall 
adherence 
level) 
86 
 
95%CI: 
[83.8;87.9] 
13 
Margalho 
(2010) 
HUC 
(*) 
 HIV+, asymptomatic 
 Followed-up at 
outpatient clinic 
 Prescribed to 
antiretrovirals ≥ 30 days 
 Portuguese nationality 
 Literacy level sufficient 
to answer to the 
questionnaire 
81 49.4 38.7 
± 
10.9 
Self-report 
(question) 
45.7 14 
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Author  
publication 
Hospital  
study period 
Inclusion criteria n 
% 
men 
Age 
(y) 
Measure of 
adherence 
% adherence Ref 
 Exclusion of subjects in 
prison and with active 
psychological symptoms, 
dementia or other 
cognitive conditions, and 
drug consumption 
Reis  
(2007) 
Joaquim 
Urbano  
(2006 – 2007) 
 Aged >18 y 
 HIV+ 
 Prescribed to 
antiretrovirals ≥ 3 
months 
 Informed consent 
 Followed-up regularly at 
outpatient clinic 
 Exclusion of subjects 
hospitalized during 
recruitment 
125 80 39.9 
± 
9.8 
Pharmacy refill 
(overall 
adherence 
level) 
 
Self-report 
(CEAT)* 
 
91.1±15.8 
 
(33.6 ≥95%) 
15
16 
17 
 
Margalho 
(2007) 
HUC 
(*) 
 HIV+ 
 Recruited at Psychology 
appointment 
 Followed-up at 
outpatient clinic 
 Exclusion of subjects in 
prison and with active 
psychological symptoms 
100 73 38.2 
± 
10.3 
Self-report 
(question) 
73.1 18 
Gonçalves 
(2007) 
HSM 
(*) 
 HIV+ 
 Informed consent 
 Followed-up at 
outpatient clinic 
210 66 - Self-report 
(AACTG) 
75.7 19  
20 
Ventura 
(2006) 
Joaquim 
Urbano 
(2002-2003) 
 HIV+ 
 Naïve 
 Informed consent 
 Followed-up at 
outpatient clinic 
 One year of treatment 
134 70.1 38.0 
± 
11.4 
Pharmacy refill 
- overall 
adherence level 
86.9 
(68.7 ≥95%) 
21 
Marin 
(2002) 
Portimão 
(2000-2002) 
 HIV+ 
 Followed-up at 
outpatient clinic 
 With more than one refill 
206 
(more 
than 
one 
refill: 
187) 
67.5 * Pharmacy refill 
(irregular) 
regular: 67.9 22 
Neto 
(2003) 
Cascais 
(1999, 2000) 
* 1999: 
369 
2000: 
473 
* * Pharmacy refill 
(*) 
1999: 42% 
2000: 60% 
 
* data not available 
 
Several measures of adherence were used, including self-report questionnaires, pharmacy-
based measures and electronic monitoring, and this heterogeneity of measures makes the 
studies’ comparison difficult.  
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For instance, Margalho et al. study showed that, among patients followed in Hospitais 
Universitários de Coimbra in 2007, 93 out of 100 were prescribed to HAART and 68 (73.1%) 
were adherent [14]. Gonçalves et al. indicated a non-adherence prevalence of 22.3% in a 2004 
study conducted in Hospital de Santa Maria [19]. Both studies included small sample sizes 
and had measured adherence by patient self-report, but each one used different questions. 
Gonçalves et al. study also identified as main reasons for non-adherence the following: 
“simply forgot” (11.5%), “impact in daily routine” (7.6%), “feeling well” (8.1%), “having 
problems with taking medication in some occasions” (6.2%) and “being busy” (6.2%) [19, 
20]. Reis et al. conducted a validation study of an adherence questionnaire (CEAT), in a 
sample of 125 subjects followed at Hospital Joaquim Urbano [15, 16]. In this study, the 
authors reported that overall adherence level, based on pharmacy refills, was 91.1±15.8%, 
although only a third of the subjects had adherence levels ≥95% [17]. Having psychological 
symptoms, poor pharmacy refill adherence and experience of adverse reactions were 
conditions identified as non-adherence predictors [15, 17]. 
 
Using pharmacy refills, Aragão et al. found a mean adherence level of 86% for the first 
regimen among the naïve patients followed at Centro Hospitalar de Cascais between 2002 
and 2008 [13]. Ventura et al. reported a similar mean adherence level of 86.9% in Hospital 
Joaquim Urbano, with a non-adherence estimate (e.g., subjects with adherence level <90%) 
of 31.3% for the first year on antiretroviral treatment, between 2002 and 2003 [21]. 
Additionally, this study also described some adherence determinants, namely, sex, place of 
residency, clinical status of the HIV infection, CD4 cell count increase and viral load at the 
end of follow-up, hospitalizations and number of skipped medical appointments [21].  
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These studies included only persistent subjects for a one year period. Since the non-persistent 
patients were not included, there may have been an underestimation of non-adherence: the 
2010 UNAIDS report indicates that the 2009 percentage of Portuguese adults known to be on 
treatment 12 months after initiation was 84% [1].  
 
Previous studies, using also pharmacy-based measures, reported similar adherence levels. A 
study conducted in Hospital de Portimão showed that, from 206 subjects followed between 
July 2000 and June 2002, 146 subjects (70.5%) were still receiving treatment at the end of the 
study period, while 39 (19%) had dropped-out from the medical appointments. Also, from the 
187 subjects with more than one pharmacy refill, 60 were classified as irregular (e.g., 
presented more than one medication gap with length superior to one month) [22]. In the 
Hospital de Cascais, a 1999 study reported a mean adherence level of 42% for 369 subjects 
receiving antiretroviral treatment, while a 2000 study in the same hospital and with the same 
methodology showed an increase in the mean adherence level to 60%, for 473 subjects under 
treatment [21]. 
 
Recently, CNSida has developed a national registry to support the clinical activities related to 
the HIV/AIDS infection. This registry (SI.VIDA) aims to collect some clinical variables such 
as viral load, CD4+ cell count over time, antiretroviral regimens used and adherence to 
therapy of HIV infected subjects [11]. For now, a feasibility study was conducted in three 
health units – Hospital de São João, Hospital Egas Moniz and Hospital Distrital de Faro – 
and concluded in May 2010. It is expected that, in the future, more Portuguese information 
about the HIV/AIDS infection may become available. 
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The study aims to characterize patient non-adherence to antiretroviral treatment among HIV-1 
infected adult subjects followed up at the HIV outpatient clinic from Hospital de Santa Maria 
(Lisbon, Portugal), a university tertiary central hospital and the largest hospital in Portugal. 
 
Specific aims were: 
1) to provide a characterization of the pattern of HAART prescription and non-adherence, 
over the period from 2005 to 2008 calendar year (Section IV.1.); 
2) to verify which factors may be associated to non-adherence to HAART (Section IV.2.); and 
3) to evaluate the completeness of the clinical and pharmacy records, according to the study 
variables (Chapter V). 
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
 Study design and Eligibility criteria 
Observational cohort study, conducted at the HIV outpatient clinic of the Hospital de Santa 
Maria with a retrospective data collection of HIV-infected adults followed up at the clinic and 
having at least one antiretroviral refill between 01-01-2005 and 31-12-2008. 
Other eligibility criteria were defined as having: 
- started antiretroviral treatment at HSM clinic when aged ≥ 18 years; 
- at least 2 medical appointments during the same period; 
- no participation in clinical trials; 
- antiretroviral drugs prescribed for HIV-1 treatment, with the exclusion of post-
exposure prophylactic treatment and other regimens besides HAART. 
Subjects were excluded if (or censored at date of being) arrested, under a social institution 
care or dependent of a third person for taking medication. Subjects were also censored at the 
date of death or at the date of the last medical appointment before moving to a different 
hospital. 
 
 Sampling 
To assess how many subjects had at least one antiretroviral refill between 01-01-2005 and 31-
12-2008, we asked for the collaboration of HSM Pharmacy for a list with all refills of solid 
forms of ARV that took place during this period and were initially prescribed by the 
physicians at the HIV outpatient clinic. Simple randomization (with R software) was then 
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used to select the potential participants. The eligibility criteria were assessed when retrieving 
the hand-written clinical record, for each subject. 
The sample size of the pilot study was calculated based in the initial assumptions for the 
ATAR-VIH project (see Annex III). In the retrospective phase of the pilot study, we also 
assumed an exclusion rate of 37%. Hence, from 320 subjects randomly selected, we aimed to 
include 200 subjects that would enable a precision estimate ±7% (α=.05) of the true frequency 
of overall non-adherence to HAART during the 2005-2008 period. Assuming a statistical 
power of 80%, and non-adherence as a dichotomous variable, we expected to detect relative 
risks ≥1.8 or more for different risk factors, when non-adherence rate among controls was 0.3. 
 
 Study variables 
Adherence was assessed as compliance (or quality of execution – see Chapter I.2) and 
assessed with the pharmacy-based measures Medication Possession Ratio (MPR) and 
medication GAPs. Treatment modifications were defined as any change at both HAART 
regimens or at individual drugs and included structured or unstructured treatment 
interruptions. Sociodemographic characteristics and clinical variables related to HIV/AIDS 
infection (e.g., viral load, CD4 and CD8 cell counts, opportunistic infections and 
comorbidities) were also retrieved from hand-written clinical records, as well as the physician 
notes on reasons for HAART modifications and evaluation of patient adherence. Information 
from adverse effects, genotyping resistance test information, and TDM was also collected. 
Annex IV shows the conceptual model with the variables collected. 
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 Data collection process 
From May to October, 2010, 3 medical students and a pharmacist collected data from the 
subjects’ clinical records. A specific form was used to retrieve information (Annex V). In the 
period before 2005, we retrieved only information about the first medical visit, the first visit 
with prescription of antiretrovirals and the following ones when treatment modifications 
occurred. After year 2005, we collected data from all visits, until December 2009. Latter, the 
collected information was registered in an electronic (Microsoft Access®) database. 
Pharmacy refills data were downloaded from the electronic registry of the HSM 
Pharmaceutical Services into a Microsoft Excel® file. 
 
 Data validation and statistical analysis 
The information registered at the electronic database was validated for specific variables 
(viral load, CD4 cell count, HAART modifications and HAART regimens) in 30% of the 
forms, selected by a random process. Regarding HAART use, we assumed that information 
from pharmacy database about medication (name, dose, refill dates, number of pills 
dispensed) was more accurate and complete. Statistical analysis plan was defined for each 
specific aim. We estimate 95% confidence intervals for parameters of interest and adopted a 
5% significance level for all statistical hypotheses tests. Analyses were conducted by using R 
software. 
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 Ethical and legal aspects 
The pilot study was authorized by the HSM Ethics Committee and the National Data 
Protection Authority (see Annex I and II). The retrospective phase did not require any 
informed consent for the data collection, since this process involved only health professionals 
and medical students under a confidentiality contract under the physicians’ supervision. 
Subjects were coded with a unique non-identifying number. The database has protected 
access. Also, only grouped data will be presented and published. No financial gratifications 
were given to the study participants, and this study has no commercial aims. The HSM Ethics 
Committee recognized the public health relevance of the study. 
 
In Chapter IV Results, we detail more information about the definition of variables and 
statistical analysis applied to each specific aim, as well as a discussion of its results. The 
Chapter V General Discussion & Conclusions presents an overall discussion of results and 
study limitations. 
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IV.1. 
Antiretroviral Prescription and Adherence in a 
Portuguese Cohort of HIV-1 infected subjects:  
an overall analysis of changes over the years 2005 - 2008 
 
Abstract 
Objectives: To evaluate the trends in adherence to antiretroviral treatment (ART), in a cohort of HIV-1 infected 
adults, and to characterize the HAART prescription pattern over the period 2005-2008. 
Methods: A sample was randomly selected from the total of HIV-1 adult infected subjects, followed up at a 
Portuguese hospital HIV outpatient clinic and that had at least one antiretroviral refill between 01-01-2005 and 
31-12-2008. Medication possession ratio (MPR) was determined using a fixed 12- or 6-month period. Non-
adherence was defined as MPR<95%. HAART prescription was analyzed according to regimens, within each 
antiretroviral class, and regarding fixed-dose combinations. 
Results: A total of 186 subjects were included, 78.5% treatment-experienced at baseline. Over the period 2005-
2008, we found a significant increase in the proportion of subjects with MPR<95% from 12.3% in 2005 to 
25.9% 2008, that was usually higher among injection drug users (IDU) and subjects with depression/anxiety. 
The proportion of subjects with at least one registry of detectable viral load had significantly decreased from 
43.5 in the first semester of 2005 to 29.2% in the second semester of 2008 (P=0.01). No significant differences 
were observed in the HAART regimens use along the study period. The two usual options were 2 NRTIs and a 
NNRTI or a PI. The use of fixed-dose combinations had significantly increased from 54.8 to 77.7% (P<0.001), 
mainly due to emtricitabine/tenofovir association. 
Conclusions: Non-adherence increased over the period 2005-2008, being higher among IDU and subjects with 
depression/anxiety, as well as during second calendar semesters. The prescription pattern seemed to be in 
accordance with guidelines for the treatment of HIV infection, including the use of fixed-dose combinations.  
Keywords: HIV/AIDS infection; patient adherence; antiretroviral treatment. 
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Background 
The prescription of Highly Active Antiretroviral Therapy (HAART) has been changing over 
the years [ 1 ]. For the period 2005-2008, new drugs and fixed-dose combinations (e.g. 
emtricitabine/tenofovir) became available, while some were withdrew (e.g. nelfinavir) [2, 3, 
4]. Besides the increase of antiretroviral agents and combination options, other factors had 
changed that might have an impact on the clinical progression of HIV/AIDS infection. For 
instance, the detection of HIV RNA viral load was possible for values below the 40 
copies/ml, while guidelines now recommend to start treatment when Lymphocyte T CD4 cell 
count <350/µl. Treatment is also recommended in some circumstances such as HIV-
associated kidney disease / neurocognitive impairment or Hodgkin’s lymphoma, even if CD4 
count is higher than 350/µl  [1, 5, 6]. 
At an individual level, high levels of adherence are required to achieve the best response to 
treatment, preventing drug resistances and reducing disease progression and death [7, 8, 9]. 
Even though there is a need to better definition of the minimum cut-off for HAART 
adherence, especially for more recently approved drugs, it is usually accepted that adherence 
should be higher than 95% in order to achieve the highest treatment efficiency [9, 10, 11]. 
Moreover, longitudinal evaluations are recommended to address adherence to HAART as a 
dynamic process [12]. 
It is widely recognized that knowledge on which HAART is used for treatment of HIV 
infection may provide useful information for  clinical evaluation with regard to safety and 
effectiveness and also for  design  cost-effectiveness strategies to improve standard care [13]. 
In fact, drug utilization studies may be used to promote appropriate drug use through 
education and other interventions, since “without a knowledge of how drugs are being 
 103 
prescribed and used, it is difficult to initiate a discussion on rational drug use or to suggest 
measures to improve prescribing habits” [14]. 
Although drug utilization studies usually rely on large samples and administrative claims, in 
some contexts (such as the Portuguese one) it may be impossible to directly link aggregate 
data about medication with information about patient’s demographic and clinical 
characterization. Another issue of concern is the level of record keeping, since computerized 
clinical databases may not be available for research purposes. In these cases, other data 
sources should be considered and an option could be collecting local data from patients’ 
clinical records and pharmacy registries [14]. To our knowledge, there are no published 
studies that describe the trends for the prescription of antiretroviral agents and adherence, 
using the same time window (2005-2008), although this has been done at marketing level and 
for previous time periods, some including pre-HAART information [13] 
In this study, we aim to evaluate the trends in adherence to HAART in a Portuguese cohort of 
HIV-1 infected adults receiving treatment over the period 2005-2008. For each semester, we 
specifically aim to determine the prevalence of adherence, based on medication possession 
ratio (MPR) ≥95%, and the proportion of individuals with detectable viral load. In addition, 
the study aims to characterize the patterns of antiretroviral prescription treatment. 
 
Methods 
Study design and participants 
Data were retrospectively collected from pharmacy and outpatient clinic registries, for the 
Prevalence and determinants of patient adherence to ART and regimen modification in a 
Portuguese cohort of HIV-infected adults (ATAR-VIH) study. This study was authorized by 
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the Ethics Committee of the Hospital de Santa Maria (Lisbon, Portugal), and by the 
Portuguese Data Protection Authority. 
 
A sample of 320 subjects that had at least one ART refill between January 2005 and 
December 2008 was randomly selected from a total of 2861 HIV-1 adult infected subjects, 
followed up at the HIV outpatient clinic of Hospital de Santa Maria (HSM, Lisbon, Portugal), 
the largest Portuguese hospital.. Sample size calculation assumed an exclusion rate of 35%, a 
non-adherence prevalence of 50%, and that the final inclusion of 200 subjects would enable a 
precision estimate ± 7% (α=.05) of the true frequency of overall non-adherence to ART 
during this period. HSM is a university tertiary central hospital and, since 2005, one of the 
two hospitals following the largest number of HIV-infected subjects in Portugal [15]. 
 
Inclusion criteria were defined as having started ART for HIV-1 infection at HSM clinic 
when aged ≥ 18 years-, and had at least 2 medical appointments between 01-01-2005 and 31-
12-2008, with no participation on clinical trials. HIV post-exposure prophylactic treatment 
and antiretroviral regimens other than HAART were excluded. Subjects were censored at the 
date of death or date of being arrested, being in a social institution or dependent of a third 
person for taking medication. Baseline was the date of the first medical appointment during 
the study period. 
 
ART prescription and adherence definition 
The pattern of overall ART usage for each semester was assessed by considering the first 
subjects’ prescription in that period. ART regimens were classified into nucleoside reverse 
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transcriptase inhibitor (NRTI) plus protease inhibitor (PI), NRTI plus non-nucleoside reverse 
transcriptase inhibitor (NNRTI), only NNRTI-containing regimen, PI and NNRTI-containing 
regimen, regimens with 4 antiretroviral drugs and other regimens. We also characterized the 
ART prescription pattern within each antiretroviral class, i.e. PI, NRTIs and NNRTIs, and the 
proportion of subjects receiving ART in fixed-dose combinations. 
 
Adherence was assessed as compliance and evaluated from the pharmacy refill registry for the 
study time window and for specific index antiretroviral drug, defined as the PI or, if not 
applicable, the NNRTI or abacavir/tenofovir [16,17]. The pharmacy registry included the 
refills ordered by physicians from the Outpatient Clinic and registered between 01-01-2005 
and 31-12-2008.  
 
For adherence assessment, we determined MPR using a fixed 12- and 6-month period. In the 
6-month assessment, MPR was defined as the number of days for which prescribed HAART 
was available for each calendar semester from January 2005 until December 2008, divided by 
number of days of each period (Figure IV.1.1).  
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Figure IV.1.1. Scheme for the calculation 6-month Medication Possession Ratio. MPR is determined 
by assessing the total number of days with ART available (*periods) from all refills occurring in each 
semester, divided by total number of days for the semester. Leftover medication from previous 
semester was taken into account when determining MPR [18]. 
 
In order to avoid an overestimation of non-adherence, we corrected the MPR denominator for 
first calendar semester of 2005, so it included only the number of days between the first refill 
and 30
th
 June. The same correction was assumed for the ART-naïve subjects in the subsequent 
semesters. The annual MPR assessment was performed similarly, for each calendar year over 
the study period. Number of pills prescribed per day was calculated based on the 
recommended daily dosage, according to the guidelines, and confirmed with the information 
from the clinical records. In case of overlapping refills, we assumed that HAART was taken 
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sequentially and accounted for the leftovers when estimating adherence [16,18]. At the end of 
each semester, subjects were classified as adherents if MPR ≥ 95%. 
Variables related to adherence and clinical outcomes 
Information from hand-written clinical records was retrieved and linked to pharmacy registry, 
by using the patients’ individual number at HSM. Collected variables included sex, age and 
race, mode of HIV transmission, date of HIV-1 diagnosis and any physician annotation of 
intravenous drug use (IDU) behaviour (current or past). Depression/anxiety was defined as 
having a physician annotation of the diagnosis of depression or anxiety, or prescription of 
antidepressants (ATC code N06A) or anxiolytics (ATC code N05B). Treatment-related 
variables were time on HAART, number of ART changes, hospitalizations and number of 
medical appointments (visits) per subject, during the study period. ART discontinuation was 
based on physician annotation or, when the patient had no visit, in the calendar semester. 
Laboratorial data on HIV plasma viral load and CD4+ T-cell counts were also collected from 
the clinical records, for each visit over the study period. The proportion of subjects with at 
least one detectable viral load was evaluated at each semester. The detection limit was ≥40 
copies/ml, with the exception of the first semester of 2005, were the limit was ≥50 copies/ml 
(due to equipment limitations). We also evaluated the proportion of subjects with CD4 cell 
count < 350 or < 200 cells/µl. 
Statistical analysis 
Descriptive statistics were used for the sample characterization at baseline. 95% confidence 
intervals (CI) were calculated for MPR estimates and proportion of detectable viral load and 
CD4 cell count, assuming a binomial distribution. A χ2 test for linear trend was used to assess 
temporal differences within each variable. Statistical analysis was performed with R software 
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(www.r-project.org), and a 5% significance level was adopted for all statistical hypotheses 
tests, with exclusion of missing data. 
 
Results 
Participant characteristics 
A total of 186 subjects were included in this study. The remaining 134 were excluded due to 
having started ART in other hospital (n=42), participation in clinical trials (n=34), had less 
than 2 medical appointments during the study period (n=14), being in a prophylactic or a non-
HAART regimen (n=13), missing clinical records (n=9), starting HAART when arrested or 
depending on another person for medication intake (n=6), not being followed up in the 
outpatient clinic (n=6), had only one ART refill in the study period (n=3) or presented HIV-2 
infection (n=4). 
At baseline, with regard to demographic characteristics, subjects were on average 39.7 ± 9.5 
years old, and the majority were male (63.4%) and Caucasian (78.6%). The 186 subjects had 
a median time of 43.5 months since HIV infection diagnosis (IQR 14.8-91.0 months). 
Acquisition of HIV infection was due to heterosexual intercourse for 50.3% of subjects, while 
injection drug use (IDU) and men having sex with men (MSM) were the modes of acquisition 
for 23.2% and 19.2%, respectively. Other modes of transmission, including occupational 
exposure and subjects with more than one possible mode, accounted for 7.3% of the cases. 
The characteristics of study’ participants are presented in Table IV.1.1, for each semester in 
the period from January 2005 to December 2008. Regarding ART experience, the sample is 
mainly constituted by prevalent users. A total of 21.5% of subjects were treatment-naïve at 
baseline, and the proportion of ART-naïve subjects significantly decreased over time. 
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Adherence evaluation 
For the period 2005-2008, medication possession ratio (MPR) was high, with median annual 
MPR being 100% in each year (Figure IV.1.2). However, a significant increase in the 
proportion of non-adherent subjects was observed, with MPR <95% (Table IV.1.2). In 2008, 
non-adherence had a prevalence of 25.9%. 
 
 
Figure IV.1.2. Histograms of medication possession ratio (MPR) annual estimates, 
over the period from 2005 to 2008.  
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Table IV.1.1 Characteristics of the study cohort, for each semester from 2005-2008 period. 
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Table IV.1.2. Medication Possession Ratio annual estimates, over the period from 2005 to 2008 
 2005 2006 2007 2008 P* 
Number of subjects 146 157 154 157  
MPR < 95%, %  
[95% CI] 
12.3  
[7.7;19.0] 
24.8  
[18.4;32.5] 
14.9  
[9.9;21.8] 
25.9  
[19.5;33.6] 
0.03 
* p-value of the χ2 test for trend (α=0.05). MPR, medication possession ratio (%). CI, confidence interval. 
 
When considering semester analysis (Table IV.1.1), we found that the proportion of subjects 
with MPR <95% in the first calendar semesters of the study period were always lower than 
the proportion observed in the second ones. The 2008 second semester showed the highest 
proportion of non-adherent subjects (24.5%). 
 
 
Figure IV.1.3. Prevalence of non-adherence, defined as MPR<95%, for each semester from 2005-2008 period. 
In all cases, p-values for linear trend were >.05. IDU, Injection Drug Use. D/A, depression/anxiety. Started with 
non-HAART, when the first antiretroviral treatment was with mono or dual antiretroviral therapy. 
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Adherence was also evaluated for different subgroups (Figure IV.1.3). A higher proportion of 
non-adherent subjects was observed among those with past or current IDU and among those 
that had past or current information of depression or anxiety. Subjects that had started ART in 
monotherapy or with a dual combination of antiretroviral drugs usually showed inferior 
estimates of non-adherence, with exception of the 2006 second semester. 
 
HAART regimens and prescription of antiretroviral drugs 
No significant differences were observed in the HAART regimens adopted at the HIV 
outpatient clinic, during the study period (Table IV.1.1). The two most usual options were 
regimens with 2 NRTIs plus 1 NNRTI or with 2 NRTIs plus PI. When considering individual 
antiretroviral agents, there was an increase in the number of subjects using atazanavir and 
fosamprenavir among the NRTIs and abacavir among NNRTIs (Figure IV.1.4). 
A significant increase was observed in the proportion of subjects using ART associations (p-
value <0.001). As shown in Figure IV.1.4, this is mainly due to the emtricitabine / tenofovir 
association and to the slight increase of the abacavir / lamivudine. There was a decrease in the 
proportion of subjects presenting at least one ART change during each semester. 
 
Virological and immunological control 
Over the study period, it was observed a significant decrease of the proportion of subjects 
with at least one registry of detectable HIV RNA viral load. In the 2008 second semester, 
29.2% of the subjects presented detectable viral load. A similar decrease was observed for the 
proportion of subjects with at least one registry of CD4 cell count < 350 cell/μl. No trend was 
observed when CD4 inferior limit was set at < 200 cell/μl. 
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Figure IV.1.4. Number of subjects prescribed to each antiretroviral drug [a) NRTIs, b) NNRTIs, c) PIs], and combinations [d)] at the first prescription of 
each semester. 
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Discussion 
Adherence to HAART was high among the subjects followed at the outpatient clinic of HSM, 
but there seems to be an increase in the prevalence of non-adherence to treatment. The 2008 
overall data revealed that a quarter of the subjects were non-adherent. These findings are 
inferior to the ones reviewed in a recent meta-analysis, in which the prevalence of adherence 
≥90% to ART was estimated to be 62% worldwide, and 61% (95%CI 58-64%) for the 52 
observed groups from Western Europe countries [7]. Some explanations could explain this 
difference. Firstly, the included studies were performed between 1999 and 2009, a larger 
period of time than the one observed in our study, and it has been described that earlier PI-
based regimens presented a worst tolerability profile [12]. Secondly, different groups were 
included in the analysis, namely hospitalized and institutionalized patients and the IDU was 
the most common (44.4%) mode of HIV acquisition. Our study included only subjects 
followed at ambulatory care level, and the majority acquired HIV infection through 
heterosexual contact. Similar to our study results, subjects with past or current IDU seem to 
have a higher prevalence of non-adherence [7]. Another aspect is that our study included only 
those subjects that had at least 2 medical appointments from January 2005 until December 
2008, which may lead to an overestimation of adherence to HAART (since we exclude those 
with only one visit to the outpatient clinic). 
Some of these aspects are also present when we compare our study results with other 
Portuguese studies. For instance, Aragão et al. found an adherence level of 86% for the first 
regimen among the naïve patients followed at Centro Hospitalar de Cascais (Portugal) 
between 2002 and 2008, using also a pharmacy-based measure of adherence [19]. However, it 
is difficult to compare our study results with this finding, since only naïve subjects were 
included and several studies have indicated that non-adherence was higher in the first year of 
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treatment. On the other hand, Aragão et al. included only subjects that had persisted in 
treatment, which usually leads to an underestimation of non-adherence: the 2010 UNAIDS 
report indicates that 84% of Portuguese adult subjects were still receiving ART 12 months 
after initiation [19, 20]. 
The 6-month analysis of adherence aimed the assessment of eventual temporal patterns of 
non-adherence. We have found that non-adherence was more prevalent in the second 
semesters, which may be related to the inclusion of the holiday seasons during these periods. 
Since ART refill usually covers one-month periods, this finding suggests that medication 
should be available for a larger period (e.g. 2 months) and that adherence during holidays 
should be reinforced by the physician. 
The 2006 and 2008 calendar years seemed to have a higher prevalence of non-adherence. A 
larger time window should be considered to confirm the bi-annual pattern, since this trend 
was not observed in other variables that could explain the observed differences, such as 
regimen changes, average of medical appointments per subject or number of hospitalizations. 
In addition, as MPR was equally assessed in every semester and took into account the 
leftovers from previous periods, we do not expect that this pattern could result from bias in 
the adherence evaluation. The exception is made for the 2005 first semester, in which we 
were not able to account for previous leftover and, thus, non-adherence could have been 
overestimated. Moreover, this method’ limitation does not explain the trend. 
Similar to other studies, our findings show that non-adherence is higher among subjects that 
had past or current IDU or had depression / anxiety disorders [12, 21]. Nevertheless, the 
overall prevalence of non-adherence in the 2008 second semester was similar to the one 
observed for the subgroup of past or current IDU and higher than that of the group with 
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depression / anxiety registry. This may highlight that other adherence’ determinants were 
more relevant in 2008. 
Regarding HAART prescription during this period, we found no significant change at 
regimen level. The most frequently prescribed regimens included a dual NRTI component 
plus a third agent, NNRTI or PI, in line with the actual guidelines on the treatment of HIV 
infection [5, 22]. At individual drug level, there was a slight increase in the use of abacavir 
and lamivudine, which probably reflects the need for using an alternative regimen (compared 
to tenofovir/emtricitabine one) for prevalent HAART users. 
There was a marked increase in the use of fixed-dose antiretroviral combinations, which 
seems mainly related to the availability of tenofovir/emtricitabine option. Since there was no 
relevant increase in the number of users for these two NRTIs, the increase of its combination 
reflects the clinical practice to simplify the prescribed regimens. Simplification is a strong 
recommendation for adherence improvement [6, 11, 22]. Although, in our study, we cannot 
evaluate if this simplification resulted from previous non-adherence, we are now conducting a 
prospective study that addresses the possible reasons for HAART changes (ongoing research). 
On the other hand, the increase of non-adherence raises the question of whether this could be 
a consequence of the combination use and, if so, the need to evaluate the economic impact of 
non-adherence with these usually more expensive options. 
Non-adherence is pointed out as a major determinant of virological control. However, our 
study shows a significant decrease in the proportion of subjects with detectable viral load, 
across the study period. When considering immunological data, a similar decrease was 
observed in subjects with CD4 cell count less than 350/µl. Two explanations are possible. 
Firstly, the fact that our cohort is mainly constituted by ART-experienced users and secondly, 
that recent studies had shown that adherence seem to be less related to viral load after viral 
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suppression is achieved and maintained [ 23 , 24 ]. Lima et al. found that, among 1305 
individuals who achieved initial viral suppression, 21% presented a subsequent virological 
rebound. However, the risk of virological rebound decreased with longer duration (in years) 
of initial viral suppression (OR, 0.37; 95% CI, 0.32 to 0.42) [23]. Another hypothesis is that 
the effectiveness of newer antiretroviral agents may be reasonable for adherence levels 
inferior to 95% [25, 26]. In fact, this cut-off was based in older studies that only considered 
PIs as antiretroviral agents, while other studies showed that sustained viral suppression was 
also obtained by subjects on NNRTI-based regimens who had adherence rates lower than 
95% [27, 28]. It seems less probable that the decrease of detectable viral load may be related 
to the decrease in the number of ART-naïve subjects, since we did not consider the first 
medical appointment with ART prescription (at which viral load is always detectable). The 
significant decrease in ART-naïve subjects may reflect the decreasing trend in the Portuguese 
incidence of the HIV infection: 16.4 (2005) to 15.8 (2008) per 100 000 population [29]. 
 
Study limitations 
Adherence and antiretroviral prescription were presented as aggregate data, according to 
calendar semester or year. This approach provided overall information of the actual clinical 
practice that, however, had to be more comprehensively analyzed. For instance, in this study, 
we did not link the prescription of ART with subjects’ stage of HIV infection or their history 
of comorbidities and other clinical conditions. Data collection from hand-written clinical 
records was necessary due to the absence of electronic databases that could be linked to 
pharmacy claims information. Actually, this was the main reason why our study had a smaller 
sample size when compared to others with similar aims [12, 13]. Furthermore, clinical records 
missed information about other demographic characteristics that might be related to 
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adherence (e.g. professional status and familiar support). Another study limitation derives 
from using a pharmacy-based measure to assess adherence: when using ART refill data, we 
are assuming that all refilled medication will be actually taken by the subjects. This is an 
already recognized problem and results in the overestimation of actual adherence [18]. 
 
Practice implications and conclusion 
Although our sample may not be representative of the total Portuguese population under 
HAART, this study provides a good description of recent clinical practice and reinforces the 
need for addressing barriers to adherence. The prescription pattern seems to be in accordance 
with guidelines for the treatment of HIV/AIDS infection, including the use of fixed-dose 
combinations as a way to simplify HAART regimens. Furthermore, physicians should 
continue to promote adherence among IDU and subjects with depression / anxiety, and during 
holiday seasons. 
 
Several questions were raised from this analysis, such as the assessment of the relationship 
between adherence and HIV clinical outcomes, and the identification of adherence 
determinants in nowadays practice. Further studies, with larger datasets and more 
comprehensive information at individual level, are required to address these questions, and to 
characterize the impact of the increased use of fixed-dose combinations. 
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IV.2. 
Determinants, pattern and outcomes of non-adherence to 
HAART in a Portuguese cohort of HIV-1 infected subjects 
 
Abstract 
Objectives: To identify the determinants of non-adherence to HAART during 2008, to characterize frequency 
and duration of medication gaps and to verify the association of non-adherence with immunological and 
virological outcomes, among HIV-1 infected adults. 
Methods: A sample was randomly selected from the HIV-1 adult infected subjects followed up at a HIV 
outpatient clinic of the largest Portuguese hospital and having at least one HAART refill between 01-01-2005 
and 31-12-2008. Average adherence was determined as medication possession ratio (MPR), and non-adherence 
was defined as MPR<95%. Detectable viral load (>40 copies/ml) and CD4 cell count <350/µl in 100% of 
recorded measurements per subject and throughout follow-up were also analyzed. 
Results: A total of 157 subjects were included in the analysis, 4.5% were HAART-naïve at baseline, 74.1% of 
the subjects had MPR≥95%. Having periods >12 months without medical appointments previous to baseline and 
3 or less years of HAART experience were significantly associated to non-adherence. The majority (81.6%) of 
the non-adherent subjects had more than one medication gap with length < 30 days. It was observed a significant 
decrease in the proportion of subjects with CD4 <350/µl and viral load >40copies/ml with the increase of the 
average adherence. Time on HAART and AIDS classification at diagnosis seemed also to be related to 
virological and immunological outcomes. 
Conclusions: Subjects with less time with HAART experience and those that had already abandon medical 
appointments for a period>12 months are more likely non-adherents. Lower to moderate average adherence 
levels and shorter HAART gaps are frequent among HIV-1 infected adults. 
Keywords: HIV/AIDS infection; patient adherence; antiretroviral treatment; pharmacy refill. 
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Background 
The relation between the success of highly active antiretroviral therapy (HAART) and 
adherence has been well documented [ 1 , 2 ]. Although some studies have shown that 
virological failure and emergence of drug resistance is not always directly associated with 
patient non-adherence to treatment [3, 4], this is still a major determinant of clinical success, 
with impact at healthcare utilization and costs [5, 6]. 
Using a pharmacy-refill measure of adherence, we have found that 25.9% of the HIV-1 
infected adults followed at ambulatory level during 2008 had a medication possession ratio 
(MPR) <95%. This unpublished data revealed a significant increase of non-adherence among 
a random sample of subjects followed up at the HIV outpatient clinic from Hospital de Santa 
Maria (HSM, Lisbon, Portugal), a university tertiary central hospital, the largest in Portugal, 
which followed around 2000 HIV-infected subjects under antiretroviral treatment in 2009 [7]. 
These findings are similar to the results of a recent meta-analysis, which reported that the 
average adherence rate of ≥90% is 62% worldwide, and reinforces the need for addressing 
barriers to adherence by identifying its associated factors [2, 8]. 
The main determinants of adherence to HAART have been already described, including 
treatment-, infection-, health system- related variables that may influence medication intake 
[9, 10]. However, it has been highlighted the need to perform local assessment of adherence 
determinants and to update this information for newer antiretroviral options [11]. 
Adherence is a dynamic and complex behaviour [9, 12]. The pattern of drug use and moment 
of therapy at which missed doses occur may also affect the level of adherence required to 
maintain viral suppression. Some studies on structured intermittent therapy had shown that 
HIV-infected subjects experienced no virological rebound, and it has been suggested that a 
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higher adherence is essential at the beginning of HAART, while lower adherence may be 
tolerated after viral suppression has been achieved and sustained for a certain length of 
time[4, 12, 13]. Thus, it seems relevant to address the pattern of non-adherence to HAART 
alongside with its determinants, in order to achieve better effectiveness of the available 
regimens [2]. 
 
Our study aimed to identify the determinants of non-adherence to HAART during 2008 and to 
describe how frequent it is for a subject to be without antiretroviral medication, and for how 
many days, in a sample of HAART-naïve or experienced HIV-1 infected adults. We also 
aimed to study the association of non-adherence with immunological and virological 
outcomes. 
 
Methods 
Study design and participants 
Data was retrospectively collected for the Prevalence and determinants of patient adherence 
to antiretroviral treatment and regimen modification in a Portuguese cohort of HIV-infected 
adults (ATAR-VIH) study. This is an ongoing observational longitudinal study, that aims to 
determine the prevalence and determinants of non-adherence to HAART and it is being 
conducted on HIV-1 adult subjects followed up at the HIV outpatient clinic from HSM. A 
sample of 320 subjects was randomly selected from a total of 2861 HIV infected subjects who 
had antiretroviral refills between January 2005 and December 2008. Sample size assumed an 
exclusion rate of 35%, a non-adherence prevalence of 50%, and that the final inclusion of 200 
subjects would enable a precision estimate ± 7% of the true frequency of non-adherence to 
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HAART (α=.05), during the period from January 2005 until December 2008. The ATAR-VIH 
study was authorized by the Ethics Committee of the Hospital de Santa Maria (Lisbon, 
Portugal), and by the Portuguese Data Protection Authority. 
With this analysis, we aim to evaluate the main non-adherence determinants for the 2008 
year. We included subjects with HIV-1 infection that had started antiretroviral treatment at 
HSM clinic when aged ≥ 18 years, that had at least two medical appointments during 2005-
2008 period and at least one medical appointment and 2 pharmacy refills during year 2008 
(study period), with no participation on clinical trials. Baseline data were retrieved from the 
last medical appointment with HAART prescription before January 1
st
, 2008. Subjects were 
followed up until last visit before 31-12-2008 or censored at date of death or date of being 
arrested, under a social institution care or being dependent of a third person for taking 
medication. 
 
Adherence definition and measure 
Adherence was assessed from the pharmacy registry that included the refills between 01-01-
2005 and 31-12-2008, and for specific index antiretroviral drug, defined as the protease 
inhibitor or, if not applicable, the non-nucleoside reverse transcriptase inhibitor or 
abacavir/tenofovir [ 14 , 15 ]. We defined the number of days with available medication 
between each contiguous refill as (pills dispensed/pills prescribed per day) for the index drug. 
Pills prescribed per day were calculated based on the recommended daily dosage, and 
confirmed with the information available from the clinical records. In case of overlapping 
refills, we assumed that HAART was taken sequentially and accounted for the leftovers when 
estimating adherence [14, 16]. 
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According to the study aims, two measures of adherence were considered: 
1) For the overall compliance evaluation, we determined individual medication possession 
ratio (MPR) using a fixed 12-month period, defined as the number of days for which 
prescribed medication was available from January until December 2008, divided by 366 days 
and expressed as percentage (Figure IV.2.1). When considering HAART-naïve subjects, 
denominator was corrected to include only the number of days between the first refill and 
December, 31
st
. MPR assumed leftovers from 2007 and was truncated at 100%. A cut-off of ≥ 
95% was assumed as good adherence, in accordance with the international guidelines on HIV 
infection management[1, 17, 18]. 
 
 
Figure IV.2.1. Schematic representation of the assessment of medication possession ratio (MPR) and medication 
GAP, during 2008 year. MPR were determined as the total number of days with ART available (*periods) from 
all refills occurring in 2008, divided by 366 days. Medication GAPs were identified as number of days without 
available ART, between refills. Leftover medication from previous refills was taken into account in both MPR 
and GAP assessment. 
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Figure IV.2.2. Variables related to subject 
(group 1), to health care utilization (group 2) and 
related to treatment and infection (group 3). 
2) Among those subjects that presented MPR <95%, we assessed the existence of single-
interval periods for which there was an insufficient refill of medication, by retrieving 
individual medication gaps (GAP), i.e. the number of days between the expected end date of a 
refill and the start date of the following one (Figure IV.2.1).  
 
Factors associated with non-adherence 
Hand-written clinical records were analysed to obtain laboratorial data and information about 
adherence determinants, after being linked to pharmacy registry, through the subjects’ 
individual number at HSM [9, 10]. Figure IV.2.2 presents the collected variables, such as 
gender and age at baseline, injection drug use (IDU) behaviour (past or current), 
hospitalizations prior to 2008 year, time since HIV-1 diagnosis at baseline (in years), viral 
load and CD4 cell count and prevalence 
of co-morbidities. Psychiatric treatment 
was defined as diagnosis of depression or 
anxiety, or taking antidepressants (ATC 
code N06A) or anxiolytics (ATC code 
N05B). Treatment-related factors 
included time on HAART at baseline, 
number of previous antiretroviral 
regimens at baseline and HAART 
changes during the study period. 
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Statistical analysis 
Descriptive statistics were used for the sample characterization at baseline and to analyse 
frequency and duration of GAPs. For the estimates of the proportion of subjects with 
MPR<95%, detectable viral load and CD4 cell count <350/µl, 95% confidence intervals (CI) 
were determined assuming a binomial distribution. All statistical analysis was performed with 
R software, version 2.12.1 (www.r-project.org). 
Based on variables described as potential determinants of non-adherence (Figure IV.2.2), we 
aimed to verify if variables related to subject (group 1), health system (group 2) and treatment 
and infection related variables (group 3) were significantly associated with non-adherence. 
Assuming non-adherence as a dichotomised variable, we compared adherent (MPR ≥95%) vs. 
non-adherent groups through χ2 (or Fisher’s exact test) or Mann-Whitney test, for categorical 
or continuous variables, respectively. We specifically evaluated possible differences in the 
proportion of subjects with at least one clinical record of CD4 cell count < 350/µl or 
detectable viral load (>40 copies/ml), for different adherence levels, by using χ2 test. A 5% 
significance level was adopted for all statistical hypotheses tests. 
A multivariate logistic unconditional regression model was performed in order to identify 
predictors of non-adherence. Factors were entered into the regression model if they were 
found by univariate analysis to be significantly or marginally associated (P ≤0.15) [19, 20]. A 
stepwise procedure was used to select variables to be included in each model. A variable was 
omitted if the p-value for the likelihood ratio test was less than 0.05 [21]. Estimates of the 
odds ratio (OR) and 95% CI were calculated for collected variables. Hosmer-Lemeshow test 
and Receiver Operating Characteristic (ROC) curves were used to assess the validity of the 
final model. 
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Results 
Participants 
As shown in Figure IV.2.3, a total of 157 subjects were included in the analysis. The cohort 
baseline characteristics are presented in Table IV.2.1. 
 
Figure IV.2.3. Study flowchart. 
 
Random sample of 320 subjects 
 
134 subjects excluded 
42 had started medication in other hospital 
34 had participated in a clinical trial 
11 started ART in HIV post-exposure prophylactic program 
14 had less than 2 appointments over the period 2005-2008 
9 had missing clinical records 
6 were not followed in the HSM outpatient clinic 
4 were arrested during the period 2005-2008 
4 were infected with HIV-2 
3 had only one ART refill in 2008 
2 never had been in HAART regimens 
2 were depending on a third person for medication intake 
1 had started ART with age <18 years old 
1 was less than 18 years-old 
 
 
157 subjects included in the analysis of 2008 adherence to HAART 
2861 subjects with at least one ART refill between 01-01-2005 and 31-12-2008 
186 subjects included in the ATAR-VIH study 
29 had no medical appointments during 2008 year 
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Table IV.2.1. Characteristics of the study cohort, at baseline 
 
(n=157) 
Male, % 63.7 
Age, mean±SD (years) 42.3±9.2 
Race, % 
 
 Caucasian 77.4 
 Black 18.5 
 Other race 0.04 
 missing information, n (%) 33 (21.0) 
Birthplace, % 
 
 Portugal 63.9 
 Angola 10.9 
 Cape Verde 9.6 
 Mozambique 7.2 
 Guinea-Bissau 4.8 
 Other 3.6 
 missing information, n (%) 74 (47.1) 
Professional status at diagnosis, % ‡ 
 
 Employed 66.4 
 Unemployed 21.4 
 Retired 4.6 
 Housewife 3.8 
 Student 3.0 
 Other 0.8 
 missing information, n (%) 26 (16.6) 
Mode of acquisition for HIV infection, % 
 
 Heterosexual contact 47.8 
 Injection Drug Use 21.6 
 Men having Sex with Men 18.5 
 Other risk group 7.6 
 missing information, n (%) 7 (4.5) 
Past or current IDU, % 26.8 
Co-morbidities, % 44.6 
Past or current Depression/Anxiety, % 38.2 
AIDS classification at diagnosis, % 
 
 Non-AIDS 53.7 
 AIDS 46.3 
 missing information, n (%) 62 (39.5) 
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(n=157) 
AIDS classification at baseline, % 
 
 Non-AIDS 62.1 
 AIDS 37.9 
 missing information, n (%) 12 (7.6) 
Detectable viral load
 (a)
, % 24.2 
Detectable viral load 12 months before baseline, % 22.9 
CD4 count < 350 cells/µl
 (b)
, % 26.8 
CD4 count < 350 cells/µl 12 months before baseline, % 24.3 
Opportunistic infections 
(c)
, % 44.6 
HAART-naïve, % 4.5 
Age when starting HAART, mean±SD (years) 36.88 ± 9.3 
Started ART with non-HAART regimens, % 22.3 
No. of HAART regimens, median (IQR) † 1.0 (1.0-2.0) 
Time on HAART, median (IQR) (months) 65.6 (33.2-110.5) 
Time since HIV diagnosis, median (IQR) (months)  84.0 (60.0-132.0) 
 missing information, n (%) 4 (2.5) 
HAART regimen, % 
 
 2 NRTIs + NNRTI 47.1 
 2 NRTIs + PI 39.5 
 3 NNRTIs 3.8 
 4 antiretroviral drugs 3.8 
 Other regimens 5.7 
Skipped medical appointments
 (d)
, % 24.2 
Hospitalized
 (e)
, % 28.0 
Previous periods >12 months
 
without medical appointments 
(f)
, % 9.6 
Other medication, % 37.0 
Adverse drug reactions 
(g)
, % 49.0 
Antiretroviral resistances, % 14.2 
Therapeutic Drug Monitoring over 2008 year, % 7.6 
† Number of different HAART regimens at baseline, including the current one. ‡ Professional status as registered in the subjects’ 
first medical appointment. Considering the clinical history previous to baseline, table shows % of subjects with at least one (a) 
medical appointment with detectable viral load, (b) medical appointment with CD4 cell count <350/µl, (c) opportunistic infection, 
(d) skipped medical appointment, (e) hospitalization, (f) one previous period of at least 12 months without medical appointments and 
(g) one adverse drug reaction. NRTI, Nucleoside Reverse Transcriptase Inhibitor; NNRTI, Non-Nucleoside Reverse Transcriptase 
Inhibitor; PI, Protease Inhibitor; IQR, Interquartile Range; SD, Standard Deviation; ART, Antiretroviral therapy; HAART, Highly 
active antiretroviral therapy, defined as any regimen containing three or more antiretroviral medications or containing a NNRTI and 
a PI; IDU, Injection Drug Use. 
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Regarding treatment’s experience, the median time on HAART was 65.6 (IQR: 33.2-110.5) 
months, 22.3% had started treatment with non-HAART regimens and only 4.5 % were 
HAART-naïve at baseline. The mean number of days of study participation was 215.9 ± 87.9, 
with a total of 1410 refills (9.0±3.3; mean±SD, refills per subject). The MPR estimates ranged 
from 0.1 to 100% (median 100%, IQR: 94.4-100.0%), with 74.1% of the subjects presenting 
MPR≥95%. 
 
Factors associated with non-adherence (MPR<95%) 
Table IV.2.2 presents the univariate analysis of factors related to non-adherence, defined as 
MPR<95%. Among variables related to subject characteristics, we found that age and co-
morbidities were significantly associated to non-adherence. Regarding age, younger subjects 
(aged ≤35years-old) were more likely to be non-adherent (OR 3.14), when compared to 
subjects older than 45 years. Having a previous record of at least one co-morbidity was also 
associated to non-adherence (OR 2.65). In group 2 (variables related to health care 
utilization), only the number of previous medical appointments at baseline was significantly 
associated to non-adherence. Subjects with ≤8 medical appointments had a higher probability 
of being non-adherent (OR 3.94). When considering the variables related to treatment and 
HIV infection (group 3), time since diagnosis of HIV infection, time on HAART, being 
HAART-naïve, the number of previous ART regimens (including non-HAART options) and 
having at least one record of detectable viral load previous to baseline were also significantly 
associated to non-adherence. Subjects with less time since diagnosis and HAART beginning 
had higher probability of being non-adherent (OR 4.33 and 4.77, respectively), as well as 
those that were HAART-naïve or were in their first HAART regimen (OR 4.67 and 2.90, 
 134 
respectively). A previous experience of detectable viral load was also associated to non-
adherence (OR 2.74). 
 
Table IV.2.2. Univariate analysis of determinants of non-adherence, according to baseline information 
Variable 
% subjects 
MPR≥95% 
% subjects 
MPR<95% 
p-value 
Univariate 
OR 
95% CI 
Group 1: Subject-related variables 
Male 
  
0.57 
  
 No 26.1 10.2 
 
1.00 
 
 Yes 48.4 15.3 
 
0.81 0.36 - 1.83 
Age (years) 
  
0.01* 
  
 Older than 45 23.6 7.0 
 
1.00 
 
 36 – 45 38.8 7.0 
 
0.61 0.22 - 1.72 
 35 or younger 12.1 11.5 
 
3.14 1.14 - 9.03 
Age when starting HAART (years) 
  
0.16* 
  
 Older than 40 22.3 7.0 
 
1.00 
 
 31 – 40 40.1 7.7 
 
0.61 0.22 - 1.70 
 30 or younger 14.0 8.9 
 
2.01 0.70 – 5.88 
Mode of acquisition for HIV infection   0.84* 
  
 Heterosexual contact 35.0 12.7 
 
1.00 
 
 Injection Drug Use 13.4 5.1 
 
1.05 0.34 - 2.97 
 Men having Sex with Men 16.6 5.1 
 
0.85 0.28 - 2.35 
 Other 5.1 2.5 
 
1.37 0.27 - 5.83 
Past or current IDU 
  
0.54 
  
 No 53.5 19.8 
 
1.00 
 
 Yes 21.0 5.7 
 
0.74 0.28 - 1.81 
Past or current Depression/Anxiety 
  
0.45 
  
 No 44.6 17.2 
 
1.00 
 
 Yes 29.9 8.3 
 
0.72 0.31 - 1-62 
Co-morbidities 
  
0.01 
  
 No 45.8 9.6 
 
1.00 
 
 Yes 28.7 15.9 
 
2.65 1.20 - 6.03 
Group 2: Related to health care system 
Number of medical appointments (2005 – 2008) 
 
0.01* 
  
 More than 16 19.1 5.1 
 
1.00 
 
 9 – 16 47.1 11.5 
 
0.91 0.33 - 2.70 
 8 or less 8.3 8.9 
 
3.94 1.20 - 13.87 
Number of medical appointments (12 months before baseline) 0.10 
  
 More than 4 15.9 2.6 
 
1.00 
 
 3 – 4 45.2 14.0 
 
1.93 0.57 - 8.44 
 2 or less 15.3 7.0 
 
2.82 0.71 - 13.85 
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Variable 
% subjects 
MPR≥95% 
% subjects 
MPR<95% 
p-value 
Univariate 
OR 
95% CI 
Mean number of medical appointments per subject's year of 
HAART experience 
< 0.01* 
  
 More than 3 19.7 12.1 
 
1.00 
 
 3 or less 56.7 11.5 
 
0.33 0.14 – 0.76 
Skipped medical appointments  
 
0.83 
  
 No 56.1 19.7 
 
1.00 
 
 Yes 18.5 5.7 
 
0.88 0.33 - 2.19 
Hospitalizations 
  
1.00 
  
 No 53.5 18.5 
 
1.00 
 
 Yes 21.0 7.0 
 
0.96 0.39 - 2.28 
Previous periods >12 months
 
without medical appointments 0.12 
  
 No 70.7 19.8 
 
1.00 
 
 Yes 5.7 3.8 
 
2.37 0.64 - 8.15 
Group 3: Related with treatment and infection 
Time since diagnosis (years)   < 0.01* 
  
 More than 10 23.6 3.8 
 
1.00 
 
 6 – 10 31.2 8.3 
 
1.62 0.52 - 5.74 
 5 or less 17.8 12.7 
 
4.33 1.44 - 14.99 
Time on HAART (years) 
  
< 0.01* 
  
More than 7 33.8 4.5 
 
1.00 
 
4 - 7 27.4  6.4 
 
1.75 0.55 - 5.92 
3 or less 15.3 12.7 
 
6.19 2.16 - 19.79 
Number of pills/day 
  
0.71 
  
 More than 4 32.5 12.1 
 
1.00 
 
 4 or less 42.0 13.4 
 
0.85 0.39 - 1.88 
HAART-naïve 
  
0.05 
  
 No 74.5 21.0 
 
1.00 
 
 Yes 1.9 2.5 
 
4.67 0.75 - 33.44 
Number of previous HAART regimen † 
  
0.01 
  
 More than 1 regimen 31.8 4.5 
 
1.00 
 
 1 regimen 44.6 19.1 
 
3.04 1.19 - 8.87 
Current ART regimen 
  
0.65* 
  
 2 NRTIs + NNRTI 35.7 11.5 
 
1.00 
 
 2 NRTIs + PI 31.2 8.3 
 
0.83 0.33 - 1.99 
 3 NRTIs 2.5 1.3 
 
1.55 0.12 - 11.86 
 4 antiretroviral drugs 2.5 1.3 
 
1.55 0.12 - 11.86 
 Other regimens 5.1 0.6 
 
0.39 0.01 - 3.28 
ART changes 
  
0.10 
  
 No 36.9 16.6 
 
1.00 
 
 Yes 37.6 8.9 
 
0.53 0.23 - 1.18 
 136 
Variable 
% subjects 
MPR≥95% 
% subjects 
MPR<95% 
p-value 
Univariate 
OR 
95% CI 
Other medication 
  
0.09 
  
 No 43.9 19.1 
 
1.00 
 
 Yes 30.6 6.4 
 
0.48 0.19 - 1.13 
Adverse drug reactions 
  
0.20 
  
 No 35.7 15.3 
 
1.00 
 
 Yes 38.8 10.2 
 
 0.61 0.27 - 1.34 
Antiretroviral resistances 
 
0.58 
  
 No 66.9 19.7 
 
1.00 
 
 Yes 9.6 3.8 
 
1.35 0.40 - 4.09 
Therapeutic Drug Monitoring over 2008 year 
 
0.73 
  
 No 70.0 22.3 
 
1.00 
 
 Yes 6.4 1.3 
 
0.63 0.06 - 3.17 
AIDS classification at diagnosis  
  
0.64 
  
Non-AIDS 39.0 14.7 
 
1.00 
 
AIDS 35.8 10.5 
 
0.78 0.27 - 2.18 
Previous LyT CD4+ cell count   0.12 
  
 < 350 cell/μl 16.6 8.3 
 
1.00 
 
 ≥ 350 cell/μl 54.1 13.4 
 
0.50 0.20 - 1.24 
12 months before baseline LyT CD4+ cell count  0.81 
  
 < 350 cell/μl 18.4 5.9 
 
1.00 
  ≥ 350 cell/μl 59.5 16.2 
 
0.85 0.31 - 2.48 
Previous viral load  
 
0.02 
  
 Non-detectable 56.7 13.4 
 
1.00 
 
 Detectable 14.6 9.6 
 
2.74 1.12 - 6.63 
12 months before baseline viral load  
 
0.81 
  
 Non-detectable 59.3 17.8 
 
1.00 
 
 Detectable 18.5 4.4 
 
0.80 0.24 - 2.32 
Opportunistic infections 
  
0.36 
  
 No 39.5 15.9 
 
1.00 
 
 Yes 35.0 9.6 
 
0.67 0.30 - 1.49 
*Qui-square test for trend. †Number of different HAART regimens at baseline, including the current one. OR, odds ratio estimate; 
CI, confidence interval; NRTI, Nucleoside Reverse Transcriptase Inhibitor; NNRTI, Non-Nucleoside Reverse Transcriptase 
Inhibitor; PI, Protease Inhibitor; ART, Antiretroviral therapy; HAART, Highly active antiretroviral therapy, defined as any regimen 
containing three or more antiretroviral medications or containing a NNRTI and a PI; IDU, Injection Drug Use. 
Table IV.2.3 shows the logistic regression model and the OR estimates. Adjusting for the 
variables that presented P≥0.15 in the univariate analysis, having periods of at least 12 months 
without medical appointments previous to baseline and 3 or less years of HAART experience 
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remained as significantly associated to non-adherence. The final model was considered 
adequate according to the Hosmer-Lemeshow test (statistic value =6.9, P=0.547). The ROC 
curves returned an area under the curve of 0.801, with a sensitivity of 80.0% and a specificity 
of 74.3%. 
Frequency and length of medication GAPs 
For non-adherent subjects (MPR<95%), we have analysed the frequency and length of 
medication GAPs. As shown in Figure IV.2.4, 18.4 % of the non-adherent subjects had only 
one GAP, whereas 71.1 % had less than 4 GAPs (median 2.5, IQR: 2.0-4.0). The majority 
(81.5%) of the observed GAPs had lengths <50 days, and 68.9 % were <30 days. The 
distribution of GAPs per subject confirmed that 81.6% of the non-adherent subjects had more 
than one GAP with length <30 days. 
Table IV.2.3. Adjusted associations for non-adherence. 
Variable β OR 95% CI p-value 
(Intercept) -3.35 0.04 (0.00 - 0.26) < 0.01 
Co-morbidities 
    
 No 
    
 Yes 0.68 1.95 (0.76 - 4.89) 0.15 
Mean number of medical appointments per subject's year of HAART experience 
 More than 3 
    
 3 or less 0.86 2.37 (0.68 – 8.24) 0.17 
Previous non-adherence periods > 12 months 
    
 No 
    
 Yes 1.96 7.14 (1.71 – 29.78) 0.01 
Viral load 
    
 Non-detectable 
    
 Detectable 0.59 1.80  (0.70 - 4.64) 0.22 
Time on HAART (years) 
    
 More than 7 
    
 5 – 7 0.44 1.55 (0.45 – 5.30) 0.48 
 4 or less 2.11 8.26 (1.89 – 36.08) 0.01 
Age (years) 
    
 Older than 45 
    
 36 – 45 -1.18 0.31 (0.10 – 0.99) 0.05 
 35 or younger 0.51 1.67 (0.54 – 5.15) 0.37 
Number of previous HAART regimen 
    
 More than 1 regimen 
    
 1 regimen 0.50 1.65 (0.55 – 4.95) 0.37 
OR, odds ratio estimate; CI, confidence interval; ART, Antiretroviral therapy 
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Figure IV.2.4. Distribution of medication GAPs, observed for the non-adherent subjects (MPR<95%) over 
2008: frequency of GAPs per subject (a); frequency of the lengths of all observed GAPs; d) number and length 
of observed GAPs, for each non-adherent subject, according to MPR%  
[0-50[ (red), [50-75[ (yellow), and [75,95[ (green). 
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Association of average non-adherence with immunological and virological outcomes 
We identified a statistically significant (P<0.001) decrease in the proportion of subjects with 
at least one 2008 record of CD4 cell count <350/µl across different adherence levels. In fact, 
this proportion was 85.7% among the subjects with MPR<50%, decreasing to 57.1% for 
subjects with MPR between 50 and 74% and to 22.1% for those with MPR≥75% (Figure 
IV.2.5). A statistically significant (P=0.008) decrease was also observed for the proportion of 
subjects with detectable viral load, though this proportion was similar in the less adherent 
levels: 57.1% among the subjects with MPR<50% and MPR 50-74%, while only 22.4% had 
detectable viral load when MPR≥75% (Figure IV.2.5). No statistically significant differences 
were observed between adherence level 75-95% and ≥95%, for both outcomes. 
 
Figure IV.2.5. Proportion of subjects with at least one record of CD4 cell count <350/µl (a) or detectable viral 
load (b), for different adherence’ levels, over 2008. No statistically significant differences were observed 
between adherence level 75-95% and ≥95%, for both outcomes. The error bars represent 95% CIs around the 
estimate of the respective proportions, assuming a binomial probability distribution and using the sample sizes 
listed. P*, p-value for the χ2 test for trend. 
a)            P*< 0.001 b)                 P*  = 0.008 
     n=7                     n=7                           n=131      n=7                    n=7                          n=134 
 140 
The decrease in the proportion of subjects with CD4 cell count <350/µl was also observed 
across different adherence levels, within time strata after HAART initiation (Figure IV.2.6) 
and according to HIV infection status (AIDS vs. non-AIDS) at diagnosis (Figure IV.2.7). The 
decrease seemed to be more evident among the subjects with 3 or more years on HAART 
when comparing to subjects with less time on HAART, as well as among non-AIDS subjects 
when comparing to those presenting AIDS at the moment of HIV infection diagnosis. 
 
 
 
Figure IV.2.6. Proportion of subjects with at least one record of CD4 cell count <350/µl (a) or detectable viral 
load (b) over 2008, for different adherence’ levels and according to time on HAART. No statistically significant 
differences were observed between adherence level 75-95% and ≥95%, for both outcomes. The error bars 
represent 95% CIs around the estimate of the respective proportions, assuming a binomial probability 
distribution and using the sample sizes listed. P*, p-value for the χ2 test for trend. 
 
a) P*= 0.15  P*< 0.001 b) P*= 0.24  P*= 0.05 
n=5        n=4     n=30 n=2        n=3     n=101 n=5        n=4     n=32 n=2        n=3     n=102 
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Figure IV.2.7. Proportion of subjects with at least one record of CD4 cell count <350/µl (a) or detectable viral 
load (b) over 2008, for different adherence’ levels and according to HIV infection status (AIDS vs. non-AIDS) at 
diagnosis. No statistically significant differences were observed between adherence level 75-95% and ≥95%, for 
both outcomes. The error bars represent 95% CIs around the estimate of the respective proportions, assuming a 
binomial probability distribution and using the sample sizes listed. P, p-value for the χ2 test for trend. 
 
 
Regarding the proportion of subjects with detectable viral load, a linear decrease (with higher 
adherence’ levels) was only identified among the subjects with less than 3 years on HAART, 
even if not statistically significant (Figure IV.2.6). Subjects with MPR 50-75% had higher 
proportions of detectable viral load among those with 3 or more years of HAART experience 
(Figure IV.2.6), as well as among non-AIDS subjects (Figure IV.2.7). We did not observe a 
significant pattern for detectable viral load distribution across the different adherence’ levels, 
among AIDS subjects (Figure IV.2.7). 
a) P*= 0.03  P*= 0.02 b) P*= 0.49  P*= 0.01 
n=5        n=3     n=43 n=2        n=3     n=85 n=5        n=3     n=44 n=2        n=3     n=85 
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Figure IV.2.8. Proportion of non-adherent subjects (MPR<95%) with at least one record of CD4 cell count 
<350/µl or detectable viral load over 2008, according to the mean duration of observed medication GAPs [a) and 
b), respectively], and considering different levels of non-adherence [c) and d), respectively]. The error bars 
represent 95% CIs around the estimate of the respective proportions, assuming a binomial probability 
distribution and using the sample sizes listed. P, p-value for the χ2 test for trend. 
c) P*= 0.01  P*= 0.10 d) P*= 0.10  P*= 1.00 
n=0        n=3     n=15 n=7        n=4     n=5 n=0        n=3     n=15 n=7        n=4     n=7 
a)  P*= 0.01 b)  P*= 0.09 
n=18 n=16  n=18 n=18  
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Medication GAPs and immunological and virological outcomes 
Among the non-adherent subjects (MPR<95%), we identified a higher proportion of subjects 
with at least one record of CD4 cell count <350/µl or detectable viral load, for those subjects 
with a mean duration of observed medication GAPs superior to 30 days (Figure IV.2.8). For 
subjects with GAP>30days, strata of MPR<50% had a higher proportion of subjects with 
CD4<350/µl. No significant differences were observed across MPR levels, for the proportion 
of subjects with detectable viral load, and there were no subjects with GAP<30days and 
MPR<50%. 
 
Discussion 
Adherence to antiretroviral treatment is a multifactorial behaviour and dependent on a given 
clinical and cultural setting [2, 9]. Our study results support earlier findings, showing 
identification of non-adherence determinants among variables related to subject 
characteristics, to health care system and to HIV infection and its treatment. Non-adherence 
complexity is also a result from different patterns of non-adherence [9,  22]. We observed that 
it ranged from short and repeated periods without medication to longer periods, with different 
impact on both immunological and virological outcomes. 
 
Non-adherence to HAART is more likely among recent HAART users but also for subjects 
that had a previous 12-month period without a medical appointment. 
It is recognized that the association between socio-demographic factors and adherence to 
HAART is unclear [9, 23]. In our cohort, younger subjects were more likely to be non-
 144 
adherent, as reported by other studies [20, 24, 25], but this association was less evident when 
adjusting for other variables. Nonetheless, having less than 3 years of treatment experience, 
which includes subjects that initiated HAART or were in their first regimen at baseline, 
remained significantly associated to non-adherence. Thus, our results reinforce the need for a 
closer follow-up at the beginning of HAART, as recommended by national and international 
guidelines [26, 27]. 
 
Having abandoned medical appointments for a 12-month period was another factor associated 
to non-adherence, and probably related to previous record of detectable viral load after 
HAART initiation. Other studies have also showed that non-adherence to HAART 
medications seems not to be a random event, since subjects reporting non-adherence were 
more likely to continue to be non-adherent between consecutive visits [ 28 , 29 ]. These 
findings suggest that attention should be paid to subjects with more HAART experience, in 
order to prevent repeated non-adherence periods. Adherence to HAART must be assessed 
frequently, alongside with other factors such as beliefs about medication and social support 
that may also impact non-adherence [9, 30, 31]. In Portugal, a prospective study is now being 
conducted to evaluate the association of these variables, not registered in clinical records, 
with HAART use among our study population. 
 
Short and repeated medication GAPs are frequent among non-adherent subjects. 
There are several pharmacy-based measures of adherence to medication [16]. The assessment 
of medication GAPs allows a characterization of how frequent it is for a subject to be without 
medication, while MPR assessment may dilute periods of undersupply of medication [32]. In 
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our study cohort and during the 2008 year, near 71% of the non-adherent subjects experienced 
1 to 3 periods without HAART, and medication GAPs with a length <50 days were frequent. 
However, several patterns of non-adherence were observed. In fact, most of study subjects 
had repeated periods of less than 30 days without medication, that resulted in moderate to 
high adherence levels (MPR>50%), while others presented longer periods without HAART 
and lower adherence levels. Using electronic monitoring of adherence, Parienti et al. also 
found a higher variability of periods without medication among lower average adherence rates 
[22, 33]. Compared to electronic monitoring, the pharmacy refill monitoring does not enable a 
complete characterization of HAART interruption patterns [22] but further studies should 
assess its validity as it may provide earlier information to promote adherence, while being 
more feasible in clinical practice and resource-poor settings [34].  
 
Non-adherence is associated with lower CD4 count and detectable viral load, but other 
factors should also be taken into account when evaluation HAART outcomes. 
Our study results showed a significant decrease in the proportion of subjects that had CD4 
count <350/µl and in the proportion of those having viral load >40 copies/ml, when increasing 
the average (MPR) adherence to HAART. A dose-response relationship between adherence 
and viral suppression has been well described in previous studies, for HAART regimens PI- 
or NNRTI-based [20, 35]. We also have found no significant differences regarding both 
outcomes, when comparing average adherence between 75 to 94% with the recommend level 
of ≥95%. Furthermore, there seem to be no differences on the probability of having detectable 
viral load in the less adherent levels (<50% and 50-75%) and the linear decrease observed 
among subjects with less than 3 years of HAART experience was marginally significant. 
Besides our study small sample size, other possible explanation is that more than 50% of our 
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study subjects were receiving a NNRTI-based regimen, for which it has been pointed out that 
viral suppression is possible with adherence levels <95% [35, 36 ]. The higher NNRTI 
“forgiveability” was showed by clinical trials and observational data and it is mainly due to 
their antiretroviral potency and long plasma drug half-lives [37], and may result in a less 
evident dose-response effect than the one described for PI-based regimens [36].  
 
We also found that subjects with MPR 50-75% and 3 or more years of HAART experience or 
classified as non-AIDS at the moment of HIV diagnosis, seem to have a higher probability of 
presenting detectable viral load. The finding that more experienced subjects may have higher 
probability of virological failure is not supported by previous studies and should be confirmed 
in a larger study sample since it may indicate the presence of antiretroviral resistances [3, 36]. 
We have collected data about resistance when it was mentioned in the clinical records, but an 
active assessment would enable a better characterization of this determinant of treatment 
failure. Hence, even though viral suppression may be possible with moderate levels of 
adherence, physicians should continue to promote the highest level of adherence possible [36, 
37].  
 
It has been described that the risk of immunological failure diminishes with a longer HAART 
experience and is associated with higher pre-treatment CD4 cell count, ongoing viral 
replication, and intravenous drug use [38]. Our study results also indicate that subjects with 3 
or more years of HAART experience had a lower probability of presenting CD4 count 
<350cell/µl, with a significant dose-response effect related to average adherence levels. 
However, we found that subjects presenting higher CD4 count at diagnosis (and classified as 
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non-AIDS) had also lower probability of having CD4 count <350cell/µl. Some possible 
hypotheses are that 1) subjects presenting AIDS at diagnosis had more difficulty in achieving 
and maintaining CD4 count ≥350cell/µl, due to a lower baseline cell count (<200cells/µl) or 
to the presence of opportunistic diseases, 2) non-AIDS subjects have a higher CD4 cell count 
that decreases linearly with lower adherence level but remains higher than the mentioned 
threshold, 3) previous findings had promoted a change in clinical practice that placed subjects 
with higher CD4 count under a closer follow-up by the physicians, and that 4) the nowadays 
earlier beginning of HAART (in some cases, even when CD4 count is >500cell/µl) had lead 
to a stronger protection of immunological failure among non-AIDS subjects [27]. Further 
studies are required to confirm this hypothesis. 
 
HAART gaps and immunological and virological outcomes 
Similar to other studies, we have found that non-adherent subjects (MPR<95%) having 
HAART gaps with a mean length ≥30days had more probability of presenting worse 
immunological outcomes. In fact, a previous study also showed that subjects with gap 
≥30days had less gain in CD4 count (80.7 cells/µl less) than those without gaps [34]. 
Additionally, when assessing the impact on CD4 count of both average adherence and 
duration of HAART gap, we observed that having a mean duration of gaps ≥30days is a 
relevant condition for presenting CD4 <350 cells/µl, since differences across average 
adherence levels were marginally significant. On the other hand, average adherence seems to 
be more relevant when subjects had a mean duration of gaps <30days. A possible explanation 
is that CD4 changes to values less than 350 cell/µl require lower levels of HAART exposition 
that may occur with single longer periods or from cumulative shorter medication gaps.  
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Regarding virological outcomes, the difference among non-adherent subjects having HAART 
gaps with a mean length ≥30 or <30 days was marginally significant. This finding may be due 
to lack of power, since previous studies showed that longer HAART gaps are associated with 
higher probability of having detectable viral load, for different antiretroviral regimens [22, 
33]. Nevertheless, our study results also indicate that subjects with mean duration of HAART 
gap ≥30 days had identical probability of showing detectable viral load across different 
average adherence levels. 
Medication gaps seem to have a different impact in immunological and virological outcomes, 
a finding that was already discussed in other studies and that is related to the causal 
relationship between adherence, virological failure and immunological decline [38]. Our 
results support Bisson et al. recommendation for the inclusion of pharmacy-based measures 
of adherence as predictors of virological failure in resource-poor settings, besides CD4 count 
[39]. The identification of HAART gaps may prevent virological failure, enabling adherence 
interventions aiming to prolong time on first-line of HAART, while CD4 count monitoring 
only detects virological failure after it has already occurred [39]. 
 
Study limitations 
A first limitation is related to the lack of power to evaluate possible associations between 
adherence and its determinants and outcomes. This is particularly relevant during the logistic 
regression analysis, which resulted in a final model that is adequate and explains non-
adherence determinants despite the fact that several variables had lost their statistical 
significance. The small sample size may also lead to spurious associations when comparing 
the immunological and virological outcomes for different adherence levels and a third 
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variable. Nevertheless, several findings are in accordance with previous studies, supporting 
their validity. 
Secondly, adherence was assessed through pharmacy-based measures, which assumes that 
subjects will take their medication once it is available after a refill. This may result in an 
overestimation of adherence to HAART because subjects may not take all of their refilled 
medication. Even so, pharmacy records correlate well with electronic monitoring, drug 
resistance, viral suppression or rebound, and survival, and we may assume that patients would 
not continue to refill a prescription without intending to adhere to HAART [35]. 
Underestimation of adherence is less likely to occur since Portuguese subjects receive 
HAART only from the pharmacy at the hospital at which they are followed. We also included 
leftovers from previous refills, resulting in a more conservative estimation of non-adherence.  
However, we were unable to correct MPR and HAART gaps assessment with information 
regarding hospitalizations during 2008 as well as treatment interruptions due to clinical 
decision that may have resulted in underestimation of HAART adherence. 
Another limitation is that adherence data and virological or immunological outcomes were 
presented only in aggregate form, and we have not assessed individual adherence as a time-
dependent variable. As a result, reverse causation is possible and subjects who experience 
poor outcomes related to virological failure may subsequently stop taking HAART. 
Confounding by indication may also be present. Although our cohort was largely HAART 
experienced, NNRTI-based regimens may have been selected as first option to reduce the risk 
of non-adherence and promote a better viral suppression at moderate adherence levels. This 
may explain why being HAART-naïve was a variable not included in the final model. 
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Finally, our study reflects the current situation of the present heterogeneous patient population 
in a country with universal access to care, at hospital care level. Hence, the study design 
implied that subjects had to survive until 2008 and a selection bias may be present with an 
overestimation of adherence. 
 
Clinical implications 
Our study results actualize information about adherence to HAART and its determinants, 
suggesting that two groups of HIV-1 infected subjects should have more frequent evaluations 
of non-adherence: subjects with less HAART experience and those that had already abandon 
medical appointments for a period>12 months. It also shows that viral load is not a good 
proxy of non-adherence, especially in some situations such as when subjects had more than 3 
years of HAART experience, and that CD4 count is less susceptible to change due to shorter 
periods of non-adherence. In this manner, pharmacy-based measures may be useful to identify 
subjects with lower to moderate average adherence levels and shorter HAART gaps, enabling 
the use of targeted interventions to promote the higher levels of adherence to medication. 
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V.1. 
Overall discussion of study results 
Antiretroviral treatment has undergone considerable changes in the last decade, with more 
options being available nowadays. Guidelines on HIV infection management recommend 
early starting of treatment and closer medical follow-up in order to assess drug resistance and 
toxicity, as well as to maintain patient’s adherence to treatment. 
Adherence to treatment is not a new issue, with physicians reporting this problem since the 
time of Hippocrates [ 1 ]. The impact of adherence has been well demonstrated in the 
HIV/AIDS infection. Adherence to antiretroviral regimens was associated with virological, 
immunological and clinical outcomes, as well as drug resistance and healthcare utilization and 
costs. In fact, adherence to HAART is recognized as an essential component of treatment 
success and high levels (>90% or >95%) are required.  
 
There have been some studies conducted in Portuguese hospitals, regarding adherence to 
antiretroviral treatment. The reported prevalence rates of patient adherence ranged from 46 to 
91%, due to different settings, study population and adherence measures. In fact, quantitative 
assessment of adherence remains a challenge and several measures were defined, but there are 
no “gold standard” to evaluate adherence and all measures show some limitations. 
 
Nevertheless, the study of patient adherence and its determinants is essential to define 
effective intervention strategies in order to promote a better use of antiretroviral drugs. This is 
particularly relevant in the Portuguese reality, due to a high rate of new HIV infection among 
Western and Central European region countries, the increasing prevalence of this condition, 
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the high AIDS-related mortality and the public expenditure with antiretroviral treatment. In a 
time of limited resources, it is relevant to identify which patients are at increased risk of non-
adherence, as potential target groups for preventive strategies. 
 
We aimed to characterize patient non-adherence to antiretroviral treatment among HIV-1 
infected adult subjects followed up at the HIV outpatient clinic from Hospital de Santa Maria 
(Lisbon, Portugal), a university tertiary central hospital and the largest hospital in Portugal. 
Over the period 2005-2008, we have observed an increase in the prevalence of non-adherence 
to HAART, from 12.3% in 2005 to 25.9% in 2008. This finding contrasts with the ones from 
a similar Spanish study, that showed a decrease from of non-adherence from 23.7% in 2005 to 
20.7% in 2008 [2]. Furthermore, the observed increase of non-adherence seemed to be related 
to an increase of the proportion of subjects with moderate adherence (MPR 75-95%), which 
may explain the decrease in the proportion of subjects with detectable viral load. In fact, 
previous studies have found that to NNRTI-based regimens, which were prescribed to most of 
our study subjects, could lead to viral suppression with adherence levels lower than 95%. 
However, moderate levels of adherence may trigger drug resistance. Therefore, the 
achievement and maintenance of high adherence levels should be promoted by healthcare 
providers, especially among IDU, subjects with depression/anxiety conditions and during 
holiday seasons.  
 
IDUs are usually referred as a risk group for non-adherence to treatment, namely active 
substance abusers [3, 4]. Although some studies have shown that history of drug use [5, 6] or 
IDU as a source of acquisition of HIV infection [7] were unrelated to adherence, others have 
found lower levels of adherence to HAART among IDUs, leading to lower virological 
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response rates [4, 8]. Our study results also showed that IDUs had a mean non-adherence rate 
higher than the mean from all subjects. Although we were unable to distinguish between 
former and current IDUs, these findings suggest that healthcare providers should promote 
adherence strategies for these subjects, by addressing the patient’s concerns about the 
medications and raising awareness of possible side effects [3]. 
 
Depression and anxiety are described as predictors of non-adherence, since they may reduce 
motivation and ability to take medication as prescribed [3]. Although we were unable to 
verify if depression/anxiety were associated with non-adherence, the proportion of subjects 
with MPR<95% was higher among those subjects with these conditions. Hence, physicians 
should assess a diagnosis of depression and provide closer monitoring of adherence is 
suggested [5]. 
 
An interesting finding was that mean adherence level was lower in the second calendar 
semesters. A possible explanation is that skipping medical appointments and medication 
refills are more likely to happen during holiday seasons (in Portugal, summer vacations 
usually take place during July-September months). Thus, healthcare providers may prevent 
non-adherence by prescribing for more than one month, alongside with the assessment of 
patient barriers to take HAART during this period. 
 
Evaluation of non-adherence determinants was incomplete when assessing adherence to 
HAART through calendar years. On the other hand, we have observed a decrease in the 
proportion of detectable viral load over years, even though non-adherence has increased. 
Hence, we aimed to evaluate determinants and patterns of non-adherence for those subjects 
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prescribed to HAART during 2008, and to verify its impact in terms of virological and 
immunological outcomes, at individual level. 
 
We have found HAART low-experienced subjects and those skipping medical appointments 
for a period >12 months to be more likely non-adherents. It has been well described that 
HAART-naïve subjects are more likely to be non-adherent during the first year of treatment 
[9]. Our study results suggest that subjects who had already experienced non-adherence – to 
treatment and medical appointments – were also at increased risk of becoming non-adherent 
for a second time. Although recent guidelines mention that adherence should be evaluated in 
the presence of virological failure, our findings support the European 2011 recommendation, 
to monitor adherence barriers in each medical appointment [10]. Other healthcare providers – 
including pharmacists at the moment of medication refill – should also assess and promote 
adherence [3, 11]. 
 
We have confirmed that subjects with high adherence to HAART were less prone to have 
detectable viral loads and CD4 counts <350/µl, but time on HAART and AIDS classification 
at diagnosis were also related to virological and immunological outcomes. Patient adherence, 
time on HAART, CD4 count at diagnosis and resistances are major determinants of clinical 
outcomes. However, further studies are required to describe the interactions between these 
factors in clinical outcomes of long-term treated subjects. 
 
Non-adherence complexity is also a result of its different patterns [12]. We observed that  
non-adherence ranged from short but repeated periods to fewer but longer periods without 
medication. Among non-adherent subjects (MPR<95%), those with medication gaps with a 
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mean length ≥30 days were at higher risk of worse immunological outcomes, even though no 
significant differences were observed when considering viral suppression. This finding may 
be due to the relationship between adherence, virological failure and immunological decline 
[13]. Since virological outcomes are more susceptible to shorter periods of non-adherence that 
immunological decline, the identification of HAART gaps may be used to prevent virological 
failure, enabling adherence interventions to prolong time on first-line of HAART [14]. 
 
 Completeness of the clinical and pharmacy records 
An important limitation of retrospective studies is the quality of data. When considering 
completeness of clinical hand-written records, we have found that several socio-demographic 
variables had a large proportion of missing information. Table V.1.1 summarizes the missing 
information for main study variables, in 2008. 
These findings may not reflect the physicians’ lack of information regarding each patient 
condition. However, records are important for quality assessment as well as for clinical 
studies [ 15 ]. The introduction of electronic medical records, integrated or not with 
surveillance systems, may result in better management of HIV/AIDS infection [16]. 
 
The pharmacy records are used for administrative purposes and seem to be more complete, 
while only intake frequency was not registered over the period 2005-2008. The integration of 
electronic prescription may prevent introduction limitations at the moment of medication 
dispensing. 
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Table V.1.1. Missing information (number of subjects and percentage) for study variables at baseline, for the 
total of 157 participants followed in 2008. 
 
n (%) 
Gender 0 (0.0) 
Age 0 (0.0) 
Race 33 (21.0) 
Birthplace 74 (47.1) 
Professional status at diagnosis ‡ 26 (16.6) 
Mode of acquisition for HIV infection 7 (4.5) 
Past or current IDU, % * 
Co-morbidities, % * 
Past or current Depression/Anxiety, % * 
AIDS classification at diagnosis 62 (39.5) 
AIDS classification at baseline 12 (7.6) 
Detectable viral load
 (a)
 9 (5.7) 
CD4 count < 350 cells/µl
 (b)
 12 (7.6) 
Opportunistic infections 
(c)
, % * 
HAART-naïve, % * 
Time on HAART 0 (0.0) 
Started ART with non-HAART regimens * 
Time since HIV diagnosis 4 (2.5) 
Skipped medical appointments
 (d)
, % * 
Hospitalized
 (e)
, % * 
Previous non-adherence periods > 12 months
 (f)
, % * 
Other medication, % * 
Adverse drug reactions 
(g)
, % * 
Antiretroviral resistances, % * 
Therapeutic Drug Monitoring over 2008 year, % * 
 
* Variables for which the absence of information may also be explained by the subjects not presenting these conditions (see 
Table IV.2.1. for more information). ‡ Professional status as registered in the subjects’ first medical appointment. 
Considering the clinical history previous to baseline, table shows % of subjects with missing information regarding the 
presence of at least one (a) medical appointment with detectable viral load, (b) medical appointment with CD4 cell count 
<350/µl, (c) opportunistic infections, (d) skipped medical appointment, (e) hospitalization, (f) one previous non-adherence 
period > 12 months and (g) one adverse drug reaction. ART, Antiretroviral therapy; HAART, Highly active antiretroviral 
therapy, defined as any regimen containing three or more antiretroviral medications or containing a NNRTI and a PI; IDU, 
Injection Drug Use. 
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 Study limitations 
Study limitations have already been discussed. They are mainly related to the small sample 
size when comparing to published studies, and to the procedure of collecting data from hand-
written clinical records. In fact, it is difficult to obtain clinical data from large datasets of 
HIV-infected subjects in Portugal, since there is no electronic database available. Hopefully, 
the registry that is now being developed by CNSida will enable more research in the future. 
Other study limitation is related to the use of pharmacy-based measures. As discussed 
previously, when using ART refill data, we must assume that all refilled medication will be 
actually taken by the subjects, which may result in adherence overestimation. Another 
limitation is that we have not assessed individual adherence as a time-dependent variable, 
which may lead to reverse causation since subjects who experience poor outcomes related to 
virological failure may subsequently stop taking HAART. Other main limitations are due to 
the cohort design, such as the possibility of confounding by indication related to the selection 
of NNRTI-based regimens as first option (to reduce the risk of non-adherence) and the 
possible selection bias related to the inclusion of subjects that had survived until 2008. 
 
 Main conclusions and clinical implications 
We can summarize the main clinical implications of the study as follows: 
 Adherence should be promoted among IDU and subjects with depression / anxiety, and 
during holiday seasons. 
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 Subjects with less HAART experience and those that had already abandon medical 
appointments for a period >12 months should be subject to a close monitoring of 
adherence to antiretroviral drugs and its barriers.  
 Viral load is not a good proxy of non-adherence especially when subjects had more than 3 
years of HAART experience, and pharmacy-based measures may enable the identification 
of subjects at risk of non-adherence and consequent drug resistance. 
 
 Future research 
As future research, we propose a national study on patient adherence to HAART and with the 
assessment of its determinants. Although we expect that the national registry being now 
developed by CNSida may provide more information on HIV infection management, our 
project results show that several variables that will not be collected in this registry are 
potentially associated to non-adherence. Hence, we propose a national multicentre cohort 
study with HIV-1 infected subjects receiving HAART.  
 
With the ATAR-VIH project, we aim to identify the prevalence and determinants of patient 
non-adherence, and to provide comparative information to support health planning regarding 
HAART utilization and HIV infection management in Portugal. The study will also enable a 
better evaluation of adherence dynamic, with the characterization of HAART modifications, 
its associated factors and its relation with patient adherence, as well as a better understanding 
of the relationship between adherence and progression of HIV/AIDS, confirming the 95% 
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adherence level assumed as the ideal or retrieving information for some parameters usually 
incorporated into pharmacoeconomic models. 
 
It is true that cohort studies are demanding, expensive and prone to irregular dropout or 
attrition [17, 18]. Nevertheless, HIV/AIDS infection-specific cohorts are epidemiological 
tools that enable the evaluation of effectiveness, beneficial/adverse effects and resistance 
profile for different HAART regimens; research in social determinants of HIV infection and 
management, in population groups such as injection-drug users, migrants, women and older 
subjects, and comparison of clinical outcomes and associated factors between subjects with a 
long experience on HAART and naïve patients. A cohort study also promotes translational 
research, e.g. regarding pharmacological or virus-host interaction mechanisms [17, 19], and a 
way to assess the impact of policy measures at local and national level, regarding HIV/AIDS 
management [ 20 , 21 ]. In this context, the ATAR-VIH project may also provide an 
opportunity to promote a national network of clinical and epidemiological researchers in 
HIV/AIDS infection and HAART utilization. 
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serious work done on it, through the elaboration of the original vague idea and through the 
consolidation of the first fleeting and passing thought. 
Vincent to Theo van Gogh, July 1880 
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Annex III 
the ATAR-VIH national project – sampling process 
 
Sampling 
A multistage cluster sampling approach will be conducted, similar to previous studies [1]. 
Information regarding the total number of HIV-1 infected subjects followed at each 
Portuguese hospital at December 31, 2011 will be asked to the CNSida or, if unavailable, to 
each Portuguese hospital. This data will update the most recently available official 
information, regarding the number of hospitals following more than 200 HIV-infected 
subjects under HAART. 
Moreover, a feasibility evaluation will be conducted, with a survey among the directors of the 
infectious diseases’ departments (or internal medicine, when applicable), from the Portuguese 
hospitals, aiming for an overall characterization of the clinical practice and research 
experience. For a random sample of 10 Portuguese hospitals following more than 200 HIV-
infected subjects on HAART, each director of the infectious diseases’ department will be 
invited to the study. Replacement of refusing hospitals will be allowed. In the selected 
hospitals, physicians will be asked to participate in the study. Their participation consists in 
the identification of eligible patients to be enrolled in a 2-month period and the filling in of a 
form related to the participants’ clinical visits. 
 
 
 
 Sample size 
According to official data, 18 093 subjects were receiving HAART in 2005. We assumed that 
the true prevalence of non-adherence to HAART was 50% and that the precision of the 
estimate of non-adherence prevalence was to be ± 5% (α=.05) of the true frequency of non-
adherence to HAART. Hence, we defined a total sample size of 373 subjects at 12-month 
evaluation, considering the formula: 
 
Assuming a 40% refusal rate, we defined that invitation should be made to at least 530 
eligible subjects. Then, we stratified the sample size assuming the participation of 10 out of 
the 24 hospitals following more than 200 subjects on HAART, in 2005. To define an estimate 
for the sample size needed in HSM, we assumed the worst scenario in which, after random 
selection, the remaining 9 hospitals were those having fewer subjects on HAART, thus 
increasing the strata in HSM (Table III.1). 
Given a statistical power of 80%, and assuming non-adherence as a dichotomous variable, it 
will be possible to detect relative risks of 1.5 or more for different risk factors, when non-
adherence rate among controls is 0.4. Also, with this sample size, we will be able to detect 
differences of viral load means of adherents vs. non-adherents. For instance, assuming a 
standard deviation of 150 copies within each group, if the true difference in the groups’ means 
is 50, we will need to study 142 subjects per group to be able to reject the null hypothesis that 
the population means of the experimental and control groups are equal (power=0.8, α=0.05). 
This sample size will allow multivariate models, even more as repeated measures will be 
taken. Assuming that lost to follow-up could be up to 20% per year, the sample size will be 
increased by 30%. Therefore, the final sample size should be 490 subjects. We should invite 
       11  NnnNPPZd
 640 eligible subjects, assuming a 30% refusal rate. To find how many patients should 
participate by study centre, we will have a stratified approach that takes into account the total 
number of HIV-infected subjects receiving HAART from that centre. 
 
Table III.1. Initial sampling estimates for the ATAR-VIH-study. 
 
n n+40% 
 1 124 199 Hospital Santa Maria, EPE  
2 0 0 Hospital Curry Cabral  
3 100 159 Centro Hospitalar Lisboa Ocidental  
4 86 138 Hospital de Joaquim Urbano  
5 0 0 Hospital São João, EPE 
6 0 0 Centro Hospitalar Lisboa Central  
7 62 100 Hospital Garcia de Orta  
8 0 0 Hospital Fernando Fonseca  
9 41 65 Centro Hospitalar de Cascais  
10 37 60 Hospitais da Universidade de Coimbra  
11 0 0 Centro Hospitalar de Vila Nova de Gaia  
12 61 98 Hospital de São Bernardo / Centro Hospitalar de Setúbal, EPE 
13 36 57 Hospital Pulido Valente  
14 0 0 Hospital Distrital de Faro  
15 0 0 Unidade Local de Saúde de Matosinhos  
16 26 42 Centro Hospitalar de Coimbra  
17 26 42 Hospital Nossa Senhora do Rosário, EPE 
18 0 0 Hospital Geral de Santo António, EPE 
19 0 0 Hospital Distrital de Santarém, EPE 
20 0 0 Centro Hospitalar Barlavento Algarvio, EPE 
21 0 0 Hospital S. Marcos 
22 0 0 Hospital Nossa Senhora da Oliveira, EPE 
23 0 0 Centro Hospitalar Médio Tejo, EPE 
24 0 0 Centro Hospitalar das Caldas da Rainha  
Total 373 596 
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Annex IV 
Conceptual Model of the ATAR-VIH project 
 
 
 
Study conceptual model (adapted from Sabaté E, ed: Adherence to long-term therapies: evidence 
for action. World Health Organization; 2003). Patient adherence to HAART is a multidimensional 
behaviour, as the associated factors may be related to patient characteristics, to health care access and 
utilization, with antiretroviral regimens or with the HIV/AIDS infection aspects. The ATAR-VIH will 
evaluate the major determinants of adherence to HAART, for the Portuguese context (black lines), and 
the impact of non-adherence on effectiveness of HAART regimens (dotted line). 
  
Annex V 
Clinical Data Collection Form (retrospective phase) 
 
Estudo ATAR-VIH: adesão à terapêutica anti-retrovírica 
 
 
Formulário para Recolha Retrospectiva de Dados - Processo Clínico 
 
CÓDIGO PARTICIPANTE: _________  DATA DE HOJE: ____  ____  2010  PREENCHIDO POR:_________ 
       (letra de máquina)           dia       mês     (iniciais) 
 
Verificação de Elegibilidade Sim Não 
No início da Terapêutica Anti-Retrovírica (TAR), o participante…   
a. é seguido no Hospital de Dia de Infecciologia? (se não, excluir) ☐ ☐ 
b. iniciou a TAR num outro hospital que não o HSM?  (se sim, excluir) ☐ ☐ 
c. iniciou a TAR em programa de toma sob observação directa?  (se sim, excluir) ☐ ☐ 
d. participou em algum ensaio clínico?  (se sim, excluir) ☐ ☐ 
e. estava detido quando iniciou a TAR?  (se sim, excluir) ☐ ☐ 
f. estava numa instituição social quando iniciou a TAR?  (se sim, excluir) ☐ ☐ 
g. tem pelo menos 2 consultas registadas entre 1 Janeiro 2005 e 31 Dezembro 2009? (se não, excluir) ☐ ☐ 
h. depende de outras pessoas para tomar a medicação ? (se sim, excluir) 
(incapacidade cognitiva grave ou física para tomar a medicação) 
☐ ☐ 
Desde o início da TAR e até 31 Dezembro de 2009, o participante…   
i. mudou de hospital desde o início da TAR?  
 (se sim, registar todos os dados até evento e a data do evento ____mês / ____ano) 
☐ ☐ 
j. passou a cumprir a TAR num programa de toma sob observação directa?  
 (se sim, registar todos os dados até evento e a data do evento ____mês / ____ano) 
☐ ☐ 
k. foi detido? (se sim, registar todos os dados até evento e a data do evento ____mês / ____ano) ☐ ☐ 
l. ficou sob o cuidado de uma instituição social? 
 (se sim, registar todos os dados até evento e a data do evento ____mês / ____ano) 
☐ ☐ 
m. passou a depender de outras pessoas para tomar a medicação ?(incapacidade cognitiva grave ou física para tomar 
a medicação) (se sim, registar todos os dados até evento e a data do evento ____mês / ____ano) 
☐ ☐ 
Dados Sócio-Demográficos (de acordo com última informação registada) 
 1.1 Sexo ☐ Masculino ☐ Feminino 1.2 Ano de Nascimento__________ ☐ sem informação (s/ info) 
 2.Naturalidade: País ______________ Distrito ______________  Etnia ___________ ☐ s/ info 
 a. Se não nasceu em Portugal, há quantos anos reside em Portugal? _________ anos ☐ s/ info 
 3.Nacionalidade: ______________  ☐ s/ info 
No início da TAR:  
 4.Residência:  
Distrito _____________  Concelho _____________ ☐ s/ info 
Alteração ou outra informação ao longo do processo: 
Data: (DD / MM / AAAA) 
  
Alteração: 
  
 5.Morava sozinho:  ☐ Sim ☐ Não ☐ s/ info 
a.Se não mora sozinho quais as pessoas com quem mora 
(marido/mulher, parceiro, filhos, etc.) ☐ s/ info 
 i. ___________________ ii.  ___________________  
 iii. ___________________ iv. ___________________ 
 6.Situação Profissional:  ☐ s/ info  
 a. Empregado ☐  profissão? __________________ ☐ s/ info 
 b. Desempregado ☐  última profissão? _____________ ☐ s/ info 
 c. Reformado ☐ última profissão? _____________ ☐ s/ info 
 d. Estudante ☐ 
 e. Doméstico ☐ 
Dados Clínicos Gerais 
 1.Data de diagnóstico da infecção VIH/SIDA:  ____ / _____ (MM / AAAA) [ou há ____ anos] ☐ s/ info 
 2.Ano provável de infecção: ___________ ☐ s/ info 
 3.Infecção por:  ☐ VIH-1 ☐ VIH-2 ☐ VIH-1 e VIH-2 ☐ s/ info 
 4.Categoria de transmissão:  ☐ s/ info ou a.  Toxicodependência IV ☐ b.  Sexual: Homossexual ☐ 
   c.  Transfusão ☐  d.  Sexual: Heterossexual ☐ 
   e.  Acidente de trabalho ☐ f. Desconhecido  ☐ 
   g. Outro ☐ Qual? __________________ 
 
 
Estudo ATAR-VIH: adesão à terapêutica anti-retrovírica 
 
 
 
 
 
1ª consulta registada e 1ª consulta com TAR prescrita 
Nesta consulta há 
registo sobre: 
1ª Consulta registada __/__/__ 1ª Consulta com TAR prescrita __/__/__  
Estadio CDC?  Sim ☐ Não ☐  Sim ☐ Não ☐ 
 A B C  A B C 
1    1    
2    2    
3    3    
CD4+ / CD8+?  Sim ☐ Não ☐ 
 células/mm3 Data: 
 Sim ☐ Não ☐ 
 células/mm3  Data: 
Carga Viral?  Sim ☐ Não ☐ 
 cps/mL Data: 
 Sim ☐ Não ☐  
 cps/mL  Data: 
Infecções 
oportunistas? 
 Sim ☐ Não ☐ 
Qual?_______________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_________________________________ 
Nenhuma ☐ 
Neoplasias?  Sim ☐ Não ☐ 
Qual?_______________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_________________________________ 
Nenhuma ☐ 
Co-morbilidades?  Sim ☐ Não ☐ 
Qual?_______________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_________________________________ 
Nenhuma ☐ 
Consumos de 
drogas? 
 Sim ☐ Não ☐ 
Qual?_______________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?________________________________ 
Nenhuma ☐ 
Terapêutica AR? 
Nome / Dose / 
Posologia 
 
Nota: indicar as associações 
fixas na mesma linha 
  Sim ☐ Não ☐ 
1.  
2. 
3. 
4. 
Outra Medicação 
prescrita? 
Nome / Dose / 
Posologia 
 Sim ☐ Não ☐  Sim ☐ Não ☐ 
1. 1. 
2.  2.  
3. 3. 
Outra Medicação 
conhecida? 
Nome / Dose / 
Posologia 
 Sim ☐ Não ☐  Sim ☐ Não ☐ 
1. 1. 
2.  2.  
3. 3. 
Comentários sobre a 
adesão à terapêutica? 
  Sim ☐ Não ☐ 
Qual?________________________________
_____________________________________ 
Recomendações 
sobre a adesão à 
terapêutica? 
  Sim ☐ Não ☐ 
Qual?________________________________
_____________________________________ 
Pedida avaliação de 
Resistências? 
 Sim ☐ Não ☐ 
 Resultado:_________________ Data: 
Sim ☐ Não ☐ 
 Resultado:_________________ Data: 
Observações sobre o 
Registo da Consulta 
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Informação registada desde 1ª consulta com TAR prescrita até 1 Janeiro 2005 (quando 
aplicável) 
 
 Número Datas 
Total de consultas   
Faltas   
Extra-consultas   
Internamentos   
Ausências superiores a 1 ano   
Só para receituário   
 
 
Informação registada desde 1 Janeiro 2005 até 31 de Dezembro de 2009 
 
 
Comentários 
Como classifica a facilidade em ler a informação do processo clínico: 1.☐ muito fácil 
          2.☐ fácil 
          3.☐ nem fácil nem difícil 
          4.☐ difícil 
          5.☐ muito difícil 
É necessário consultar o médico assistente? ☐ Sim
 motivo?_________________________________________      
 ☐ Não 
Outras notas 
 
 
 
 
 
 
 
 
 Número Datas 
Total de consultas   
Faltas   
Extra-consultas   
Internamentos   
Ausências superiores a 1 ano   
Só para receituário   
  
 
Sobre as consultas em que está registada mudança de TAR, preencher a tabela seguinte: 
Nesta consulta há 
registo sobre: 
__/__/__ (dd/mm/aa) __/__/__ (dd/mm/aa) __/__/__ (dd/mm/aa) __/__/__ (dd/mm/aa) 
Data da Consulta 
anterior? 
__/__/__  
CD4+/CD8+: ________ células/mm3 
Carga Viral: ________ cps/mL 
__/__/__ 
CD4+/CD8+: ________ células/mm3 
Carga Viral: ________ cps/mL 
__/__/__ 
CD4+/CD8+: ________ células/mm3 
Carga Viral: ________ cps/mL 
__/__/__  
CD4+/CD8+: ________ células/mm3 
Carga Viral: ________ cps/mL 
Motivo da 
mudança de 
regime? 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?________________________
____________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
__________________________ 
Nova Terapêutica 
AR? 
Nome / Dose / 
Posologia 
 
Nota: indicar as 
associações fixas na 
mesma linha 
1.  1.  1.  1.  
2. 2. 2. 2. 
3. 3. 3. 3. 
4. 4. 4. 4. 
Notas sobre a 
Medicação? 
    
Comentários 
sobre a adesão à 
terapêutica? 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
____________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
Recomendações 
sobre a adesão à 
terapêutica? 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?________________________
____________________________
____________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
___________________________
__________________________ 
TDM?  Sim ☐ Não ☐ 
Resultado?_________________ 
Sim ☐ Não ☐ 
Qual?_____________________ 
Sim ☐ Não ☐ 
Qual?____________________ 
Sim ☐ Não ☐ 
Qual?____________________ 
Pedido 
resistência? 
 Sim ☐ Não ☐ 
Resultado?_________________ 
Sim ☐ Não ☐ 
Qual?_____________________ 
Sim ☐ Não ☐ 
Qual?____________________ 
Sim ☐ Não ☐ 
Qual?____________________ 
Eeitos adversos?  Sim ☐ Não ☐ 
Quais?____________________ 
Sim ☐ Não ☐ 
Quais?____________________ 
Sim ☐ Não ☐ 
Quais?____________________ 
Sim ☐ Não ☐ 
Quais?____________________ 
Estadio CDC   Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
 A B C  A B C  A B C  A B C 
1    1    1    1    
2    2    2    2    
3    3    3    3    
CD4+ / CD8+?  Sim ☐ Não ☐ 
________ cél/mm
3
 Data: 
 Sim ☐ Não ☐ 
________ cél/mm
3
 Data: 
 Sim ☐ Não ☐ 
________ cél/mm
3
 Data: 
 Sim ☐ Não ☐ 
________ cél/mm
3
 Data: 
Carga Viral?  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
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Nesta consulta há 
registo sobre: 
__/__/__ (dd/mm/aa) __/__/__ (dd/mm/aa) __/__/__ (dd/mm/aa) __/__/__ (dd/mm/aa) 
________ cps/mL Data: ________ cps/mL Data: ________ cps/mL Data: ________ cps/mL Data: 
Infecções 
oportunistas? 
 
 Sim ☐ Não ☐ 
Qual?______________________
__________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?________________________
________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
Neoplasias? 
 
 Sim ☐ Não ☐ 
Qual?______________________
__________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?________________________
________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
Co-morbilidades?  Sim ☐ Não ☐ 
Qual?______________________
__________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?________________________
________________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
Consumos de 
drogas? 
Sim ☐ Não ☐ 
Qual?______________________
__________________________ 
Nenhuma ☐ 
Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
Sim ☐ Não ☐ 
Qual?________________________
________________________ 
Nenhuma ☐ 
Sim ☐ Não ☐ 
Qual?_______________________
_________________________ 
Nenhuma ☐ 
Observações 
sobre o Registo 
da Consulta 
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Informação registada desde 1 Janeiro 2005 até 31 Dezembro 2009 
Nesta consulta 
há registo sobre: 
__ / __ / __ __ / __ / __ __ / __ / __ __ / __ / __ 
Estadio CDC?  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
 A B C  A B C  A B C  A B C 
1    1    1    1    
2    2    2    2    
3    3    3    3    
CD4+ / CD8+?  Sim ☐ Não ☐ 
 células/mm3 Data: 
 Sim ☐ Não ☐ 
 células/mm3 Data: 
 Sim ☐ Não ☐ 
 células/mm3 Data: 
 Sim ☐ Não ☐ 
 células/mm3 Data: 
Carga Viral?  Sim ☐ Não ☐ 
 cps/mL Data: 
 Sim ☐ Não ☐ 
 cps/mL Data: 
 Sim ☐ Não ☐ 
 cps/mL Data: 
 Sim ☐ Não ☐ 
 cps/mL Data: 
Infecções 
oportunistas? 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
Neoplasias?  Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
Co-
morbilidades? 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
 Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
Mudança 
terapêutica? 
 Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
Motivo da 
mudança de 
regime? 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
__________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
____________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
Terapêutica AR? 
Nome / Dose / 
Posologia 
 
Nota: indicar as 
associações fixas na 
mesma linha 
 Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
1.  1.  1.  1.  
2. 2. 2. 2. 
3. 3. 3. 3. 
4. 4. 4. 4. 
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Informação registada desde 1 Janeiro 2005 até 31 Dezembro 2009 
Nesta consulta 
há registo sobre: 
__ / __ / __ __ / __ / __ __ / __ / __ __ / __ / __ 
Outra Medicação 
prescrita? 
Nome / Dose / 
Posologia 
 Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
1. 1. 1. 1. 
2.  2.  2.  2.  
3. 3. 3. 3. 
Outra Medicação 
conhecida? 
Nome / Dose / 
Posologia 
 Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐  Sim ☐ Não ☐ 
1. 1. 1. 1. 
2.  2.  2.  2.  
3. 3. 3. 3. 
De efeitos 
adversos? 
 Sim ☐ Não ☐ 
Quais?____________________ 
Sim ☐ Não ☐ 
Quais?____________________ 
Sim ☐ Não ☐ 
Quais?____________________ 
Sim ☐ Não ☐ 
Quais?____________________ 
Notas sobre a 
Medicação 
    
Há registo de 
comentários 
sobre a adesão à 
terapêutica? 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
____________________________
_________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
____________________________
_________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________
___________________________ 
Existem 
recomendações 
sobre a adesão à 
terapêutica? 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
____________________________ 
 Sim ☐ Não ☐ 
Qual?_______________________
____________________________ 
 Sim ☐ Não ☐ 
Qual?______________________
___________________________ 
TDM?  Sim ☐ Não ☐ 
Resultado?_________________ 
 Sim ☐ Não ☐ 
Resultado?_________________ 
 Sim ☐ Não ☐ 
Resultado?_________________ 
 Sim ☐ Não ☐ 
Resultado?_________________ 
De pedido de 
resistência? 
 Sim ☐ Não ☐ 
Resultado?_________________ 
 Sim ☐ Não ☐ 
Resultado?_________________ 
 Sim ☐ Não ☐ 
Resultado?_________________ 
 Sim ☐ Não ☐ 
Resultado?_________________ 
Consumos de 
drogas? 
Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
Sim ☐ Não ☐ 
Qual?________________________ 
Nenhuma ☐ 
Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
Sim ☐ Não ☐ 
Qual?_______________________ 
Nenhuma ☐ 
Observações 
sobre o Registo da 
Consulta 
    
 
  
Annex VI 
Evaluation of patient adherence to HAART and regimen 
modification, in a Portuguese cohort of HIV-1 infected adults: 
the ATAR-VIH project protocol 
Summary 
Background: HIV/AIDS infection requires continuous promotion of patient adherence to 
antiretroviral treatment. This is a complex behaviour determined by factors related to the patient 
characteristics, HIV/AIDS progression, HAART complexity and tolerability, and health services 
organization. The ATAR-VIH project aims to determine the prevalence of patient non-adherence to 
HAART, as well as to study and model potential determinants of medication adherence dynamic. 
Design: The study is an observational, multicentre cohort (study) with a prospective 18-month follow-
up of HIV1-positive subjects. Eligible subjects are required to have a treated HIV1 infection, age ≥18 
years-old when starting HAART, and no previous participation on a clinical trial. The study will have 
a multistage cluster sampling approach, with the systematic recruitment of subjects from a random 
sample of Portuguese hospitals following more than 200 HIV-infected subjects on HAART. The 
overall sample size is 490 subjects, assuming a 30% refusal rate, and an estimate of non-adherence 
prevalence of 50%. Clinical records will be reviewed, and questionnaires will be applied to both 
patients and their physicians, at defined moments. All data will be further assembled in a central 
electronic database. Analysis includes logistic regression models, and Cox's regression model, to 
evaluate determinants of compliance and persistence on HAART. 
Discussion: With the ATAR-VIH study, we aim to provide comparative information to support health 
planning regarding HAART utilization and HIV infection management. 
Keywords: HIV/AIDS infection; patient adherence; regimen modification; antiretroviral 
